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que no se acuerde de lo que le contaste…) y después, que por cosas del destino, estos últimos años hemos estado 
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“El hombre que ha perdido la facultad de maravillarse, es un hombre muerto” 
Pierre Curie (1859 – 1906) 
  
  
  
Resumen 
  
Los canales de potasio dependientes de voltaje (KV) son proteínas de membrana involucradas en diversos procesos 
fisiológicos y patológicos tales como la respuesta inmune y la función cardiovascular. Nuestro primer objetivo fue 
determinar el posible papel que los canales heterotetraméricos KV7.1/KV7.5 en músculo liso vascular. Para ello, 
estudiamos los niveles de expresión de ambos canales en diferentes miocitos vasculares. Se estudió la interacción 
de ambos canales tanto en un sistema de expresión heterólogo como en células nativas de aorta de rata. Los 
canales KV7.1 se localizan en dominios enriquecidos de lípidos en las membranas celulares. La presencia de 
canales KV7.5 modula su localización en estos dominios y por tanto su regulación fisiológica. En aquellos tejidos 
donde ambas isoformas están presentes, la localización de canales en membrana es fuera de las balsas lipídicas. 
Gracias a la técnica de patch-clamp se determinó que los canales KV7.1/KV7.5 eran canales funcionales. El 
resultado obtenido de la activación de los canales KV7.1/KV7.5 fueron corrientes fenotípicamente intermedias entre 
las obtenidas para cada uno de los canales por separado. Además, se demostró que, en presencia de subunidades 
reguladoras (KCNE1 Y KCNE3), los canales muestran características electrofisiológicas y farmacológicas propias. 
Retigabine es un fármaco (activador) ampliamente usado en el estudio de los canales KV7. Los canales KV7.1/KV7.5 
son susceptibles de regulación por retigabine. Por último, se estudió la implicación de estos canales en la regulación 
del tono vascular. Se midió la capacidad de relajación de arterias coronarias, pre-constreñidas con bloqueantes de 
canales KV7. Se determinó que los canales KV7.1/KV7.5 están presentes en dichas arterias e involucrados en la 
regulación del tono vascular. Por otro lado, se estudió el canal KV7.1, junto con la subunidad reguladora, KCNE1, 
con la que forma una de las corrientes más importantes de la fase de repolarización del potencial de acción cardíaco 
(IKs). Se analizaron los efectos de la aplicación aguda y crónica de ácidos grasos poliinsaturados (AGPIs), DHA y 
AA, en la corriente generada por KV7.1/KCNE1 expresados en células COS-7 mediante la técnica de patch-clamp. 
La perfusión aguda de DHA y AA aumentó la magnitud de la corriente de los canales KV7.1/KCNE1. DHA, pero no 
AA, hizo más lenta la cinética de activación de la corriente. Ambos, aceleraron la corriente de cierre de los canales. 
La aplicación crónica de estos compuestos, no aumentó la magnitud de la corriente. Sin embargo, DHA desplazó la 
dependencia de voltaje de los canales a valores más electronegativos del potencial de membrana, e hizo más rápida 
la cinética de activación y la cinética de cierre de los canales. La aplicación crónica de AA ralentizó la cinética de 
activación y aceleró la cinética de cierre. Además, DHA crónico disminuyó la expresión de KV7.1 pero no de KCNE1, 
e indujo una redistribución de KV7.1 en la membrana celular. El efecto producido por los ácidos grasos sobre los 
canales KV7.1/KCNE1, depende tanto de la naturaleza del compuesto, n-3 o n-6 AGPIs, como del modo de 
administración, agudo o crónico. Los mediadores lipídicos derivados de AGPIs n-6 y n-3, como lipoxinas y resolvinas 
(cuya producción aumenta tras la ingesta de aspirina), han surgido como nuevos y potentes agentes que regulan la 
inflamación aguda promoviendo la resolución. Los canales iónicos juegan un papel esencial en la fisiología de los 
macrófagos. Por ello, se estudió los efectos de estos derivados lipídicos tanto en macrófagos derivados de médula 
ósea (MDMO) cuya activación se relaciona con los canales KV1.3/KV1.5, como en los canales KV7.1/KCNE1 donde 
se habían previamente estudiado los efectos de los AGPIs. Las lipoxinas, pero no las resolvinas, revertieron la 
activación de los macrófagos inducida por el lipopolisacárido (LPS). Sin embargo, la resolvina D1 bloqueó de una 
manera mucho más potente los canales KV7.1/KCNE1.  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Abstract 
 
 
  
Voltage-dependent potassium channels are spanning-membrane integral proteins involved in several and diverse 
physiological and pathological processes such as immune response or cardiovascular function. The first goal of this 
study was to elucidate the role of KV7.1/KV7.5, as a heterotetramer complex, in vascular smooth muscle. To that end, 
we studied the expression levels of both channels in rat vascular myocytes, as well as their interaction in both a 
heterologous system and in aorta artery cells. KV7.1 channels targets lipid-enriched domains in plasma membrane. 
The presence of KV7.5 channels modulates KV7.1 channels-targeting and, indeed, their physiological regulation. In 
those tissues where KV7.1 channels are the only ones expressed, as in the heart, KV7.1 channels are targeting lipid 
rafts. However, when both isoforms are expressed together, as in aorta artery and cava vein, the distribution of both 
channels throughout the membrane changes. Using patch-clamp technique we demonstrated that KV7.1/KV7.5 
channels were functional, and we studied their electrophysiological and pharmacological properties. The activation of 
the channels generated a phenotypically intermediate current, which properties were between both the 
homotetrameric channels alone. In addition, electrophysiological characteristics of the channels were studied in the 
presence of different regulatory subunits (KCNE1 and KCNE3). In the presence of regulatory subunits KV7.1/KV7.5 
channels showed their own electrophysiological properties. Retigabine is an activator drug of KV7.2-7.5 channels. 
KV7.1/KV7.5 channels can be regulated by retigabine as KV7.5 channels. We studied the possible role of these 
channels in the control of the vascular tone. To that end, we measured the relaxant response of coronary arteries 
induced by retigabine in constricted arteries by different blockers of KV7 channels. We demonstrated that KV7.1/KV7.5 
are involved in the control of the vascular tone. Otherwise, we studied the KV7 first member, the KV7.1 channel, with 
the KCNE1 regulatory subunit. Together, they form one of the most important current of the repolarization phase of 
the cardiac action potential (IKs). We analyzed, using the patch-clamp technique, the acute and chronic exposition of 
polyunsaturated fatty acids (PUFAs), DHA and AA, in KV7.1/KCNE1 channels expressed in COS-7 cells. Also, in 
DHA analysis, we used western blot and isolation lipid rafts techniques. Acute DHA and AA exposition increased the 
magnitude of KV7.1/KCNE1 currents. DHA but not AA slowed the activation kinetics. However, both PUFAs 
accelerated the deactivation kinetics. Chronic exposition to these compounds did not modify the magnitude of the 
currents. However, DHA shifted the activation curve toward more negative membrane potentials and accelerated the 
activation and deactivation kinetics of the channels. On the contrary, AA slowed the activation whereas it accelerated 
the deactivation process. Chronic exposure to DHA, decreased the KV7.1 but not KCNE1 protein expression. Also, it 
induced a redistribution of KV7.1 channels in the plasma membrane. PUFAs effects on KV7.1/KCNE1 channels 
depends on both the compound’s chemical nature, n-3 or n-6 PUFAs, as well as the time of exposure, which might 
be acute or chronic. It has been described that enriched PUFAs diet has anti-inflammatory properties. Moreover, n-3 
or n-6 PUFAs lipid-derived mediators such as lipoxins and resolvins (which levels are increased by the consumption 
of aspirin), have been emerged as potent anti-inflammatory agents that promote the resolution phase of the 
inflammation process. Ion channels, and specially potassium ion channels, play an essential role in macrophages 
physiology. Accordingly, we studied the lipid-derived mediators effects on both bone marrow derived macrophages 
(BMDM), which LPS-dependent activation are related with the increased of KV1.3/KV1.5 expression, and in 
KV7.1/KCNE1 channels where the PUFAs effects have been studied. Lipoxins, but not resolvins, could reverse the 
LPS-activated macrophages. However, resolvins KV7.1/KCNE1 block were much more potent.
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1.1 ION CHANNELS 
Ion channels represent one of the main mechanisms of cellular signaling of almost all live cells. Our ability to do 
gymnastic, to perceive a colorful world and to process language relies on rapid communication among cells. Such 
signaling, the fastest in our bodies, involves electrical fluxes produced when ion channels open and close (1). Fast 
electrical signaling is made possible by the homeostatic mechanisms that establish the standard environment and 
content of animal cells: high Na+ concentration [Na+] in the blood and extracellular fluid, and high [K+] (but low [Na+] 
and [Ca2+]) in the cytoplasm. Gradients are established and maintained by active transporters and pumps, which 
prepare the way for rapid changes in membrane voltage to be produced by passive transport through ion channels. 
These pore-forming proteins allow ions to flow only “downhill”, as dictated by their electrochemical gradients, but they 
do it rapidly (the rate of passage of ions through one open channel is often more than 106 ions per second) and 
selectively. Opening a Na+ or Ca2+ selective channel permits Na+ or Ca2+ to flow down its gradient into a cell, making 
the intracellular voltage more positive. Opening a K+ selective channel permits K+ to flow from the cell and restores 
the voltage to a negative value. The dimensions of a typical cell and its membrane allow the voltage to be changed 
rapidly back and forth many times, with relatively small changes in concentration. This is essentially how all cellular 
electrical signaling is produced (1, 2).  
These ion channels are spanning-membrane integral proteins that allow the flux of ions across them, promoted by 
their electrochemical gradients. The movement of charged ions generates electrical currents. The measure of how 
these currents flow through the membrane is known as conductance or membrane conductance.  
The fundamental properties of currents mediated by ion channels were analyzed by the British biophysicists Alan 
Hodgkin and Andrew Huxley as part of their Nobel Prize-winning research on the action potential (AP), published in 
1952 (3, 4). The existence of ion channels was confirmed in the 1970s by Bernard Katz and Ricardo Miledi using 
noise analysis (5). It was afterwards shown more directly with an electrical recording technique known as the "patch 
clamp", which led to a Nobel Prize to the German researchers Erwin Neher and Bert Sakmann, the technique's 
inventors (6). Thousands of researchers continue to pursue a more detailed understanding of how these proteins 
work. More recently, the Nobel Prize in Chemistry for 2003 was awarded to two American scientists: Roderick 
MacKinnon for his studies on the physico-chemical properties of ion channel structure and function, including x-ray 
crystallographic structure studies, and Peter Agre for his similar work on aquaporins (7, 8).  
There are more than 75 genes whose expression is related with potassium channels subunits in humans. For this 
reason, KV channels are the most extensive and diverse group of ion channels (9). KV channels are constituted by 4 
pore-forming subunits (α-subunits), each formed by six transmembrane domains, TM, (S1-S6) with intracellular N- 
and C-terminus. S1 to S4 conform the voltage sensing domain (VSD), whereas S5-S6, connected by the P-loop, 
form the central cavity of the ion pore (10). Based on this oligomeric organization, it is considered that KV channels 
belong to a family of cation channels, not necessarily activated by voltage, that includes NaV and CaV channels 
(formed by only one subunit with four similar repeats of six TM segments) (11, 12),Ca+-activated K+ channels, cyclic 
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nucleotide-activated channels (13), hyperpolarization activated cation channels (14), inward-rectifier K+ channels (15, 
16), two-pore K+ channels (17, 18), TRP channels and glutamate-activated channels (19) (Figure 1) 
  
1.2 VOLTAGE-GATED POTASSIUM CHANNELS 
Voltage-gated ion channel protein superfamily is formed by more than 140 members and it is one of the largest 
groups of signal transduction proteins able to change their structural conformation as a consequence of changes in 
the membrane electrical field (20). These conformational changes promote the transition from the closed to the open 
and/or inactivated states (20-25). Excitable tissues generate action potentials (APs), without the need of any external 
stimuli, after the activation of Na+ and/or Ca2+ channels. The AP is controlled by the coordinated activation of KV, NaV 
and CaV channels. Thus, KV channels are involved in the maintaining of the resting membrane potential, the AP 
duration, the heart contraction, neuronal signaling, as well as other processes such as the immune activation, 
neurohormonal secretion, cell proliferation or cell volume regulation (26-29). At hyperpolarized membrane voltages, 
the open probability (po) of KV channels is very low (~ 10-9); but, after depolarization, KV channels increase their open 
probability with a very high precision (~ 1) (23). KV channels comprise a big and diverse family among human 
potassium channels, with 12 known subfamilies (KV1-KV12) (30). Activation of KV channels generates potassium 
currents with different biophysical properties. KV1-4 α-subunits can interact (between members of the same 
subfamily) and form homo- and heterotetramers (Figure 2). Subunits belonging to KV5, KV6, KV8 and KV9 subfamilies 
are known as “silent channels” that do not form homotetramers. They can heterotetramerize with other α-subunits. 
Usually, they interact with KV2 subunits, generating functional KV2/KVS channel complexes in which the KVS subunits 
modulate the KV2 current (31-33). KV7 channels can form homotetramers and heterotetramers channels, but 
Figure 1: Schematic representation of the TM spanning segments of 
KV channels and cation related channels. The white background 
represents the extracellular side of the plasma membrane. Light blue 
segments represent the TM segment that conforms the ion conduction 
pore. Taken from: Swartz et al., (2004) Nature Rev Neurosci 5:905-916. 
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structurally are more similar to KV10-12 subfamilies (34). Additional intracellular domains and/or accessory subunits 
modulate the gating properties of KV channels (35-37). Taking in mind the structure of the KV channels, we can divide 
them in two groups. All KV channels belonging to each group share homology in the pore region and they exhibit very 
low matches in other regions. On the one hand, KV1-4 channels exhibit an N-terminal that has a tetramerization 
domain (T1), dangling centrally below the TM core, which determines different functional characteristics and allow 
the assembly of KV monomers as well as the assembly of regulatory subunits (Figure 2B) (38). On the other hand, 
KV7 and KV10-12 subfamilies, are characterized by the absence of an N-terminal T1 domain (Figure 2C), have a long 
C-terminal domain forming a compact tetrameric structure in a central position immediately below the cytoplasmic 
pore opening. These channels are characterized by a very big cytoplasmic region (almost 80% of total protein), 
although structural details of this region is still unknown (39). However, it is known that the gating properties are 
strongly influenced by cytoplasmic domains. In both KV structures, the N- and C- termini encircle the main terminal, 
which are likely to interact with the surroundings in the transmembrane (TM) core (Figure 2BC). Due to their 
accessibility, the cytoplasmic regions of the channels are targets for cell-physiological control of the channel function 
A B
C
Figure 2: Summary of structural components of Kv channels. (A) Schematic representation of the tetrameric organization of 
a Kv channel. A structural folding model of one of the four  subunits is shown on the right. (B) General organization of the Kv1–
Kv4 channels group with the T1 “tetramerization domains” hanging centrally below the transmembranal core and attached to it 
through four linkers continued from the first transmembrane helices. In this case, the C-terminus structures probably track to the 
periphery surrounding T1 and extending to its bottom. (C) General architecture of the Kv7 and Kv10–Kv12 channels characterized 
by a C-terminus (i.e., the C-linker/cyclic nucleotide-binding domain (CNBD) region of the Kv10–Kv12 channels or the A–D helical 
regions of the Kv7 channels) forming a compact tetrameric structure in a central position immediately below the cytoplasmic pore 
opening. In this case the N-terminus probably surrounds the C-terminus and extends to its bottom establishing extensive 
contacts with its top and side surfaces. Note that in both models the initial N-termini structures are likely to interact with the gate 
surroundings in the transmembrane core. S4 segment is also depicted as a reference. Taken from: Barros et al., (2012). Front 
Pharmacol. 3:49. 
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(i.e. β-regulatory subunits, KCNEs, syntaxin, G β-gamma proteins, SNARE complex, Ca2+/calmodulin, PIP2, PKC, 
PKA, etc.). 
1.2.1 Ion pore and selectivity filter of KV channels 
The role of all K+ channels is to conduct K+ ions with a high selectivity over other cations across the cell membrane. 
The differences between Na+ ion and K+ ion are practically undetectable, the atomic radius are 0.95 Ǻ and 1.33 Ǻ for 
Na+ and K+ ions, respectively. However, this difference in size is managed with a very high precision (1000:1) by K+ 
channels to select K+ and not Na+ ions. This high selectivity does not compromise the rates of conduction for K+ ions, 
which is similar to the diffusion limit value (40, 41). The fact that the rates of conduction will not be affected by 
electrostatic repulsion is due to several properties of the ion pore. The first K+ channel crystalized was the bacterial 
KcsA channel at a 3.2 Å resolution (7). This channel is a tetramer, with four identical subunits arranged symmetrically 
around a central ion pore. Each subunit consists of two transmembrane α-helices connected by a P-loop; the inner 
(closer to the ion pore) and the outer (closer the membrane), which are equivalent to S5 and S6 in KV channels 
(subsequently confirmed in Long SB et al., 2005 (42)) (Figure 3). From external side (extracellular medium) to 
internal side (cytosol) of the channel model, it can be considered two regions, the broad region (upper region) and 
the narrowest region (inner region). The upper region of the ion pore is the K+ selectivity filter region, because is 
where is located the selectivity filter. (marked in yellow in Figure 3A) In the inner region, the pore is lined by inner 
helices and is considered as gating part (Figure 3A). This configuration is known as the inverted teepee. Just inside 
the upper region of the pore, the selectivity filter is between the extracellular medium and the central water-filled 
cavity, where the hydrated K+ ions remain suspended within the crystal structure (41). The inner helices converge to 
a hole and there is the amino acid sequence (TVGYG) considered the selectivity filter of K+ channels. This amino 
acid sequence is highly conserved in nature and is also known as K+ channel signature sequence (7, 41). Their side 
chains do not point into the pore, but the strongly dipolar carbonyl groups of α carbons do. The presence of water-
filled cavity and the oriented α-helices helps the moving of ions, into the low dielectric membrane environment 
(Figure 3C). Thus, K+ ions remain hydrated at the membrane center and it will be stabilized there thanks to the C-
terminal negative ends-charge of α-helices (43). K+ ions confront with evenly spaced layers of carbonil oxygen atoms 
and a single layer of threonine hydroxyl oxygen atoms. This disposition gives rise to 4 numbered spaces (1 to 4), in 
the selectivity filter, where the K+ ion will be surrounded by four oxygen atoms above and four oxygen atoms below 
(red circles, Figure 3B). This arrangement of the oxygen atoms in the selectivity filter surrounding K+ ions, mimics the 
water that is held in the central cavity. Therefore, K+ ions can diffuse from the selectivity filter to the central cavity 
being energetically compensated (40). The passage model suggests that K+ occupies two of the four spaces and that 
between them there is a water molecule (Figure 3). In summary, the selectivity filter has several binding sites for K+ 
ions that mimic hydrated K+ ions breastplate. They achieve right conductions rates due to the electrostatic repulsion 
compensation, and by coupling the selectivity filter conformation to the binding of the K+ ions (41). A few years later, 
the crystal structure of the first KV channel (KV1.2) was performed (42). The pore structure of KV channels differs from 
that of the non-voltage-gated bacterial K+ channel KcsA due to a sharp-bend in the S6 helices (equivalent to the 
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inner helices of the KcsA channel) This bend occurred at a Pro-X-Pro sequence that is conserved in KV channels 
(44). 
 
 
 
1.2.2 Voltage-sensor domain of KV channels 
KV channels sense and change their conformation depending on the membrane potential. Different studies reported 
that the voltage sensor domain (VSD) of KV channels resides in the S1-S4 segments (45-47). In particular, the S4 is 
rich in positively charged basic residues and, thus, it represents the major component of the voltage sensor. The 
movement of these charged amino acids through the membrane (gating charges) provides the energy necessary to 
promote the channels to open. In addition, negative charges in S1, S2 and S3 also contribute to this process (20, 23-
25, 48, 49). S3 is formed by two helices named S3a and S3b (Figure 4C). In the crystal structure of KV1.2 (42), S3b 
forms, together with S4, a helix-turn-helix structure called the voltage-sensor paddle (42). Membrane depolarization 
produces an outward movement of the S4 inducing further conformational changes that results in the opening of the 
channel pore leading to selective K+ permeation. This movement has been monitored electrically as the gating 
current or by voltage-clamp fluorometry(50-53). 
 
 
 
 
Figure 3: The ion conduction pore of K+ channels. (A): Two of the four subunits from the KcsA pore are shown with the 
extracellular side on top. Each subunit contains an outer helix close to the membrane, an inner helix close to the pore, a pore 
helix (red) and a selectivity filter (gold). Blue mesh shows electron density for K+ ions and water along the pore. (B) Close-up 
view of the selectivity filter with dehydrated K+ ions at positions 1 through 4 (external to internal) inside the filter and a hydrated 
K+ ion in the central cavity below the filter. (C) Schematic view of the stabilizing mechanism of K+ channels. Central cavity water-
filled and oriented helices pointed their partial negative charge (red) toward the cavity where a cation (green) is located. Adapted 
from: Doyle et al., (1998). Science. 280(5360):69-7 and Mackinnon et al.,(2003). FEBBS Lett. 27;555(1):62-5 
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1.2.3 KV channels gating 
KV channels are mostly intracellular being their TM segments essentially in contact with the lipid bilayer to sense 
voltage membrane and respond to its changes. Moreover, both C- and N- termini face to the cytosolic medium and 
are widely regulated by the different protein and lipids present in the cytosol. The comparison of the structures of K+ 
channels trapped in the open conformation, MthK, KVAP and KV1.2 (42, 54, 55), and channels kept in the closed 
conformation, KcsA and KirBac1.1 (7, 56), suggests that the KV gate opening is linked to a conformational change of 
the S6 helix. The S6 helix of KV channels has a high conserved sequence PXP motif. Results of accessibility studies 
(44, 57, 58) suggest that the opening of the S6 bundle takes place at the PVP motif of KV1 channels. The crystal 
structure of the rat KV1.2 (59) supports this view and shows that widening of the S6 occurs because of a bend at the 
PVP motif. Opening of the gate is associated with the bending of the S6 helix which can occur at either a glycine or a 
PVP motif. Several studies on different channels suggest the S4-S5 linker and the end of S6 are involved in coupling 
(60-62). The crystal structure of KV1.2 demonstrates this interaction clearly. The distal end of the S4-S5 linker comes 
close to the internal end of S5 below the PVP motif, with extensive contacts between side chains of the two regions. 
This structural picture of the activated conformation suggests that to close the gate, the S4-S5 linker would have to 
Figure 4: Schematic view of the voltage-sensor of K+ channels. (A) Ribbon representation of the transmembrane region of 
Kv2.1 paddle–Kv1.2 chimera channel tetramer (Kvchim, viewed from the side, and oriented with the extracellular solution above. 
The pore is colored blue; the voltage sensor paddle (S3b and S4) and the linker helix (S4-S5) between voltage sensor and the 
pore in red; and S1, S2, and S3a gray. The voltage sensor closest to the viewer was removed for clarity. K+ ions in the selectivity 
filter are shown as green spheres. (B) Ribbon representation of the pore and S4-S5 linkers in the hypothetical closed 
conformation (C) from a model constructed from the Kvchim and KcsA structures and in the open conformation (O) from the 
crystal structure of Kvchim. In the hypothetical closed state, based on the closed conformation of KcsA, the S4-S5 linker helices 
are pushed down to maintain their same contacts with the pore. (C) View of the voltage sensor and S4-S5 linker helix of the open 
conformation from Kvchim. Side chains of the positively charged residues on S4 (labeled as R0, R1, R2, R3, R4, and K5) and the 
negatively charged residues forming ionizing hydrogen bonds (dashed black lines) with the positive charges, as well as those of 
the three residues (labeled F, E, and D) forming an occluded binding site in the voltage sensor, are shown as sticks and colored 
according to atom types (yellow, carbon; blue, nitrogen; red, oxygen; and green, phenylalanine). Taken from: Tao et al., (2010) 
Science 2;328(5974):67-73. 
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move inward, shutting down the S6 gate (42). Therefore, the S4-S5 linker and C-terminus end of S6 are critical for 
coupling between voltage-sensor movement and channel opening. 
1.3 KV1 SUBFAMILY CHANNELS 
This subfamily is constituted by 8 members (KV1.1 – KV1.8). In the present Doctoral Thesis we have focused on two 
of them, KV1.3 and KV1.5, and a brief description of their electrophysiological characteristics are given in this section. 
1.3.1 KV1.3 channels 
The expression of KCNA3 gene generates a 575 amino acid protein. KV1.3 traffics very efficiently to the cell 
membrane (63). It is activated after membrane depolarization and has a slow and cumulative inactivation (64-66). 
KV1.3 also targets nuclear membrane, mitochondrial membrane and Golgi apparatus (67, 68). KV1.3 channels are 
involved in several processes like cell volume regulation, maintaining of the resting membrane potential and 
apoptosis. KV1.3 is mostly expressed in neurons and in immune cells, being significantly important in hypothalamus 
and olfactory bulb, and in T and B lymphocytes, macrophages and dendritic cells (69, 70). KV1.3 alterations are 
related to several autoimmune diseases (71). KV1.3 has also been studied in other tissues where its role appears 
less relevant such as kidney, smooth muscle, colon epithelia and testes (72-74). It is also involved in processes 
related to the insulin response, where the glucose transporter, GLUT4, is involved (75, 76). Moreover, KV1.3 
channels are being described as possible targets for obesity (77, 78). Therefore, KV1.3 is considered a putative 
therapeutic target for several diseases.  
1.3.2 KV1.5 channels  
KV1.5 (KCNA5) was cloned for the first time from a human ventricle library (79). In the human heart KV1.5 channels 
are responsible for the rapid repolarizing phases of the AP (phases 1 and 3 of atrial APs). However, this current 
could not be recorded from human ventricular cardiac myocytes (80-83). KV1.5 channels are mostly expressed in 
atria, where they generate the so-called ultra-rapidly activating delayed outward-rectifying K+ current (IKur) (84-87). 
KV1.5 is considered as a potential molecular target for antiarrhythmic drugs useful in the treatment of supraventricular 
arrhythmias (86, 87). Also KV1.5 channels have been described in other tissues but in a lesser extent, such as 
GABAergic neurons, human fetus, skeletal and smooth muscle, and immune cells. 
Like, KV1.3 channels, KV1.5 are also expressed in cells from the immune system. In fact, they play crucial roles in 
cells from the immune system and proliferation (88, 89).  
1.3.3 Bone marrow derivate macrophages express KV1.5 and KV1.3 channels 
Macrophages are highly regulated cells of the immune system. They can be involved in several actions, among 
them, acting as antigen presenting cells (APCs), taking part in T-signaling and/or regulating cytokine release. The 
molecular signals leading the different activation programs in macrophages i.e. proliferation, activation, resolution or 
tolerance proceed from the extracellular medium and they will determine the direction of the immune response, 
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driving it to inflammation or resolution (90). KV channels play a pivotal role in the regulation of macrophages. Indeed, 
the electrophysiological properties of macrophages depend on their state of functional activation (91). Thus, changes 
in membrane potential that occur as a consequence of the modulation of ion channels are among the earliest events 
after macrophage activation (92, 93). Hence, the expression of KV1.3 channels is increased as a consequence of the 
macrophage activation by lipopolysaccharide (LPS) and proliferation, whereas Kir channel expression is reduced 
under these conditions. Previous reports demonstrate that macrophages KV outward current is generated after the 
activation of KV1.3/KV1.5 heterotetrameric channels (91, 94). It is also known that the innate activation increases the 
KV1.3:KV1.5 ratio of these heteromeric channels. On the contrary, alternative activation of macrophages leads to a 
decrease in the KV1.3:KV1.5 ratio (94). The influx of extracellular Ca2+ is an essential requirement for the activity of 
many cellular processes (92, 95, 96). Therefore, KV1.3 and the Ca2+-activated K+ (KCa3.1) channels regulate Ca2+ 
influx through the Ca2+ release-activated Ca2+ (CRAC) channel, which consists of the Ca2+-sensor stromal interaction 
molecule 1 (STIM1) and the pore-forming protein CRACM1 (Orai1) (97-100). In T cells, this crucial influx of Ca2+ is 
only possible if they can keep their membrane potential negative by a counterbalance of K+ efflux through KV1.3 
and/or KCa3.1 (101, 102) and both channels are regarded as targets for immunosuppression (101). Interestingly, 
inflammation is involved in several cardiovascular pathologies, from atrial fibrillation or atherosclerosis to myocardial 
infarction or heart failure (103-106).  
1.4 KV7 CHANNELS 
The KV7 subfamily of potassium channels (KV7.1-KV7.5) plays a crucial role on cardiac, neuronal, cochlear and 
vascular function (107, 108). These channels are constituted by homo- or heterotetramers of KV7 subunits (108). 
Each KV7 member exhibits a characteristic tissue expression pattern. Thus, KV7.1 is mainly expressed in cardiac 
tissue (where they are responsible, together with the regulatory subunit KCNE1, of the cardiac IKs). KV7.2 to KV7.5 are 
predominantly distributed throughout the CNS and peripheral nerves and are therefore referred to as neuronal KV7 
channels (109). In fact, the activation of KV7.2, KV7.5, KV7.2/KV7.3 and KV7.5/KV7.3 channels generates the so-called 
M-current, crucial for the control of neuronal excitability (108, 110). In addition, KV7.4 is also expressed in sensory 
cells of the cochlea. KV7 channels are a subfamily of KV channels of great physiological importance also in the 
kidney, gastro-intestinal tract, inner ear, testis, skeletal and smooth muscle(111). In fact, KV7.1, KV7.4 and KV7.5 
channels are also highly expressed in vascular smooth muscle where they are important regulators of the vascular 
tone in veins and arteries. 
Mutations in KV7 channels may trigger cardiac arrhythmias, deafness and epilepsy (112-115), displaying a prominent 
role in human disease (110). The diversity and complexity of KV7 channels is further increased by the interaction of 
the channels with different types of KCNE subunits.  
As it was described, KV pore and voltage sensor domains are well-conserved structures within KV channels (7, 42). 
KV7 channels are characterized by the largest C-terminal that, besides being the tetramerization domain, it has 
several domains for modulation (38).
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1.4.1 Role of C-terminal in KV7 channels 
The C-terminal  domain in KV7 channels is much longer (300-500 residues) than in other KV channels, playing a 
critical role in assembling, trafficking and gating (116). The secondary structure predicts four helices (A-D helices), 
which are present in all members of the KV7 subfamily. Schematically, C-terminus is subdivided in two parts: i) the 
proximal region, susceptible of PIP2 regulation and constitutively associated with calmodulin (CaM), and ii) the distal 
part mediating tetramerization due to tandem coiled-coil (CaM) (Figure 5).  
CaM is a constitutively tethered to the C- terminal of KV7 channels both in the presence and in the absence of Ca2+ 
(117-119), and thus, the C-terrminus acts as a Ca2+ sensor necessary for the gating, folding and trafficking of these 
channels (116). Also, the proper function of KV7 channels requires the tethering of PIP2 to a binding site that overlaps 
with that of CaM (120-122). It has been described that KV7.1 channels are activated by both PIP2 and 
Ca2+/calmodulin mediating IKs current, and mutations that alter PIP2 or Ca2+/calmodulin binding site yield different 
forms of Long-QT syndrome (123-126). Furthermore, KV7 channels are targets of signaling cascades in which 
different protein kinases (PKC, PKA, Src Kinase, SGK1.1) are involved (127-130). Some of these kinases act 
through the interaction with AKAP proteins (128, 131). In the KV7.1 C-terminus, there is a leucine zipper that acts as 
scaffold, recruiting a signaling complex of proteins such as proteinphosphatase 1 or PKA, which is essential for the 
regulation of this channel via β-adrenergic receptor (132, 133). The two tandemly arranged coiled-coil helices C and 
D are the structures that make possible the tetrameric assembly (also known as A-domain). Analyses of the helix C 
confirm that it is dimeric and undergoes self-association to form dimer of dimers and confirm that are absolutely 
necessary to form functional channels (134). In the most distal part of C-terminal there are two binding sites for two 
different regulatory proteins. Below helix D, it is located the Nedd4-2 ubiquitin ligase binding-site, which ubiquitinates 
KV7 and, thus, modulates KV7 channel density in the plasma membrane. This interaction seems to be crucial in cell 
excitability and in several pathophysiological conditions such as cardiac ischemia, epilepsy, Alzheimer´s disease or 
chronic pain (116). KV7.2 and KV7.3 channels are also regulated by Ankiryrin-G that binds to a site at the distal part of 
C-terminus known as C3-motif. The role of this protein is to anchor the C-teminus with other TM protein complexes 
and to connect it with the cytoskeleton via actin-spectrin proteins (135). 
 
Figure 5: Schematic representation of C-Terminal of KV7 
channels. Grey cylinders represent the TM segment of the 
subunit. Green and yellow cylinders represent Helix B and Helix 
A respectively, which are the structures recognize as binding 
site for CaM and PIP2. Phosphorylation sites by Src Kinase and 
by PKC are indicated by encircled P. For KV7.2 are represented 
the AKAP79/150. Blue cylinder represents the conserved site for 
the auxiliary β -subunit KCNE1 and the AKAP-Yotiao in KV7.1 
and in brown and purple are represented ankyrin-G (in KV7.2-
KV7.3) and ubiquitin protein ligase Nedd4-2 (in KV7.1, KV7.2, 
and KV7.3), respectively. Taken from: Barros et al., (2012). 
Front Pharmacol. 3:49. 
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1.4.2 KCNE regulatory subunits 
Ion channels are present, in different tissues, forming signaling complexes or channelosomes. In the past decade a 
myriad of protein-protein interactions involved in intracellular signaling have been described (131, 136). KCNE family 
is encoded by KCNE genes consisting in 5 known members (KCNE1-5) (137, 138). The KCNE structure consists in a 
single TM domain with the N-terminus facing the extracellular medium and a cytosolic C-terminus, which interacts 
with C-termini of the α-subunits (137, 139). Each one of these KCNE proteins can modulate multiple KV channel α-
subunits (72, 138, 140). KCNE1-5 proteins modulate membrane targeting of KV7 channels, single-channel 
conductance, voltage-dependence, gating kinetics, ion selectivity and pharmacology (137, 164). 
KV7.1 channels interact with all KCNE family members. KCNE2 almost abolished the KV7.1 current. KCNE3 subunit 
generates constitutively active KV7.1 channels (110, 141, 142). These interactions between KCNE3 and KV7.1 
appear to stabilize the activated “up” state configuration of S4, which the authors propose as a prerequisite for full 
opening of the KV7.1 channel activation gate (143). KCNE4 and KCNE5, at physiological membrane voltages, reduce 
the magnitude of KV7.1 current (144). 
KV7.5 channels interact with all KCNE family members, but only KCNE1 and KCNE3 induce changes in the current. 
KCNE1 enhance KV7.5 currents and slow their activation kinetics while KCNE3 drastically inhibits KV7.5 currents 
(137). 
1.4.3 KV7.5 channels 
KV7.5 was cloned simultaneously by two laboratories (145, 146). KV7.5 subunit is a protein formed by 897-932 amino 
acids (depending on the splicing variant) with a predicted molecular mass of ~99-102 kDa. The homology between 
KV7.5 and other members can be summarized as KV7.5 ~ KV7.4 (65%) > KV7.3 = KV7.2 (50%) > KV7.1 (40%) (137, 
145, 146) (Figure 6).  
 
 
 
KV7.5 channel exhibits the longest C-terminus of all the KV7 subfamily members. It shares well-conserved sites with 
other members, i.e. structural regions susceptible to be phosphorylated by PKC. However, KV7.5 channel lacks the 
N-terminal consensus site for cAMP-dependent phosphorylation that is present in KV7.1 and KV7.2 (147). KV7.5 
channel is mostly expressed in different areas of the brain, as well as in skeletal and smooth muscle (137, 145, 146). 
KV7.5 channel is inhibited by the activation of M1 muscarinic receptor, suggesting that KV7.5 are playing a specific 
role in generating “M-current” in different locations of nervous system (145, 146, 148).  
In vascular smooth muscle, KV7.5 channels play a crucial role maintaining the resting membrane potential (149-151). 
KV7.5 and all KCNE subunits are expressed in rat skeletal muscle and vascular smooth muscle. However, the 
physiological role of the interactions between them remains unclear (137, 145, 146).    
KCNQ1 
KCNQ2 
KCNQ3 
KCNQ4 
KCNQ5 
Figure 6: Dendrogram of KCNQ (KV7 
channels) using the ClustalX program. 
Taken from: Schroeder et al., (2000). J Biol 
Chem. 275:24089-24095. 
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KV7.5 currents were firstly studied in Xenopus oocytes. KV7.5 currents activate very slowly, being not fully activated 
after 3-s test pulses, displaying a delay in the activation, like other KV7 currents. KV7.5 currents exhibit faster 
activation than KV7.4, but slower than KV7.2 currents, and much slower than KV7.1 currents (145, 146, 152, 153). 
After applying depolarizing pulses to potentials positive to +40 mV, KV7.5 currents accumulate, indicating a fast 
inactivation. The activation midpoint is ~ -46 mV (145, 146). Finally, KV7.5 channels display a marked inward 
rectification at potentials positive to 0 mV (145, 146).  
1.4.4 KV7.1 channels 
KV7.1 channels have been previously known as KVLQT1 or KCNQ1 channels. It was previously described by Wang 
and colleagues in 1996. They first described KV7.1 channels when they reported a disorder of cardiac repolarization 
that led to long QT syndrome (LQTS) type 1. This LQTS type 1 was produced by an autosomal dominant mutation in 
the KCNQ1 gene (112, 113). KV7.1 channels are an essential part of cardiac IKs (KV7.1 channels are the α-subunit of 
the cardiac slowly activating delayed-rectifier K+ current) (152, 153). 
KV7.1 channels exhibited distinct biophysical properties in the absence and in the presence of KCNE1. KV7.1 
channels expressed alone activate and deactivate slowly, compared with others KV channels (154). However, the 
activation process is faster than in other members of KV7 channels. Depolarization of KV7.1 channels elicits outward 
K+ currents at membrane potentials positive to-70 mV. The I-V relationship showed a steady-state at high positive 
potentials (+40 mV- +60mV) (155). 
After depolarization, and the characteristic activation, KV7.1 channels rapidly inactivate. This inactivation process can 
be observed in the tail currents, which shows a “hook” (a little current increased with a subsequent slow decay) 
(156). A possible explanation for the non-linear I-V relationship is the inactivation process. This “hook” tail is also 
observed in KV11.1 channels (HERG channels), it seems to be that the deactivation process is slower than the 
recovery of the fast inactivation of the channels (157). 
An important regulator for KV7.1 channels is PIP2, which promotes the channels to open. The rundown observed 
when recording KV7.1 currents, is a consequence of PIP2 depletion. In fact, same results are observed with the 
activation of lipid-phosphatases (for instance with voltage sensing phosphatases, VSP) (26). Importantly, recent 
studies suggest that PIP2 serve as a cofactor that mediate “voltage sensing domain-pore gating domain” coupling in 
KV7.1 channels 
Aside from heart, KV7.1 channels are also expressed in pancreas, adrenal and thymus gland, placenta, intestine, 
brain, inner ear, kidney, smooth and skeletal muscle (133, 152). 
1.4.4.1 KV7.1/KCNE1 channels 
The assembly of KV7.1 and KCNE1 represents the cloned counterpart of the cardiac IKs current (152, 153). Although 
in the human heart KCNE1 is the highly expressed, it has been described the presence of several KCNEs in this 
tissue (142).
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The slowly activating delayed-rectifier K+ current, IKs, modulates the repolarization of cardiac action potentials. This 
was described, at the same time, by Sanguinetti and colleagues and Barhanin and colleagues, in 1996. Sanguinetti 
and colleagues used CHO cells as heterologous expression system (Barhanin and colleagues achieved the same 
conclusions using COS-7 cells). Thus, they expressed the cDNA of KV7.1 channels (KVLQT1) and KCNE1 (mink) in 
those cells. KCNE protein family was also named minK-related peptides (MiRPs). This name was assigned to this 
family protein because the first member KCNE1 was called minK (from “minimal K+ channel”) because it was thought 
that it generated K+ channels by itself (158). In fact, when regulatory subunit was transfected into Xenopus oocytes, 
that endogenously express KV7.1 channels, it assembles with them generating the slowly activated K+ current (see 
below IKs current) (152, 153). 
The KV7.1/KCNE1 current did not saturate after long depolarization pulses, contrary to what was observed for KV7.1 
channels alone (i.e. the I-V relationships are completely different)(155). KCNE1 protein not only delayed the 
activation process, but also increases the amplitude of the currents and right-shifts the voltage-dependence of the 
channels. KCNE1 eliminates the inactivation observed in KV7.1 channels (72, 146, 152, 153, 159-161). 
There is still controversy about the stoichiometry between α- and KCNE subunits (i.e. 4:4 or 4:2 subunits) (162-165). 
The available data suggest that KCNE1 could be inserted into the lipid-filled space between two adjacent VSD (166). 
It seems that KCNE1 directly interacts with regions located in S1, S4 and S6 TM domains (166-169). KV7.1/KCNE1 
channels are highly regulated by PIP2 and PKA protein. This regulation is very important, it is related to the activation 
mechanism of the channels and specifically related to heart rates (see below). 
KV7.1/KCNE1 channels are not only expressed in the heart, where this current plays a crucial role in the 
repolarization of the cardiac AP, but also in the endolymph of the inner ear, playing a crucial role in the homeostasis 
of the K+, in the brain acting on the neuronal electrical signal, pancreas and kidney (133, 170).  
1.4.5. KV7 channels pharmacology 
The main KV7 channels activators are; i) retigabine (RTG) and its analog, flupirtine (activators of KV7.2-7.5 channels) 
(174); ii) meclofenamic acid, a non-steroidal anti-inflammatory acid that activates KV7.2 and KV7.3 but not KV7.1 
channels (175); and finally iii) R-L3 and mefanamic acid, specific activators of KV7.1 channels (176, 177). 
XE991 and linopirdine are potent blockers of all members of KV7 subfamily, but they do not discriminate between 
individual isoforms (171, 172). Chromanol 298B is a selective blocker of KV7.1 channels (173). 
KCNE regulatory subunits modulate the pharmacology of KV7 channels (86). In such a way, the effects of blockers 
and activators in KV7.1 channels can be either enhanced or decreased by the presence of KCNE1. The anti-
inflammatory mefanamic acid (activator), tetraethylammonium (TEA) and chromanol 293B exhibited lower potency 
on KV7.1 channels than in KV7.1/KCNE1 channels (176, 177). The modulation produced by KCNE1 seems to be 
allosteric, i.e. facilitating the binding of the drugs to the KV7.1 channels (178). However, when the effects of XE991 
(KV7 blocker) were tested in Xenopus oocytes, block-induced was greater in KV7.1 than in KV7.1/KCNE1 channels, 
being the effects time- and voltage- dependent (172).
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1.5 PHYSIOLOGICAL ROLE OF KV7 CHANNELS  
1.5.1 Role of KV7 channels vascular in smooth muscle (VSM) 
The smooth muscle contractility depends on the increase of intracellular Ca2+. Schematically, after an increase in 
intracellular Ca2+ concentration, this ion binds to calmodulin activating MLCK that phosphorylates the 20-kDa light 
chain myosin protein (LC20) at Ser19. The LC20 phosphorylation is essential for the cross-bridge between actin and 
myosin and therefore, for contraction (179). The maintenance of the contractility force is due to other proteins such 
as Rho or PKC, which inhibit the myosin light chain phosphatase. There are two main mechanisms by which Ca2+ 
can be increased: i) entering from the extracellular media, or ii) being released from intracellular stores. On the one 
hand, the Ca2+ release from sarcoplasmic reticulum (the main intracellular Ca2+ store) is produced via IP3-dependent 
mechanism. On the other hand, the increase of Ca2+ from the extracellular media is produced through VDCCs or via 
nonselective cation channels. The activity of VDDCs depends on the Vm, in such a way that more positive potentials 
promote a higher open probability of these channels. Potassium channels are the main responsible of the 
hyperpolarization of the cell membranes. Thus, their activity will determine the open probability of VDDCs and 
indirectly the smooth muscle contraction (Figure 7). 
Among others, KV7 channels are involved in the control of the vascular tone. They control the resting membrane 
potential of vascular smooth muscle cells (VSMC) and therefore the contractility in several rodent and human arteries 
(180-182). Vascular musculature mostly expresses KV7.1, KV7.4, and KV7.5 channels. However, a relationship 
between functional currents and specific genes has not been established (111). Homo- and heterotetramerization of 
KV7 isoforms shapes K+ currents in VSMC. It has been described that KV7.4 and KV7.5 channels form functional 
heterotetrameric channels that are involved in the regulation of contractility in VSM. This complexity is further 
increased by KCNE regulatory subunits. The main expression of different types of KV7 channels and the combination 
with the KCNEs regulatory subunits are quite variable and depend on the type of vascular bed. KCNEs mRNAs are 
relatively abundant in aorta, carotid and femoral artery (111). 
KV7 channels are involved in different signaling pathways that lead to relaxation and vasodilatory actions, or to 
contractility and vasoconstriction (Figure 7). In the endogenously pathways, the Gs- and Gq-coupled receptor are 
involved. On the one hand, Gs-coupled receptor is activated by adenosine or isoprenaline (relaxant mediators, as in 
β-adrenergic regulation) and activates PKA, via AMPc, which promotes the activation of the channels and therefore 
the vasorelaxation. On the other hand, Gq-coupled receptor mediates activation of PKC that promotes the inhibition 
of the channels, favoring contractility (Figure 7).
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Figure 7: KV (KV7) channels signaling pathway involved in contractile state of smooth muscle. Activation of channels 
results in relaxation and vasodilation while block of them implies contraction and vasoconstriction. KV (KV7) channels are highly 
regulated by Gs- and Gq-coupled receptor signaling. Vasodilatoy actions induced by adenosine and isoprenaline are mediated y 
Gs-coupled receptor via AMPc. Gq-coupled receptor negatively modulates vasoconstrictor actions via PKC. Taken from: Stott et 
al., (2014). Drug Discov. Today 19:413-424. 
 
Because it is established that activators of KV7 channels lead to relaxation and vasodilatory actions, whereas 
blockers produce contractility and vasoconstriction, several pharmacological tools were used to determine the role of 
KV7 channels on VSM. However, the presence of heteromeric channels (and their regulation by KCNEs subunits) 
makes difficult to properly interpret the results obtained using these pharmacological tools. It has been observed that 
KV7.1 channels are the most abundant in portal veins and they are also expressed in pulmonary arteries. There are 
discrepant studies concerning the role of KV7.1 in coronary arteries, due to the pharmacological effects observed 
(183-185). 
1.5.2 Role of KV7 channels in the heart 
The heart is the organ responsible for pumping blood to the rest of the body. The electrical and mechanical 
mechanisms that underlies this process are fine-tune regulated and coupled. NaV, CaV and KV channels play a critical 
role in the generation, maintenance and repolarization of the cardiac action potential. In general terms, the ventricular 
cardiac action potential is divided in 5 phases. “Phase 0” is determined by NaV channels activation (INa), which leads 
the generation of cardiac AP. Afterwards, during “Phase 1” there is a fast and short repolarization promoted by Ito (KV 
channels) followed by a stable state of depolarization carried out by CaV channels (ICaL). During the “Phase 2” or 
“plateau” a massive entry of Ca2+ ions is produced (with a slight exit of K+ ions), which is coupled with the contraction 
process of ventricular cardiac muscle. “Phase 3” or “repolarization phase” is due to the outward currents IKr, and IKs 
(also IKur in atria). These K+ currents promote the total repolarization of cell membrane. 
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The maintaining of the resting potential of cardiac myocytes is due to the activity of NaK- and Na-Ca ATPase as well 
as the activity of inward K+ current (IK1). This is “Phase 4” (Figure 8). 
 
 
1.5.2.1 KV7.1/KCNE1 channels in heart 
KV7.1/KCNE1 channels are the cloned counterpart of the IKs current, which plays a crucial role in the heart 
repolarization. Mutations in both components are related with several congenital diseases that can lead to dead (long 
QT syndrome: LQTS, short QT syndrome: SQTS, atrial fibrillation: AF or Brugada Syndrome: BS) (186). Thus, 
mutations in potassium channels that exhibit a loss-of-function can be responsible of a prolongation of the cardiac AP 
and thus, to a LQTS. This congenital syndrome may lead to a potential lethal tachycardia (torsades des pointes) 
(187). On the contrary, gain-of-function mutations in potassium channels involved in AP repolarization leads to a 
shortening of the AP duration, which can develop in a SQTS and also cardiac arrhythmias. These different 
channelopathies can finally develop sudden cardiac death. KV7.1/KCNE1 channels are highly regulated channels. 
They are regulated by different compounds and are targets for antiarrhythmic drugs(152, 153, 157, 188, 189). PIP2 
modulation of KV7.1 is coupled to cardiac physiology via α1-adrenergic receptors (190). In this manner, less activity 
of KV7.1/KCNE1 channels are observed as a consequence of the decrease of α1-adrenergic stimulation, when the 
levels of PIP2 are reduced. Therefore, in this situation, the cardiac action potential is prolonged (133). 
In addition, activation of the β1-adrenergic receptor results in the activation of KV7.1/KCNE1 channels via cAMP. β1-
adrenergic stimulation is involved in the increase of cardiac rates, which leads to the shortening of cardiac action 
potentials. This process is especially important in stressed-mediated situations (191). The increase of cAMP levels 
involves the activation of PKA, which through the macromolecular complex of the AKAP Yotiao and C-terminus of 
KV7.1 channels drives the phosphorylation of the N-terminus of the KV7.1 α-subunit (132). The phosphorylation not 
only increases the magnitude of IKs, but also accelerates the activation process promoting the shortening of the 
cardiac action potential (132, 192).
 
Figure 8: KV7.1/KCNE1 channels and the ventricular 
myocyte action potential. A: KV7.1 α -subunit and KCNE1 
subunits suggested stoichiometry of KCNE-containing KV 
channel complex. B: ventricular action potential waveform 
indicating the major ionic currents that contribute to its 
morphology and duration. Adapted from: Crump et al., 
(2014) Front Genet 24;5:3. 
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1.5.3 Physological role of n-6 and n-3 PUFAs on KV7 channels 
Omega 3 (n-3) and omega 6 (n-6) polyunsaturated fatty acids (PUFAs) are essential nutrients. They are mainly 
obtained from diet in foods such as fish and vegetal oils (for n-3 PUFAs, EPA / DHA and ALA, respectively), and from 
vegetal oils or meats for n-6 PUFAs (AA) (193). Docosahexanoic acid (DHA) and Arachidonic acid (AA) are the most 
abundant fatty acids in mammalian membrane.  
n-3 and n-6 PUFAs are integrated in plasma membrane as part of phospholipids. They not only playing a 
fundamental structural role and contribute to membrane fluidity, but also regulate several processes as free PUFAs 
(being released by the activity of different phospholipases, such as PLA2, PLC or PLD, PUFAs). 
The dramatic increase in the n-6/n-3 ratio in the diet of the population of Western countries after the industrial 
revolution has, at least in part, contributed to the rise in cardiovascular disease (194, 195). An increased intake of 
omega 3 fatty acids (n-3 PUFAs) has been reported to have beneficial properties for cardiovascular health (196) and 
neurological disorders such as epilepsy and pain (197). Sinclair et al described in 1944 the rarity of cardiovascular 
disease CVD in Greenland Eskimos, who consumed a diet rich in n-3 PUFAs (whale, seal and fish) (198, 199). Since 
that moment, large evidence from cellular and animal studies (200) and from clinical trials outcomes (201-204) 
suggested that an increased intake of fish oil fatty acids has favorable effects on cardiovascular health. These 
beneficial effects mainly occur through the prevention of sudden cardiac death (SCD) that is often preceded by 
ventricular arrhythmias; suggesting that n-3 PUFAs are antiarrhythmic. However, not all studies have demonstrated 
cardioprotective effects in CVD with PUFA consumption. The recent randomized trials Alpha OMEGA and OMEGA 
involving patients who suffered a myocardial infarction did not showed any improvement in the clinical results 
following n-3 PUFA supplementation (205, 206). Moreover, pro-arrhythmic actions have been also described for n-3 
PUFAs in animal models during acute regional myocardial ischemia (207) and a deleterious effect due to an increase 
risk of cardiac death was reported in men with stable angina (without myocardial infarction) advised to eat fish (208) 
and in patients with an implantable cardioverter defibrillator (ICD) (209). These differences could be explained by the 
fact that a diet rich in fish oil could be antiarrhythmic in some patients and proarrhythmic in others. 
PUFAs affects in a different way the voltages gated channels. It has been described that PUFAs modulates cardiac 
ion currents, i.e. it inhibits IKur, Ito, ICa, and IKr and it increases IK1 and IKs. It is also described that PUFAs block NaV 
channels (210-218). 
The mechanism of action by which PUFAs modify ion channel activity has been debated for years. Several theories, 
ranging from: 1) nonspeciﬁc effects on the cell membrane (219) to: 2) speciﬁc binding to the ion channel (213, 220-
223), have been proposed. The identification of residues in the ion channel protein involved in n-3 PUFAs sensitivity 
argues in favor of the second theory. Thus, for hKCa1.1 channels, PUFAs binding site is located in the pore domain 
segments (S5-S6). Moreover, Hoshi and colleagues, described that DHA increased hKCa1.1 currents, but it was 
greater in the presence of specific beta-regulatory subunits (290). For shaker K+ channels and KV7.1 channels, it has 
been proposed that DHA binding site is localized in the S3-S4 of the VSD  
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Indirect mechanism has also been suggested, PUFAs can alter the lipid composition of the membrane, i.e. the 
reported effects on the cell membrane fluidity. 
The effects of AA and DHA on HERG channels were tested in CHO cells. Both PUFAs block HERG channels in a 
time-, voltage- and state-manner, which is consistent with an open channels block mechanism. DHA showed more 
affinity for this state of the channel than AA. It seems that AA also interact with the inactivate state; this modulation 
by AA was also observed in other K+ channels. Previously reports showed that AA introduced a rapid-voltage 
inactivation into non-inactivating KV channels (allosterically closure mechanism) (210-218). 
During ischemia and reperfusion, AA levels rise at the intracellular and extracellular levels (306). This increase is 
related to a protected role to prevent arrhythmias. Moreover, similar role has been proposed to DHA because it 
blocks NaV and CaV channels and enhances IKs currents. In all these situations, there is a shortened of the cardiac 
AP. In addition, these compounds block IKr, IK1 and Ito which results in a lengthened cardiac AP. The sum of the 
results suggests an elongate refractory period and a shorter cardiac excitability (210-218).  
Among other targets, the beneficial actions of n-3 PUFAs occur through the modulation of KV7 channels. In the heart, 
n-3 PUFA decrease the expression of KV7.1 channels reducing the risk of arrhythmia by shortening the action 
potential duration (216, 225, 226). In the neuronal system, the activation of KV7.2/KV7.3 channels (major components 
of the neuronal M-current) decreases neuronal excitability and therefore the risk of seizure (227). 
On the contrary, the effects of n-6 PUFAs are associated with pro-inflammatory processes (228). For instance, the 
increase in the n-6/n-3 ratio, promoted by a disbalance diet, raises the risk of cardiovascular diseases (229).  
1.5.3.1 n-6 and n-3 PUFAs derivatives are specific pro-resolving mediators  
The inflammation process exhibits two active steps, the pro-inflammatory and the resolution phases. The last one 
was considered a passive one until few years ago. Both are orchestrating by different immune cells and compounds, 
whose composition and levels change through the development of the whole process. Resolution of acute 
inflammation involves a recruitment of active programs, which make possible return to pre-inflammatory states (230). 
n-6 PUFAs metabolites: Lipoxins 
AA is an essential fatty acid involved in a plethora of physiological process. Its metabolism generates several 
compounds (prostaglandins PGs, tromboxanes TXs, leukotriens LTs, and HETEs) that are involved in different 
processes such as inflammation, control of the vascular tone, platelet aggregation, etc. In general they are related 
with in pro-inflammatory effects (231). However, AA-derived metabolites, such as LXA4 and e-LXA4, have an active 
role in the resolution phases of the inflammatory processes (232). Briefly, AA is metabolized by two main enzymes; 
COX (COX1, constitutively active, and COX2, triggered by aspirin and inflammatory processes) and LOX enzymes. 
COX especially promotes the synthesis of PGs, whereas LOX activity leads the synthesis of 5-HETE, 5-HpETE and 
LT (series 4) both mainly in cells of the immune system (granulocytes, mastocytes, monocytes and macrophages) 
(228). LXA4 and e-LXA4 are products of the LOX-5 and COX-2 metabolism, respectively (see scheme below, Figure 
9). The effects triggered by LXA4 and e-LXA4 are mediated, at least in part, by the ALX receptor (233, 234)
Introduction 
 
20 
 
 
 
n-3 PUFAs metabolites: Resolvins 
Increased levels of EPA and DHA in the plasma membrane displace AA of the lipid environment. This increase in n-3 
PUFAs also displace the enzymatic production balance to the production of n-3 PUFAs-derived metabolites (231, 
235). The main n-3 PUFAs derivatives are maresins, protectins and resolvins. These derivatives, together with LXA4 
and e-LXA4, act in the resolution of inflammation and are known as SPMs (specialized pro-resolving mediators).  
There are two main groups of resolvins (Rv): i) metabolites from EPA (RvE), and ii) DHA metabolites (RvD). RvE 
group can also be subdivided in RvE1 and RvE2. RvD can be subdivided in those that appear in the absence of 
aspirin (17-S-hidroxi Rv, 17-S RvD1) and those triggered by the consumption of aspirin and that are metabolized 
through the activity of COX-2 (17-R-hidroxi,17-R RvD1 or ATRvD1). 
It is important to mention that n-3- and n-6-derived metabolites (resolvins and lipoxins) share the same cellular 
receptor (230). 
In inflammation there is an increase in the enzymatic synthesis of resolvins. RvD1 showed a potent anti-inflammatory 
and pro-resolution effectiveness. It has been observed in kidney ischemia an improving of the functional and 
morphological injury, reducing the interstitial fibrosis and blocked Toll-like receptor that mediates macrophages 
activation (236-238). Moreover, RvD1 blocked the neutrophil recruitment and also controls inflammation after 
oxidative stress. Several cardiovascular diseases, such as atrial fibrillation, myocardial infarction or heart failure, 
involve inflammation (104, 239-241). Therefore, the knowledge of the precise mechanisms that lead these 
mechanisms may help to find new molecular targets for the treatment and/or prevention of these diseases. 
Figure 9: Schematic view of Arachidonic acid metabolism. Modified from: Yee-Ping 
et al., (2009) Prostaglandins Leukot Essent Fatty Acids 81(5-6):357-366.  
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Figure 10: Schematic view of Resolvins Synthesis route. n-3 PUFAs are derived from dietary essentially fat (especially enriched 
in fish). RvD1 and AT-RvD1 are derived from DHA, whereas RvE1 is derived from EPA. COX-2, cytochrome P450, and 5- and 15-
lipoxygenase enzymes are involved in these processes. Adapted from: Ji R et al., (2011) Trends Neurosci. 34:599-609. 
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Voltage dependent potassium channels are membrane proteins highly modulated by several physiological, 
pharmacological and pathological events and are involved in a plethora of pathophysiological process, including 
immune response, cardiac arrhythmias and vascular function. 
It has been demonstrated that KV7 channels control vascular tone (182, 242). Indeed, KV7 biophysical properties 
resemble K+ currents recorded in arterial and venous musculature. However, a relationship between functional 
currents and specific genes has not been established (242). Heterotetramerization of KV7 isoforms shapes K+ 
currents, and this complexity is further increased by KCNE regulatory subunits (243, 244). Cardiovascular 
musculature mostly expresses KV7.1, KV7.4, and KV7.5 channels (111, 181). Accordingly, KV7 blockers produce 
contractions that may vary in magnitude depending on the vascular bed (245, 246). The existence of channel 
combinations makes difficult to decipher pharmacological implications. Therefore, determining the KV7 isoforms that 
control smooth muscle tone is crucial. 
It has been described that n-3 or n-6 PUFAs can exert anti- or proarrhythmic actions, maybe due to their interaction 
with cardiac ion channels. However, the effects of n-3 and n-6 PUFAs and their metabolites (LXA4, 15-epi-LXA4 and 
RvD1) on KV7 channels and their different effects after acute or chronic administration are not completely understood 
(247). The scenario becomes more difficult because PUFAs active metabolites are involved in the resolution of 
inflammation (230, 248) (lipoxins and resolvins), and their effects on cardiac KV channels have not been studied until 
now. They can exert their anti-inflammatory effects through their initial actions on KV channels.  
The Hypothesis of the present Doctoral Thesis is that KV7 channels have crucial effects on the cardiovascular 
system, and that the effects of polyunsaturated fatty acids and their derivatives on these channels can trigger 
important effects on cardiac arrhythmias and vascular tone. 
The Main Objective of the present Doctoral Thesis is to analyze the functional effects of KV7 channels in vascular 
smooth muscle, and their modulation by polyunsaturated fatty acids and their metabolites (LXA4, 15-epi-LXA4 and 
RvD1) on KV7.1/KCNE1 channels. 
In order to achieve this Objective, our specific objectives are to determine: 
 The role of KV7.1/KV7.5 channels in vascular smooth muscle. 
 The electrophysiological effects of docosahexaenoic (n-3) and arachidonic acids (n-6) on KV7.1/KCNE1 
channels. 
 The electrophysiological effects of 15-epi-LXA4, LXA4 and resolvin D1 on KV channels in bone marrow 
derived macrophages and in KV7.1/KCNE1 channels. 
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3.1 PRIMARY CELL CULTURE 
3.1.1 Rat blood vessel myocytes 
The procedures used conformed the NIH guidelines (Guide for the care and use of laboratory animals) (NIH 
publications number 23–80) revised in 2011; and from Directive 2010/63/EU of the European Parliament on the 
protection of animals used for scientific purposes were approved by the Ethics Committee of the University of 
Barcelona. Rat aorta, coronary artery and cava venous myocytes were isolated by enzymatic digestion as previously 
described (249) and they were used for confocal and electrophysiological studies (250). Briefly, coronary arteries 
(250-350 μm internal diameter) were isolated from male Wistar rats (250 to 300 g) in Krebs solution. For myocyte 
isolation, arteries were cut into small segments and placed into a nominally Ca2+-free physiological salt solution 
(PSS, Table 2) containing (in mg/mL): papain 1, dithiothreitol 0.8, and albumin 0.7 for 20 min. Thereafter, artery 
segments were incubated for additional 15 min in Ca2+-free PSS (Table 2) containing (in mg/mL) collagenase F 1, 
collagenase H 0.3, and albumin 0.7. Cells were stored in Ca2+-free PSS (4 ºC) and used within 8 h of isolation (Table 
2). These experiments were performed in Drs. Cogolludo and Felipe´s Laboratories. (250). 
3.1.2 Guinea-pig cardiac ventricular myocytes 
The procedures used conformed the NIH guidelines (Guide for the care and use of laboratory animals) (NIH 
publications number 23–80) revised in 2011; and from Directive 2010/63/EU of the European Parliament on the 
protection of animals used for scientific purposes and approved by the University of Milano-Bicocca ethics review 
board. 
Adult Dunkin-Hartley guinea-pig were anesthetized by 100 mg/kg sodium thiopental (Sigma Aldrich) and euthanized 
by cervical dislocation and exsanguinated. Cardiac ventricular myocytes were isolated by using a retrograde 
coronary perfusion method previously published (251) with minor modifications. Briefly, hearts were quickly removed, 
and the ascending aorta was connected to the outlet of a Langendorff column, perfused with: 1st) normal Tyrode’s 
solution (37°C), 2nd) Ca2+-free Tyrode solution, 3rd) Ca2+-free Tyrode solution with collagenase and trypsin and 4th) 
Ca2+-free Tyrode solution. Cells were maintained at 4ºC until use (225). These experiments were performed in Dr. 
Zaza´s Laboratory. 
3.1.3 Bone marrow-derived macrophages (BMDM) 
The procedures used conformed the NIH guidelines (Guide for the care and use of laboratory animals) (NIH 
publications number 23–80) revised in 2011; and from Directive 2010/63/EU of the European Parliament on the 
protection of animals used for scientific purposes and approved by the Institutional committee on bioethics 
(authorization 28079-37A to the Instituto de Investigaciones Biomédicas “Alberto Sols”, Madrid). BALB/c mice (aged 
8 to 12-weeks) were sacrificed by CO2 chamber euthanasia. Pelvises, femurs and tibiae were dissected removing 
adherent tissue. Total bone marrow was obtained by flushing pelvises, femurs and tibiae with Dulbecco´s Modified 
Eagle´s Medium (DMEM). Bone marrow mononuclear phagocytic precursor cell were propagated in suspension by
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 culturing in DMEM containing 10% fetal bovine serum (FBS), 100 UmL-1 penicillin, 100 µgmL-1 streptomycin (all from 
Gibco, ThermoFisher), and 0.2 nM recombinant murine M-CSF (Pepro-Tech) in tissue-culture plates. The precursor 
cells were becoming adherent within 7 days of culture. For priming of BMDM, cells were maintained in DMEM 
medium supplemented with 10% FBS for 14 h prior to use. Experiments were carried out in phenol-red free DMEM 
medium and 2% of heat-inactivated FBS plus antibiotics (234). The cellular extraction was performed in Dr. Boscá´s 
Laboratory. 
3.2 CULTURE CELL  
3.2.1 COS-7 cells  
The fibroblast-like cell line from African green monkey COS-7 was obtained from the American Type Culture 
Collection (Rockville, MD, US). COS-7 cells were cultured in DMEM supplemented with 10% FBS, 100 U mL-1 of 
penicillin and 100 µg mL-1 streptomycin (all from Gibco). Cells were grown in a humidified atmosphere with 5% CO2 
at 37ºC. COS-7 cells have an endogenous acid-sensitive K+ current (252) which did not interfere with the recordings 
obtained after transfecting the cells with KV7 subfamily channels, which are the potassium channels of our interest. 
Moreover, these cells do not express any endogenously accessory subunits, which could interfere or modify the 
current of interest, being COS-7 a good cell model for this study. 
For electrophysiological recordings, cells were incubated in 35 mm pretreated sterilized dishes, whereas for protein 
extraction and Western blot, cells were grown in 100 mm culture dishes (Falcon). 
3.2.2 HEK293 cells 
The HEK293 cell line (Human Embryonic Kidney derived cell line) was obtained from the American Type Culture 
Collection (Rockville). HEK293 cells were cultured in DMEM supplemented with 10% FBS, 100 UmL-1 of penicillin 
and 100 UmL-1 streptomycin (all from Gibco). HEK293 cells exhibit a very small endogenous KV currents (~200 pA) 
(253), which do not interfere with the currents elicited by the over expression channels that were transfected in this 
study. It is also a good cellular model because, although the mRNA of regulatory subunits has been observed; there 
is no evidence of this type of proteins which could modulate the channels of interest (253). For patch-clamp 
experiments, cells were grown in 35 mm sterilized dishes (Falcon). For confocal studies, HEK293 cells were plated in 
poly-lysine coated coverslips (136, 254). 
3.2.3 Transfection process 
For patch-clamp experiments, KCNQ1 and KCNQ5 cDNA were transfected or co-transfected in COS-7 cells using 
0.5 g pEYFP-N1-KCNQ1 plasmid that codifies for KV7.1 channels and 1 g pEYFP-N1-KCNQ5 plasmid that 
codifies for KV7.5 channels (both kindly provided by Dr. Felipe, University of Barcelona, Barcelona, Spain). For the 
electrophysiological studies on KV7.1/KV7.5 heterotetrameric channels, both plasmids were co-transfected. For 
electrophysiological experiments with omega-3 and omega-6 PUFAs, and their metabolites on the KV7.1-KCNE1
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 currents, transfection of COS-7 cells was performed with 0.5 g pEYFP-N1-KCNQ1 and 0.5 g pECFP-C1-KCNE1 
(which codifies for KCNE1 regulatory subunits).  
In those experiments in which the electrophysiological effects of lipoxin A4 (LXA4) and 15-epi-lipoxin-A4 (e-LXA4) on 
KV1.5 and KV1.3 currents were analyzed, HEK293 cells were transfected with KV1.5 (0.5 µg) and KV1.3 (0.2 µg). 
KV1.5 was cloned into a modified pBK plasmid (kindly provided by Dr. M.M. Tamkun, Colorado State University, Fort 
Collins, CO, USA) and KV1.3 cloned into pEYFP-C1 (gift from Dr A. Felipe, University of Barcelona, Barcelona, 
Spain). In all cases, transfection was performed together with 0.5 g of the reporter plasmid EBO-pcD-Leu2-CD8 (for 
selection transfected cells) per 35 mm culture dish (136). 
Transient transfections were carried out in cells at 60-80% confluence following the FuGENE6 transfection method 
(Promega). The ratio g DNA:L Fugene was 1:3. Before experimental use, transfected HEK293 or COS-7 cells 
were incubated with polystyrene microbeads precoated with anti-CD8 antibody (Dynabeads M450, Dynal) 
 
For confocal studies, coinmmunoprecipitation and Western blot (WB) analysis, HEK293 cells were transfected with 
MetafecteneTM (Biontex) nearly at 80% confluence, following the manufactor’s directions. 
For protein extraction and posterior WB related to the effects of n-3 PUFAs, 100 mm culture dishes were transfected 
at 60 to 80% confluence with 4 g of pEYFP-N1-KCNQ1 with or without 4 g pECFP-C1-KCNE1 using Fugene 6 
(see above). Afterwards, culture cells were incubated (48 h) with DHA (30 and 100 M) or without it for control 
conditions. 
3.3 DRUGS AND REAGENTS 
The KV7 specific activators and blockers used in the present Doctoral Thesis were: retigabine (RTG, also called 
ezogabine), chromanol 293B and linopirdine (Table 1). All of them were dissolved in DMSO to yield stock solutions of 
3.10-2 M. RTG stock solution was diluted to 1-30 µM concentration, with external solution for its use in patch-clamp 
and in rat arterial reactivity experiments. Further dilutions of chromanol 293B and linopirdine stock solution were 
performed as previously described (250). 
In the present Doctoral Thesis, we used DHA (n-3 PUFA) and Arachidonic acid (AA) (n-6 PUFA) (Table 1). Both 
PUFAs were diluted in absolute ethanol to yield stock solution of 10-2 M and 10-4 M. DHA and AA were ampoule
Figure 11: Polystyrene microbeads 
binding cells as selection process.  
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 aliquoted and stored under an inert argon atmosphere (in order to prevent oxidation of the samples) at -20 ºC. DHA 
was used at the concentration range of 20-100 µM and AA was used at a concentration of 20 µM, after being diluted 
in external solution (see below) (212). 
Table 1: Classification of products used. Left to right: common name, chemical name and reference. 
Common name Chemical name Reference and origin 
Retigabine 
N-(2-Amino-4-(4-fluorobenzylamino) phenyl) 
carbamic acid ethyl ester 
90221- Sigma-Aldrich 
Chromanol 293B 
trans-N-[6-Cyano-3,4-dihydro-3-hidroxy-2,2-
dimethil-2H-1-benzopyran-4-yl]-N-methyl-
ethanesulfonamide 
C2615- Sigma-Aldrich 
Linopirdine 
1,3-Dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-2H-
indol-2-one 
L134- Sigma-Aldrich 
Docosahexanoic acid 
(DHA) 
cis-4,7,10,13,16,19-Docosahexaenoic acid 53171- Sigma-Aldrich 
Arachidonic acid (AA) Eicosa-5Z,8Z,11Z,14Z-tetraenoic acid 10931- Sigma-Aldrich 
17(S)-Resolvin D1 
(RvD1) 
7S,8R,17S-trihydoroxy-4Z,9E,11E,13Z,15E,19Z-
docosahexaenoic acid 
Sc-204877- Santa Cruz 
Biotechnology 
Lipoxin A4 (LXA4) 
5S,6R,15S-trihydroxy-7E,9E,11Z,13E-
eicosatetraenoic acid or 5(S),6(R),15(S)-triHETE 
90410- Cayman Chemical 
Company 
15-Epi-lipoxin A4 (e-
LXA4) 
5(S),6(R),15(R)-trihydroxy-7E,9E,11Z,13E-
eicosatetraenoic acid 
90415- Cayman Chemical 
Company 
 
The effects of DHA and AA metabolites, 17(S)-Resolvin D1 (RvD1), LXA4 and 15-e-LXA4 were also studied (Table 1). 
These compounds were dissolved in ethanol and stored protected from light at -80 ºC to prevent oxidation. They 
were used, for electrophysiological recordings, at a 5-500 nM concentration range. 
3.4 ELECTROPHYSIOLOGICAL RECORDINGS 
Electrical activity is part of animal physiology. In the XIX century, experiments performed by Galvani (1791), Volta 
(1792) and Matteuci (1840) detected bioelectricity. They showed that the muscular contraction could be induced after 
applying electrical stimulation. In the early 50´s, Cole and Marmont introduced the basis of the work which make 
possible that Hodgkin and Huxley investigate the time- and voltage- conductance for Na+ and K+ ions that form the 
basis of the time course of the action potential (3, 4). These studies led them to get the Nobel Prize in 1963. Later on, 
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Sackmann and Neher (1976) developed the patch-clamp technique that permits the recording of the activity of single 
ion channels after establish high resistance seals between microelectrodes and the cell membrane. They got the 
Nobel Prize of Physiology or Medicine on 1991. 
The electrophysiological experiments used in the present Doctoral Thesis were performed by using the patch-clamp 
technique (255). The aim of this technique is the recording of ionic currents, generated either: 1) by a single ion 
channel (i: unitary current) or 2) by the activation of all the channels present in the cell membrane or in a membrane 
patch (I: macroscopic current). In the present Doctoral Thesis, we have recorded the current generated by the 
activation of all channels present in the cell membrane.This technique is a refinement of the voltage-clamp technique 
and uses a glass micropipette pulled to a fine tip of approximately 1-4 m containing an electrode. The recording 
electrode or “patch pipette” is filled with a saline solution and sealed (with a high resistance, G) onto a patch on the 
surface of the cell membrane, allowing the researcher to keep constant the voltage while measuring the current 
flowing across the membrane of a cell or even from a single channel localized in the membrane patch. 
Several configurations of the patch-clamp technique were developed (cell-attached, whole-cell, inside-out and 
outside-out patch-clamp). The most commonly used when studying macroscopic ion currents across the cell is the 
whole-cell patch-clamp technique. In this approach, after the seal is formed between the electrode and the cell 
membrane, a gentle suction is applied, rupturing the cell membrane in the patch and gaining access to the 
cytoplasm. Consequently, the internal pipette solution enters in direct contact with the intracellular space. The cell 
membrane is voltage clamped, and the recorded currents are a composite of the activity of all ion channels present in 
the cell membrane (Figure 12). 
A variation of the same procedure is the perforated-patch technique. In this configuration, the internal solution 
contains a small concentration of an antifungal agent (like amphotericin B or nystatin), which diffuses into the 
membrane patch forming small pores in the cell membrane, which provides electrical access into the intracellular 
space, without dialyze the cell cytoplasm; thus, retaining most intracellular signaling mechanisms. 
In the present Doctoral Thesis, the whole-cell and the perforated patch-clamp configurations were used to record the 
ion currents. Before experimental use, transfected HEK293 or COS-7 cells were incubated with polystyrene 
microbeads precoated with anti-CD8 antibody (Dynabeads M450, Dynal). A suspension of guinea-pig ventricular 
myocytes, rat vascular myocytes, BMDM, HEK293 or COS-7 cells were plated in a 0.5 mL chamber which was over 
an inverted microscope (TMS, Nickon). After 15 min for settlement of the cells, they were perfused with external 
solution (which mimics extracellular media, Table 2) at a constant speed.  
Micropipettes were made from borosilicate glass capillary tubes (GD-1 model, Narishige) on a horizontal puller (P-87 
model, Sutter Instrument Co.) and heat-polished with a micro-forge (MF-83, Narishige). After heat-polishing, the 
resistance of the patch electrodes tip (filled with the internal solution) averaged 2-4 M. The patch electrodes were 
filled with an internal solution whose composition mimics the cytosol media (see below, Table 2). 
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Figure 12: The patch clamp technique configurations. The started configuration cell- atached (A) from which it is possible to 
achieved the others. (B) Whole cell configuration, (C) Outside-out configuration and (D) inside-out configuration. Modified from: 
Hamill et al., (1981) Pflügers Arch. 391:85-100 
In BMDM, transfected HEK293 cells, guinea-pig ventricular myocytes and rat coronary myocytes, the whole-cell 
configuration of the patch-clamp technique was used (234). Transfected HEK293 cells and rat coronary myocytes, 
currents were recorded at room temperature (23-25ºC) at a stimulation frequency of 0.03 Hz. In rat coronary 
myocytes, to reduce the contribution of other delayed rectifier potassium currents (such as KV1), long (4 s) 
depolarizing pulses were applied (249). Current-voltage relationships (I-V relationships) were constructed by 
measuring the currents at the end of the pulse (250). 
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 Table 2: Composition of the internal and the external solutions of different cell types.  
                                         Internal solution 
                                       (mM) 
                     External solution 
                   (mM) 
 
Cell 
lines 
Guinea-pig 
myocytes 
Vascular 
smooth 
muscle 
cells 
 
Cell 
lines 
Guinea-pig 
myocytes 
Vascular 
smooth 
muscle 
cells 
K-aspartate 80 110  NaCl 130 154 130 
KCl 50 23 110 KCl 4 4 5 
Phosphocreatine 3 5 - CaCl2 1.8 2 - 
CaCl2 - - - 
MgCl2 1 1.2 1.2 MgCl2  - 3 1.2 
KH2PO4 10 - - 
Mg-ATP 3 - - HEPES-Na 10 5 10 
Na-GTP  - 0.4 - 
glucose 10 5.5 10 
Na-ATP  - 5 5 
HEPES-K 10 5 10 
EGTA-K 5 10 10 
Adjusted with 
KOH 
pH 7.25 pH 7.3 pH 7.3 
Adjusted 
with NaOH 
pH 7.40 pH 7.40 pH 7.3 
 
Isolated guinea-pig ventricular myocytes were re-suspended in external solution (Table 2). Only rod-shaped, Ca2+- 
tolerant myocytes were used within 12 h from dissociation. Measurements were performed only in quiescent 
cardiomyocytes with clear-cut striation at physiological temperature. The solution temperature was monitored at the 
pipette tip with fast-response digital thermometer (BAT-12, Physitemp) and kept at 36 ± 0.5 °C. The composition of 
the internal solution used in the experiments performed in guinea-pig ventricular myocytes is shown in Table 2. IKs 
was elicited after applying a 5 s depolarizing step at +20 mV every 20 s. Holding potential was set at 
-40 mV to inactivate Na+ channels. Nifedipine (10 µM) and E-4031 (5 µM) were added to the external solution (Table 
2) to inhibit the L-type Ca current (ICaL) and the rapidly activating delayed rectifier K+ channel (IKr), respectively (225).
Elicited currents from COS-7 transfected cells were registered using the perforated patch-clamp configuration of the 
patch-clamp technique. Amphotericin B (100 μg/mL) (PHR1662- Sigma-Aldrich) was added to the internal solution to 
make pores in the membrane seal (203, 207, 256, 257). 
Electrophysiological recordings were performed using an Axopatch-200B amplifier (Molecular Devices, Sunnydale, 
CA, USA). Current recordings were low pass-filtered and sampled at 2 kHz with an analog-to-digital converter 
DigiData 1440A (Molecular Devices) (data acquisition system). Command voltages and data storage were controlled 
with pClamp10 software (Axon Instruments). Gigaohm seal formation was achieved by suction (2-5 GΩ). Thereafter, 
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capacitance and series resistance compensation were optimized and, usually, 80% compensation of the effective 
access resistance was obtained. Uncompensated series resistances were 4-8 M and voltage errors from 
uncompensated series resistance were less than 2 mV. 
The holding potential was set to -80 mV (unless other comments are stated), and the interpulse interval was set to a 
minimum of 10 s or 30 s, depending on the ion current that we are recording. The voltage pulse protocols were 
adjusted to determine the biophysical properties of each channel. Time constants of activation, inactivation and 
deactivation were determined by fitting the current recordings with a single or double exponential functions: 
y = A1exp (-t/τ1) + A2exp (-t/τ2) + C 
where τ1 and τ2 are the system time constants, A1 and A2 are the amplitudes of each component of the exponential, 
and C is the baseline value (207, 256, 258, 259). The voltage dependence of channel activation was fitted to a 
Boltzmann equation: 
y = 1/[1 + exp((E Vh)/s)] 
in which s represents the slope factor, E represents the applied voltage, and Vh the voltage at which 50% of the 
channels are activated (136, 258). Origin 8.5 (OriginLab Software, Northampton, MA) and CLAMPFIT software were 
used to analyze data, perform least-squares fitting and for data presentation. 
3.5 RECORDING OF RAT ARTERIAL REACTIVITY  
For contractile tension recording, rat endothelium-intact coronary arteries rings were mounted in a wire myograph as 
previously described (249). After an equilibration period of 30 min, vessels were stretched to a resting tension 
corresponding to a transmural pressure of 100 mmHg. Coronary artery rings were first stimulated by raising the K+ 
concentration of the buffer (to 80 mM) in exchange for Na+. Vessels were washed three times and allowed to recover 
before a new stimulation (185, 250). 
Afterward, vessels were incubated with vehicle (DMSO, control), chromanol 293B (10 µM) or linorpiridine (10 µM) 
during 20 min before the stimulation with serotonin (5-HT, 1 µM). Finally, the relaxation induced by RTG (1-30 µM) 
was analyzed (185, 250). 
3.6 INMUNOCYTOCHEMISTRY 
Enzymatically isolated smooth muscle cells from rat coronary aorta or cava vessels were seeded into sterile 12 mm 
diameter gelatine coated glass coverslip for up to 48 hours. After fixation for 15 min with methanol (-20 ºC) at room 
temperature, cells were washed twice with phosphate buffered saline (PBS) during 5 min to rehydrate cells and 
block. Cells were permeabilized during 1 h with blocking buffer (PBS containing 0.4% Triton X-100 and 3% bovine 
serum albumin). After incubating with rabbit anti-KV7.1 (1:100, APC-022 Alomone Labs) and rabbit anti-KV7.5 (1:500, 
APC-155 Alomone Labs) antibodies at 4 ºC overnight, cells were incubated at 37 ºC for 15 min. Cells were washed 
Material and Methods 
37 
with wash buffer (PBS containing 3% bovine serum albumin) and exposed to a secondary antibody CY3 conjugated 
donkey anti-rabbit (1:200, Jackson inmunoresearch) for 2 h. Then, cells were stained with 4,6-diamidino-2-
phenilindole (DAPI) for 5 min at 37ºC. Glass coverslips were mounted with Aqua Poly/Mount (from Polysciences, 
Inc). These preparations were examined with a Leica TCS SL laser scanning confocal spectral microscope (Leica 
Microsystems). A 63× oil immersion objective lens (NA 1.32) and a double dichroic filter (458/514 nm) was used to 
acquire images (250). 
3.7 PROTEIN EXTRACTION, CO-INMUNOPRECIPITATION AND WESTERN 
BLOT 
Rat heart, brain, aorta and cava were frozen in liquid nitrogen. Samples were softly processed with a polytron 
homogenizer in MBS (0.15M NaCl, 25 mM MES) at 4 ºC. Nuclei and debris were pelleted by centrifugation at 12,000 
× g for 10 min. The resulting supernatant was centrifuged at 100,000 × g for 1 h. The pellet of crude membranes was 
resuspended in the same buffer (0.5 mL/g tissue). 
In the case of HEK293 cells, they were lysed (24 h after transfection) in 1% Triton X-100, 50 mM Tris, pH 7.2, 150 
mM NaCl, 1 mM EDTA supplemented with 1 μg/mL aprotinin, 1 μg/mL leupeptin, 1 μg/mL pepstatin and 1 mM 
phenylmethylsulfonyl fluoride. Homogenates were centrifuged at 12,000 × g for 10 min, and the supernatant was 
aliquoted and stored at -20ºC. 
For co-immunoprecipitation experiments, samples were pre-cleared with protein G/A-Sepharose beads (Santa Cruz 
Biotechnology) in order to eliminate not specific binding between the reagents used and the proteins. Then, A/G 
protein was precipitated and discarded. The samples were incubated overnight with monoclonal anti-GFP, which also 
reacts with YFP, and polyclonal anti-KV7.1, -KV7.5 and -KCNE1 antibodies (4 ng/μg protein, Roche) at 4 °C. Protein 
sepharose (30 μl) was added to each sample for 4 h at 4 °C. Antibody-bound sepharose beads (and therefore, 
protein-bound antibody) were centrifuged at 5,000 × g for 45 s at room temperature and then washed to remove all 
the antibody and channel unbound or non-specifically bounded. The beads were removed, washed four 
times in NGH buffer (50 mM HEPES, 150 mM 5 NaCl, 1% Triton X-100, 10% Glycerol, pH 7.2) and resuspended in 
70 μl of Laemmli SDS loading buffer. Protein samples (50 μg) and immunoprecipitates were boiled in Laemmli SDS 
loading buffer and were separated on 10% SDS-PAGE gels. Samples were transferred to nitrocellulose membranes 
(Immobilon-P, Millipore) and were blocked in 5% dry milk with 0.05% Tween-20 in PBS before immunoreactions. 
Membranes were immunoblotted with antibodies against KV7.1 (1:200, APC-022 Alomone Labs) or KV7.5 (in house, 
1:500) (136, 148, 250). These experiments were performed in Dr. Felipe´s Laboratory.  
Transiently transfected COS-7 cells (see above) were incubated in the absence and in the presence 30 and 100 μM 
of DHA and EPA. For total protein extraction, cells were washed and then centrifuged. The pellet was lysed and 
homogenate as previously described in (225). Samples were separated into aliquots and stored at -80ºC. The 
amount of protein (20-40 μg/lane) was resuspended in SDS loading buffer and boiled first at 55ºC during 12 min, in 
order to detect KV7.1, and then heated at 95ºC for 5 min, to analyze KCNE1. Samples were run in 7-10% SDS-
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PAGE, and transferred to a PVDF membrane (GE Healthcare). Membranes were blocked and incubated with anti-
GFP antibodies (1:1000, cat. nº 11814460001 Roche) and anti-β- actin (1:40000, Sc-1615 Santa Cruz 
Biotechnology). Horseradish peroxidase linked goat anti-mouse (1:10000, Calbiochem) as secondary antibody was 
used. Immunoblot signals were visualized by chemiluminescence using ECL-plus reagent (Amersham, GE Healthcare). 
Quantification of band intensity was performed with the Image J software. 
3.8 LIPIDS RAFTS EXTRACTION 
Lipid rafts are specific membrane domains rich in cholesterol and sphingolipids. They are resistant to detergent 
solubilisation at 4°C and are destabilized by cholesterol- and sphingolipid-depleting agents. The methods used to 
isolate the lipid rafts are based on the insolubility of these structures in the non-ionic detergent Triton X-100. 
Following ultracentrifugation on sucrose density gradients, lipid rafts will float away from the soluble proteins, forming 
a cloudy band at the top of the centrifugation tube.  
Lipid raft isolation was performed from HEK293 cells transiently transfected with pECFP-N1-KCNQ1, pEYFP-N1-
KCNQ5 and co-transfected with pECFP-N1-KCNQ1/pEYFP-N1-KCNQ5, and also from COS-7 cells transiently 
transfected with pECFP-N1-KCNQ1 and pECFP-N1-KCNE1. In the last case, cells were previously incubated in the 
absence and in the presence of 100 µM of DHA, and crude membrane preparations from rat tissues were used as 
samples in lipids rafts isolation assay, as previously described (260, 261).  
Briefly, transfected cells were washed twice in cold PBS, scrapped and centrifuged for 8 min. The pellet was 
resuspended in 0.5 mL of MES-buffered saline containing 1% (v/v) Triton X-100, MES 25 mM, NaCl 150 mM, pH 6.5 
and supplemented protease inhibitors and homogenized by repeated passing (10 times) through a 25G (0.4 × 1.6 
mm) needle. The addition of 1.5 mL of 53.28 % sucrose prepared in MES buffer yielded to the homogenate a final 
concentration of 40 % sucrose and it was placed at the bottom of an ultracentrifuge tube. Then, a 5-30 % linear 
sucrose gradient was formed above the homogenate and centrifuged at 39,000 rpm at 4 ºC for 20-22 h in a SW41 
rotor (Beckman Instruments). A light scattering band confined to the 15-20 % sucrose region was observed that 
contained endogenous caveolin used as a positive control, but excluded most of other cellular proteins. Gradient 
fractions (1 mL) were collected from the top, separated by SDS-PAGE and analyzed by western blotting. Filters were 
inmunoblotted with antibodies against KV7.1 (1:200, APC-022 Alomone Labs) and KCNE1 (1:1000, APC-163 
Alomone Labs) or KV7.5 (in house, 1:500). Caveolin, a marker of lipids rafts fractions, was detected with anti-pan-
caveolin antibody (1:2500, BD Transduction Laboratories), and an anti-clathrin antibody was used to characterize 
non-floating fractions (1:1000, Chemicon) (225, 250). 
3.9 STATISTICAL ANALYSIS  
Data are expressed as mean ± SEM of n experiments. Comparisons were performed by a paired (between means 
values in control conditions versus mean values in the presence of drug for a single variable) or unpaired (between 
two different groups of conditions) Student’s t- test. ANOVA was used to compare more than two groups. Differences 
were considered significant if P < 0.05.  
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4.1 PART I. ROLE OF KV7.1/KV7.5 IN VASCULAR SMOOTH MUSCLE  
4.1.1 Expression of KV7.1 and KV7.5 in different tissues  
KV7 channels are widely distributed in the different tissues and even within different regions of a same tissue. In order 
to know the expression pattern of KV7.1 and KV7.5, several approaches were made.  
Figure 13A shows the levels of expression of these proteins in five different tissues (from rat). On the one hand, 
KV7.1 channel is expressed in brain, skeletal muscle and heart, and, to a lesser extent, in aorta and cava. On the 
other hand, the highest KV7.5 channel expression was observed in brain and aorta, lower in skeletal muscle and 
cava, and it was not present in the heart. The expression pattern of KV7.1 and KV7.5 channels was also analyzed in 
isolated rat coronary myocytes by immunocytochemistry and we observed that both channels are present in these 
cells (Figure 13B). In order to elucidate the presence of homo- and/or heterotetramers of these channels in rat 
coronary myocytes, we analyzed the pharmacology of the K+ currents in these cells (Figure 13C). 
 
 
Figure 13: Expression pattern and function of KV7.1 and KV7.5 channels. A: KV7.1 and KV7.5 abundances in plasma 
membrane preparations of rat brain, quadriceps (skeletal muscle, SkM), heart, aorta artery and cava vein. B: 
Immunocytochemistry of KV7.1 and KV7.5 channels in isolated coronary myocytes from rat. Myocytes were stained with anti-
KV7.1 (left) or anti-KV7.5 (right). Bars represent 20 µm. C: KV currents in isolated rat coronary myocytes. Left panel shows 
representative KV current recordings after applying 4-s depolarization pulses from a holding potential of -60 mV to +10 mV, in the 
absence (black traces) or in the presence of chromanol 293B (10 µM, blue traces) or chromanol 293B plus linopirdine (10 µM, 
red traces). Right panel shows I-V relationships in the absence (control condition, black circles), in the presence of chromanol 
293B (10 µM, blue circles) or in the presence of linopirdine plus chromanol 293B (red circles). Data show the mean ± SEM of 6 
experiments per group. *: P < 0.05, **: P < 0.01 vs.control  
 
Chromanol 293B (selective blocker of KV7.1) and linopirdine (blocker of all members of KV7, (173) were used to 
demonstrate that these currents are, at least in part, the consequence of the activation of KV7 subfamily channels 
(184, 262). Figure 13C shows representative current traces obtained after applying 4 s depolarizing pulses from -60 
to +10 mV recorded in isolated coronary myocytes. Current recordings were studied in the absence (control), in the 
presence of 10 µM chromanol 293B and in the presence of 10 µM linopirdine plus 10 µM chromanol 293B. Block 
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produced by chromanol 293B and chromanol 293B+linopirdine was similar (39.48 ± 4.5 %, n = 6, and 39.35 ± 3.0 %, 
n = 5, P > 0.05, respectively), suggesting that the KV7 subfamily channels are involved in the K+ currents elicited by 
isolated coronary myocytes. Concomitantly to the expression pattern of KV7.1 and KV7.5 channels (Figure 13B), K+ 
currents were similarly blocked by linopirdine and chromanol 293B (Figure 13C).  
KV7 channels are present in several cardiovascular tissues and it is known that they can form heterotetramer 
channels (263, 264). To assess if KV7.1 and KV7.5 channels interact, we first performed co-immunoprecipitation 
experiments in rat aorta myocytes and HEK293 cells (Figure 14). 
 
Figure 14: Co-inmunoprecipitation assay of KV7.1 and KV7.5 channels. A: Anti-KV7.1 and anti-KV7.5 were used for 
immunoprecipitation (IP) and immunoblotting (IB) in rat aorta myocytes. The presence of KCNE1 in the co-inmunoprecipitation 
complex was also analyzed, immunoprecipitating KCNE1. B: KV7.1 inmunoprecipitates with KV7.5 channels in transfected 
HEK293 cells with KV7.1 and KV7.5 channels. Anti-KV7.5 in IP, in experimental condition (left) and in positive control condition 
(right). The resulting IPs were IB with anti-KV7.1 and anti-KV7.5 in experimental condition (left) and in positive control condition 
(right) respectively. SM: starting material, SN: immunoprecipitated supernatant and IPP: immunoprecipitated.  
Figure 14A shows co-immunoprecipitation assays performed in rat aorta myocytes. Both approaches: i) 
immunoprecipitation (IP) with anti-KV7.1 and immunoblotting (IB) with anti-KV7.5 and ii) IP with anti-KV7.5 and IB with 
anti-KV7.1 antibody were done. We obtained positive results in both conditions (IPP detected signal). Because 
smooth muscle cells also express KCNE subunits, an IP with anti-KCNE was performed and it was blotted by using 
both, anti-KV7.1 and anti-KV7.5. In both cases, there was a positive result, although the intensity when IB with anti-
KV7.5 was lower. The results obtained when a co-immunoprecipitation assay was performed in transient transfected 
HEK293 cells with KV7.1-YFP and KV7.5-YFP were similar to those performed in rat aorta myocytes. All these results 
suggest that KV7.1 subunits interact with KV7.5 subunits and that this complex might be interacting with KCNE1 
regulatory subunits.  
4.1.2 KV7.1 but not KV7.5 channels target lipids rafts 
The spatial location of cardiovascular ion channels in lipid raft microdomains is physiologically relevant (265-267). In 
fact, it has been demonstrated that vascular smooth muscle caveolar rafts are important for muscular reactivity (268). 
Previous studies demonstrated that KV7.1 and KV7.5 differentially target to lipid rafts (225, 269, 270). Lipid rafts 
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fractions were detected using caveolin protein, whereas clathrin fractions indicate areas of plasma membrane out of 
lipid-enriched microdomains. We first, transfected HEK293 cells with KCNQ1-YFP or KCNQ5-YFP in order to 
analyze the targeting of each channel. The results confirmed that KV7.1 channels target caveolin-rich membrane 
fraction. In contrast, KV7.5 channels did not fractionate with caveolin.  
 
Figure 15: KV7.1 and KV7.5 channels differentially target to lipids rafts. Caveolin indicates low-buoyancy rafts and clathrin 
distributes in nonfloating fractions, numbers denote different fractions from the top (1) to the bottom (12) of the sucrose density 
gradient. A: KV7.1 channels target to lipids rafts (top) whereas KV7.5 channels not (middle) in previously transfected HEK293 
cells. Both channels were co-transfected in HEK293 cells and they were not detected in lipids rafts (bottom). B: Representative 
sucrose gradient fractions of the heart (top), aorta artery (middle) and cava vein (bottom). 
 
Thus, KV7.1 was enriched in rafts (44 ± 8 %; Figure 15 A-top), whereas KV7.5 was almost completely confined to 
clathrin fractions (90 ± 3%; n = 3, P < 0.05, Figure 15A-middle). We next analyzed whether or not KV7.1/KV7.5 
heterotetrameric channels target lipid rafts. When HEK293 cells were cotransfected with KV7.1 and KV7.5, KV7.1 
shifted out from raft domains (96 ± 7%; Figure 15A). 
Secondly, we analyzed lipid rafts approaches in different tissues (Figure 15B). As we can observe, KV7.1 channels 
were located in caveolin-enriched microdomains in those tissues in which KV7.5 channels were not expressed, as 
heart. However, in the tissues in which both channels were expressed, aorta artery and cava vein, neither of the 
channels targeted  lipids rafts. These results confirm that when KV7.5 channels are present, KV7.1 channels location 
change along the plasma membrane. 
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4.1.3 KV7.5 and KV7.1 α-subunits form functional heterotetrameric channels. 
The co-IP and lipid raft targeting experiments indicate that both KV7.1 and KV7.5 α-subunits physically interact. In 
order to know if these heterotetramers are able to generate a functional channel, patch-clamp experiments in COS-7 
cells transfected with KV7.1, KV7.5 and KV7.1+KV7.5 were performed. To that end, COS-7 cells were transiently 
transfected or co-transfected with KCNQ1-YFP and KCNQ5-YFP plasmids. Figure 16A shows current records 
generated after the activation of KV7.1 or KV7.5 homotetramers and KV7.1/KV7.5 heterotetrameric channels. Currents 
were evoked by a series of 5.5-s pulses from a holding potential of -80 mV to +100 mV in 20 mV steps and returned 
to -40 mV. Figure 16B shows the I-V relationships obtained after measuring the current at the end of the 5.5 s test 
pulse versus the membrane potential. Figure 16C shows the voltage-dependence of activation of the currents 
analyzed after measuring the initial magnitude tail currents at -40 mV. 
 
Figure 16: Electrophysiological properties of KV7.1, KV7.5 and KV7.1/KV7.5 currents. A: Current traces recorded after 
applying depolarizing 5.5-s pulses from a holding potential of -80 mV to +100 mV in +20 mV steps. B: I-V relationships obtained 
after measuring the ion current at the end of the test pulse. C: Activation curves of KV7.1, KV7.5 and KV7.1/KV7.5 current 
obtained after representing the initial tail current amplitude vs. the previous step potential. Vh and s were obtained after fitting the 
activation curves to a Boltzmann equation. Data are presented as mean values ± SEM of n = 7-13 experiments. 
The obtained values were fitted to a Boltzmann equation from which we obtained the midpoint of activation (Vh) and 
the slope of the curve (s) (see Materials and Methods section). Thus, we obtained values of Vh = -18.9 ± 1.4 mV and 
s = 9.0 ± 0.8 mV (n = 17) for KV7.1 channels; Vh = -40.0 ± 2.8 mV and s = 13.5 ± 2.0 mV (n = 13) for KV7.5 channels; 
and Vh = -43.2 ± 1.9 mV and s = 8.9 ± 1.2 mV (n = 8) for KV7.1/ KV7.5 channels.  
Therefore, the phenotype of the KV7.1/KV7.5 current was intermediate between KV7.1 and KV7.5 channels. They had 
a Vh similar to that of KV7.5 (-43.2 ± 1.9 mV vs. -40.0 ± 2.8 mV, P > 0.05), but more negative than KV7.1 (-43.2 ± 1.9 
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mV vs. -18.9 ± 1.4 mV, P < 0.05). However, the KV7.1/KV7.5 slope factor was similar to that of KV7.1 (8.9 ± 1.2 mV 
vs. 9.0 ± 0.8 mV, P > 0.05), but steeper than that of KV7.5 (8.9 ± 1.2 mV vs. 13.5 ± 2.0 mV, P < 0.05). 
To further investigate the electrophysiological properties of KV7.1/KV7.5 channels, activation and deactivation kinetics 
of the current elicited by a 5.5-s pulse to +60 mV, from -80 mV, followed by a -40 mV pulse, were analyzed in these 
three types of channels. The activation kinetics was analyzed by fitting the current recorded at + 60 mV to a mono- or 
a bi-exponential equation. The deactivation kinetics was analyzed by fitting the tail currents (recorded on returning to 
-40 mV from +60 mV), which represent the closing process of the channels, to a mono-exponential equation. 
 
Figure 17: Activation and deactivation processes of KV7.1, KV7.5 and KV7.1/KV7.5 channels. Representative traces of 
activation process (obtained using the protocol shown in the left-top of the figure) of KV7.1 (A), KV7.5 (B) and KV7.1/KV7.5 
channels (C). The inset of each panel shows the deactivation traces for each channel. Activation and deactivation kinetics were 
obtained after fitting traces to a mono- or bi- exponential equation (see Material and Methods). 
In the case of KV7.1 channels, both, activation and deactivation processes, were fitted to a monoexponential function 
(Figure 17, Table 3). Activation kinetics for KV7.1 current was faster than that reported for other KV7 channels, 
whereas the deactivation kinetics was slower than that displayed by the other KV7 members (154, 155). KV7.2-5 
display slowly activating and deactivating K+ currents with distinct electrophysiological and pharmacological 
properties (109). KV7.5 currents were fitted to a bi-exponential and to a mono-exponential equation for activation and 
deactivation process, respectively. KV7.5 channels have a slow activation kinetics (n = 14, P < 0.01 vs. KV7.1) and 
fast deactivation kinetics (n = 14, P < 0.01 vs. KV7.1, Table 3), which are more common for the KV7 subfamily. Albeit 
KV7.1/KV7.5 activation process were fitted to a bi-exponential equation, the slow time constant of activation was 
faster than the slow time constant of activation of KV7.5 currents (n = 9, P < 0.01 vs. KV7.5, Table 3), being the 
activation process faster in KV7.1/KV7.5 channels than in KV7.5 channels, but slower than in KV7.1 (n = 9, P > 0.05 vs. 
KV7.1 channels, Table 3). However, the deactivation kinetics of KV7.1/KV7.5 channels was similar to that observed for 
KV7.1 channels (n = 9, P < 0.01 vs. KV7.5, P > 0.05 vs. KV7.1, Table 3) 
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Table 3. Activation and deactivation kinetics of KV7.1, KV7.5 and KV7.1/KV7.5 channels.  
 Activation Deactivation 
Channel τs τf Af/ (Af+As) τ 
KV7.1  36.1± 6.1**#  887.4 ± 172## 
KV7.5 1178.7 ± 131.8** 89.1 ± 15.1** 0.43 ± 0.03 300.1 ± 21.5** 
KV7.1/KV7.5 512.1 ± 88.7## 37.5 ± 6.8## 0.50 ± 0.08 605.4 ± 73.6## 
Data are shown as the mean ± SEM of n = 9-25. **: P < 0.01 vs. KV7.1/ KV7.5 channels, #: P < 0.05 and # #: P < 0.01 vs. KV7.5 
channels. 
4.1.4 Modulation of KV7.1/ KV7.5 channels by KCNE subunits 
KV7 channels are highly regulated by KCNE regulatory subunits, providing the channels additional 
electrophysiological properties. KV7.1 channels interact with all members of the KCNE family (KCNE1-5). In the 
heart, KV7.1 channels interact with the KCNE1 subunit generating the IKs, which is one of the most important currents 
contributing to the cardiac AP repolarization. In other tissues, such as intestinal or mammary airway epitheliums, 
KCNE3 interacts with KV7.1 channels forming a constitutively active KV channel (146, 271, 272). KCNE1-5 assemble 
with KV7.5 channels, but KV7.5 electrophysiological characteristics are only modifyed by KCNE1 and KCNE3. Indeed, 
while KCNE1 slows the activation and suppresses the inward rectification of the channel, KCNE3 drastically 
decreases the KV7.5 currents (137). 
In order to know if KV7.1/KV7.5 channels were susceptible of regulation by KCNEs regulatory subunits, the effects of 
KCNE1 and KCNE3 on KV7.1/KV7.5 currents were studied in COS-7 cells co-transfected with KCNQ1-YFP and 
KCNQ5-YFP.  
Figure 18 shows the effects produced by the KCNE1 and KCNE3 regulatory subunits in KV7.1/KV7.5 channels. At first 
sight, KV7.1/KV7.5/KCNE1 currents look very similar to the KV7.1/KCNE1 current because of the extremely slow 
activation induced by KCNE1. However, after analyzing the electrophysiological properties, we can observe that 
KV7.1/KV7.5/KCNE1 currents have specific biophysical and pharmacological features, different from those of 
KV7.1/KCNE1. KCNE1 slows the activation kinetics of the KV7.1/KV7.5 current (n = 16, Table 4) and dramatically 
right-shifts its voltage-dependence by ~ +80 mV (n = 16, Table 5, Figure 18). 
KCNE3 regulatory subunit effects on KV7.1/KV7.5 channels were also analyzed. KCNE3 accelerated the activation 
process (Table 4). KCNE3 slightly shifted the activation curve towards negative potentials (by 10 mV, n = 7, P > 0.05) 
(Table 5, Figure 18B) and it significantly shifted the activation curve if we compare it with the Vh values obtained for 
KV7.1 channels alone (Table 5). 
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Table 4. Activation and deactivation kinetics of KV7.1/KV7.5, KV7.1/KCNE1, KV7.1/KV7.5/KCNE1 and 
KV7.1/KV7.5/KCNE3 channels measured at +60 mV.  
 Activation Deactivation 
Channels τs τf Af/ (Af+As) τ 
KV7.1/KV7.5 512.1 ± 88.7** 37.5 ± 6.8** 0.50 ± 0.08 605.4 ± 73.6* 
KV7.1/KCNE1 3757.8 ± 440.8## 837.5 ± 407.8## 0.72 ± 0.06 439.1 ± 30.5# 
KV7.1/KV7.5/ 
KCNE1 
2490.9 ± 42.0## 634.9 ± 75.0## 0.49 ± 0.08* 306.6 ± 28.8##** 
KV7.1/KV7.5/ 
KCNE3 
522.1 ±106.1¶¶ 45.6 ± 6.5¶¶ 0.84 ± 0.07#&¶ 368.2 ± 30.5 
Data are shown as the mean ± SEM of n = 7-29. #: P < 0.05 vs. KV7.1/ KV7.5 channels, ##: P < 0.01 vs. KV7.1/KV7.5 channels *: 
P < 0.05 vs. KV7.1/KCNE1, **: P < 0.01 vs. KV7.1/KCNE1. ¶: P < 0.05 vs. KV7.1/KV7.5/KCNE1 channels, ¶¶: P < 0.01 vs. 
KV7.1/KV7.5/KCNE1. 
 
KV7.1/KV7.5/KCNE1 deactivation kinetics was faster than KV7.1/KV7.5 and KV7.1/KCNE1 channels. However 
KV7.1/KV7.5/KCNE3 deactivation kinetics was similar to that observed for KV7.1/KV7.5 channels (Table 4). These 
results suggest that KV7.1/KV7.5 channels are highly regulated by KCNEs regulatory subunits. They are able to 
modify the biophysical KV7.1/KV7.5 channels properties. 
Table 5. Half-activation (Vh) and slope (s) of the steady-state activation of KV7.1, KV7.5 and KV7.1/KV7.5 
currents in the absence and in the presence of KCNE1 and KCNE3.  
 KV7.1 KV7.5 KV7.1/ KV7.5 
Vh (mV) 
s (mV) 
-18.9 ± 1.4 
9.0 ± 0.8  
-40.0 ± 2.8## 
13.5 ± 2.0*# 
-43.2 ± 1.9## 
8.9 ± 1.2 
KCNE1          Vh (mV) 
s (mV) 
+29.4 ± 2.4## 
18.9 ± 0.8## 
-42.2 ± 0.9 
11.3 ± 2.0 
+49.0 ± 2.9**¶¶ 
23.0 ± 1.5**¶ 
KCNE3          Vh (mV) 
s (mV) 
+59.4 ± 3.2 
22.7 ± 1.8 
-45.9 ± 0.9 
11.5 ± 2.0 
-50.0 ± 2.9 
7.2 ± 0.3 
Data are shown as the mean ± SEM of n = 7-29. *: P < 0.05 and **: P < 0.01 vs. KV7.1/KV7.5 channels. #: P < 0.05 and ##: P < 
0.01 vs. KV7.1 channels. ¶: P < 0.05 and ¶¶: P < 0.01 vs. KV7.1/KCNE1 channels. Parameters of KV7.5/KCNE1 and KV7.5/KCNE3 
currents were obtained from Xenopus oocytes. 
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Figure 18: Voltage-dependent K+ currents recorded in COS-7 cells expressing KV7.1/KV7.5/KCNE1 and 
KV7.1/KV7.5/KCNE3 channels. Currents were evoked by a series of 5.5-s pulses from -100 to +100 mV in 20 mV steps from a 
holding potential of -80 mV and returned to -40 mV. Representative current records from COS-7 cells transfected with 
KV7.1/KV7.5/KCNE1 (A, left) and KV7.1/KV7.5/KCNE3 (B, left). I-V relationships measured at the end of the pulses of 
KV7.1/KV7.5/KCNE1 currents (A, middle) and of KV7.1/KV7.5/KCNE3 currents (B, middle). Voltage dependence of activation. 
Activation curves were obtained by plotting the normalized initial magnitude tail current vs. the test membrane potential. Data 
were fitted to a Boltzmann equation that is shown with a solid line for KV7.1/KV7.5/KCNE1 channels (A, right) and 
KV7.1/KV7.5/KCNE3 channels (B, right). Data show the mean ± SEM of 7-16 cells per group. 
Since the current elicited by KV7.1/KV7.5/KCNE1 channels was similar to KV7.1/KCNE1 channels, we wanted to 
investigate the pharmacological consequences of the presence of KV7.5 in this heterotetramer channel. Thus, to 
assess this approach, a selective KV7.1/KCNE1 channel blocker, chromanol 293B, was used to compare the blocking 
effects of this drug on KV7.1/KCNE1 and on KV7.1/KV7.5/KCNE1 channels. 
Figure 19 shows chromanol 293B effects on KV7.1/KV7.5/KCNE1 channels. Chromanol 293B (5 µM) blocks 
KV7.1/KCNE1 channels by 12.3 ± 3.0 % (n = 3, P < 0.05, Figure S1) and KV7.1/KV7.5/KCNE1 channels by 53.0 ± 3.0 
% (chromanol 293B conditions vs. control conditions, n = 9, P < 0.05, Figure 19) Therefore, block induced by 
chromanol 293B block was greater in the presence of KV7.5 subunits. Chromanol 293B did not changed the gating 
properties of KV7.1/KV7.5/KCNE1 channels. Moreover, block was not time- or voltage-dependent. All these results 
suggest that KV7.1, KV7.5 and KCNE1 subunits are able to assemble and form functional channels, with specific 
electrophysiological and pharmacological properties.  
 
-100 -75 -50 -25 0 25 50 75 100
0.0
0.2
0.4
0.6
0.8
1.0
N
o
rm
a
liz
e
d
 c
u
rr
e
n
t 
Membrane Potential (mV)
Vh = +49.0 ± 2.9 mV
s = 23.0 ± 1.5 mV
-80 mV
+100 mV
5.5 s
-40 mV
2
0
0
 p
A
1 s
Kv7.1/Kv7.5
KCNE1
Kv7.1/Kv7.5
KCNE3
-100 -75 -50 -25 0 25 50 75 100
0
400
800
1200
1600
C
u
rr
e
n
t 
(p
A
)
Membrane Potential (mV)
-100 -75 -50 -25 0 25 50 75 100
0.0
0.2
0.4
0.6
0.8
1.0
N
o
rm
a
liz
e
d
 c
u
rr
e
n
t 
Membrane Potential (mV)
s = 7.2 ± 0.3 mV
Vh = -50.0 ± 2.9 mV
-100 -75 -50 -25 0 25 50 75 100
0
100
200
300
400
C
u
rr
e
n
t 
(p
A
)
Membrane Potential (mV)
2
0
0
 p
A
1 s
A
B
PART I: Physiological and pharmacological study of KV7.1/KV7.5 channels   Results 
 
49 
 Figure 19: Chromanol 293B effects on KV7.1/KV7.5/KCNE1 currents. A: Representative current records from COS-7 cells co-
transfected with KV7.1/KV7.5/KCNE1. Currents were evoked applying the protocol shown on the top of the figure in the absence 
or in the presence of 5 µM chromanol 293B. B: Representative traces obtained after applying 5.5 s pulses of +60 mV from a 
holding potential of -80 mV, in the absence (black trace) and in the presence of 5 µM chromanol 293B (blue trace), the 
percentage of block is shown. C: I–V relationship measured at the end of the pulses for KV7.1/KV7.5/KCNE1 currents in the 
absence (black circles) and in the presence of 5 µM chromanol 293B (blue circles). D: Activation curves were obtained by 
plotting the normalized tail currents vs the membrane potential. Data were fitted to a Boltzmann equation that is shown with a 
solid line (black circles represent control conditions while blue circles represent 5 µM chromanol 293B conditions). Data show 
the mean ± SEM of 9 cells. 
4.1.5. Pharmacological properties of KV7.1/ KV7.5 channels 
To further study the pharmacological characteristics of KV7.1/KV7.5 heterotetrameric channels, experiments with a 
KV7.2-5 activator were performed. To that end, the effects of the antiepileptic drug retigabine (RTG) were analyzed. 
RTG is an activator of KV7.2-5 channels that have no activator effect on KV7.1 channels. RTG (10 µM) increased 
KV7.5 currents at all membrane potential tested (Figure 20B, middle). Thus, at +60 mV RTG (10 µM) increased the 
KV7.5 current by 198.5 ± 57.3 % (n = 6, P < 0.05). However, this drug blocks KV7.1 currents at all membrane 
potential tested, arising a mean value, at +60 mV, of 14.9 ± 3.4% (n = 8, P < 0.05 Figure 20B, left) as previously 
reported (174). KV7.1/KV7.5 currents were registered after applying 5.5-s pulses from a holding potential of -80 mV to 
+100 mV in 20 mV steps. Potassium currents were analyzed in the absence and in the presence of the drug. RTG 
(10 µM) increased the current by 130.6 ± 16.5 % at +60 mV (n = 6 P < 0.01). RTG did not modify the voltage 
dependence of activation of KV7.1 channels, but shifted the activation curves of KV7.1/KV7.5 channels towards 
negative potentials (-43.7 ± 2.0 mV vs. -51.4 ± 2.5 mV, n = 7, P < 0.05), without modifying the slope factor (9.22 ± 
1.4 mV vs. 12.0 ± 1.8 mV, n = 7, P > 0.05), in the same manner as it was observed in KV7.5 channels (n = 4, -40.1 ± 
7.3 mV vs. -55.0 ± 7.9 mV, P < 0.05, and 15.7 mV ± 5.1 vs. 26.2 ± 7.8 mV, P > 0.05) (Figure 20C, right) 
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Figure 20: RTG effects on KV7.1, KV7.5, and KV7.1/KV7.5 channels. Currents were evoked by a series of 5.5-s pulses from -
100 to +100 mV in 20 mV steps from a holding potential of -80 mV and returned to -40 mV. A: Representative current records 
from COS-7 cells transfected with KV7.1 (left), KV7.5 (middle), and KV7.1/KV7.5 (right) in the absence and in the presence of 
RTG (10 µM). B: Voltage-dependent effects of RTG. I-V relationship measured at the end of the pulse for KV7.1, KV7.5, and 
KV7.1/KV7.5 channels in the presence of RTG (10 μM). C: Voltage dependence of activation. Activation curves were obtained by 
plotting the normalized peak tail currents vs. the membrane potential of KV7.1, KV7.5, and KV7.1/KV7.5 channels in the absence 
(dashed line) and in the presence of RTG (10 μM) (solid line). Data were fitted to a Boltzmann equation that is shown with a 
solid line. Green dots represent the relative current showed as IRetigabine/IControl vs. membrane potential. Results are shown as the 
mean ± SEM of 6 to 8 cells per group, *: P < 0.05. 
RTG increased KV7.5 and KV7.1/KV7.5 currents by shifting the voltage dependence of the activation of these 
channels towards more negative membrane potentials, thus facilitating activation and stabilizing the ion channel in 
the open conformation. Indeed, the maximum increase produced by RTG was observed at -40 mV both, in KV7.5 and 
KV7.1/KV7.5 channels However, the increase and the slight block induced by RTG was not voltage dependent for 
KV7.5, KV7.1/KV7.5 and KV7.1 channels (green circles, Figure 20C). 
We did not see any effect on the time constants of the activation or deactivation process on KV7.1 channels were 
observed (Figure 21A, Table 6). However, RTG slowed the activation of KV7.5 and KV7.1/KV7.5 channels (Table 6, n 
= 5-8, P < 0.05, Figure 21BC). No effect on the time constants of the deactivation processes of KV7.5 and 
KV7.1/KV7.5 channels, were observed (Table 6, n = 5-8, P > 0.05, Figure 21BC inset). 
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Figure 21: Activation and deactivation process of KV7.1, KV7.5 and KV7.1/KV7.5 channels in the absence and in the 
presence of RTG (10 µM). Representative current traces of KV7.1 channels (A), KV7.5 channels (B) and KV7.1/KV7.5 channels 
(C) in the absence (black trace) and in the presence of 10 µM RTG (green trace), obtained using the protocol shown in the left-
top. The inset of each panel shows the deactivation current for each channel in the absence (black trace) and in the presence of 
10 µM RTG (green trace). Activation and deactivation kinetics were obtained after fitting traces to a mono- or bi- standard 
equation. *: P < 0.05, n = 6-9 cells per group.  
Table 6: Activation and deactivation Kinetics of KV7.1, KV7.5 and KV7.1/KV7.5 channels in the absence (Control) and the 
presence of RTG (10 µM).  
 Activation Deactivation 
Channels Control RTG Control RTG 
 τs τf τs τf τ τ 
KV7.1  46 ± 12  50 ± 11 858 ± 300 1187 ± 384 
KV7.5 1178 ± 132 89 ± 15 2409 ± 400* 222 ± 53* 300 ± 2 640 ± 126 
KV7.1/KV7.5 520 ± 100 33 ± 6 2371 ± 609** 137 ± 34* 605 ± 73 490 ± 67 
Data are shown as the mean ± SEM of 5-12 experiments per group, **: P < 0.01 vs. Control, *: P < 0.05 vs. control. 
4.1.6. Role of KV7.1/ KV7.5 channels on the vascular tone 
All the events that we have analyzed suggest that KV7.5/KV7.1 heterotetrameric channels are functional channels 
present in cardiovascular system. Our last aim was  to analyzed if these heterotetrameric channels play a specific 
role in the regulation of the vascular tone. Vessels were incubated with vehicle (DMSO, control), chromanol 293B (10 
µM) or linopirdine (10 µM) for 20 min before the stimulation with serotonin (5-HT, 1 µM). Finally, the relaxation 
induced by RTG (1-30 µM) was analyzed. RTG induced a relaxant response that was differentially inhibited by the 
presence of  
chromanol 293B (10 µM) and linopirdine (10 µM). In control conditions, RTG (10 µM) was able to achieve the 
relaxation of the coronary arteries, whereas 30 µM of RTG was needed to complete the relaxation process in the 
presence of chromanol 293B. 
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Finally, higher RTG concentrations (>30 µM) were needed to complete the relaxation process in the presence of 
linopirdine, an inhibitor of the KV7 channels subfamily (Figure 22). All these results suggest that KV7.1/KV7.5 
heterotetramers are present in rat coronary arteries and they might play a specific role in the vascular tone. 
 
Figure 22: Recordings of rat coronary arteries reactivity. Representative traces (A) and average values (B) showing the 
vasodilation induced by RTG in coronary arteries incubated with chromanol 293B and linopirdine as compared with those 
incubated with vehicle (control) for 20 min before the addition of the vasoconstrictor 1 μM serotonin (5-HT). Results are means ± 
SEM. *: P < 0.05; **: P < 0.01; ***: P < 0.001 vs. control and ##: P <0.01 linopirdine vs. chromanol 293B (1-way ANOVA) of n= 4-
5. Black traces indicate control; blue traces, chromanol 293B; and red traces, linopirdine. 
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4.2 PART II. n-3 and n-6 PUFAs AND THEIR DERIVATIVES, RESOLVIN D1 
AND LIPOXIN A4, MODULATE KV7.1/KCNE1 CURRENT 
4.2.1 DHA and AA modulate KV7.1/KCNE1 gating 
PUFAs antiarrhythmic properties have been related to their ability to modulate Na, Ca and K channels (210, 273). 
KV7.1 and KCNE1 are the two major pore-forming and ancillary subunits, respectively, responsible for the biophysical 
properties of IKs channels (152, 210). It has been reported that eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) do not increase KV7.1 current, although DHA, but not EPA, increases the magnitude of the KV7.1/KCNE1 
current in Xenopus oocytes (210). In cardiac myocytes from pigs fed with a PUFAs enriched-diet, IKs magnitude was 
greater than that recorded in myocytes from control animals (216). Therefore, the aim of this part of the present 
Doctoral Thesis was to study how n-3 and n-6 PUFAs modulate KV7.1/ KCNE1 channels, the counterpart of the IKs 
4.2.1.1 DHA and AA increase KV7.1/KCNE1 current 
First, we analyzed the effects of AA (20 µM) on the KV7.1/KCNE1 channel. AA strongly increased the amplitude of 
the current (Figure 23). During the perfusion of COS-7 cells transfected with KV7.1/KCNE1 channels, a time-curse of 
the AA effect was analyzed. The maximum increase of the current was achieved after ~12 min. Figure 23 shows how 
the maximum increased produced by AA was achieved in the pulse #20 followed by a slight decrease of the current. 
We also analyzed the effects of DHA on KV7.1/KCNE1 channels, obtaining similar qualitative results.  
 
Figure 23: Time-course of acute AA (20 µM) effect. A: KV7.1/KCNE1 original traces recorded from a holding potential of -80 
mV to +60 mV during 5.5-s pulses. Control condition is shown in violet traces, KV7.1/KCNE1 traces in the presence of 20 µM AA 
reached their maximum increase at pulse 20 (orange traces). B: Representative increase of KV7.1/KCNE1 current in the 
presence of 20 µM AA. Current magnitude at the end of the pulses vs. the number of pulses needed to achieve the maximum 
increase, is represented (Results are shown as the mean ± SEM. n = 9). 
These experiments were performed using 20 µM of each compound (DHA and AA). The choice of DHA 
concentration is based on the SOFA Trial and on the reported EC50 for the effects of PUFAs on ion channels, that 
ranges between 5.0 and 16.4 µM (214, 274). For better comparisons between n-3 and n-6 PUFAs effects on 
KV7.1/KCNE1 current, the same AA concentration was used.
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Figure 24: Voltage-dependent effects of DHA. A: Current traces obtained after applying the pulse protocol shown in the top, in 
the absence and in the presence of DHA (20 µM). B: I-V relationships obtained under control conditions and after perfusion with 
DHA (20 µM). C: Activation curves of KV7.1/KCNE1 current obtained after representing the maximum tail current amplitude vs. 
the previous step potential. D: Ratio between the current in the presence of DHA and the current in control conditions. Data are 
shown as the mean ± SEM. *: P < 0.05, n= 5. 
We analyzed the effects of DHA and AA on KV7.1 channels in transfected COS-7 cells. No significant changes on the 
current elicited by these channels were observed (Figure S2, (225)). However, when we analyzed the effects of DHA 
and AA in the presence of the KCNE1 regulatory subunit, a great increase in the KV7.1/KCNE1 current was observed 
(Figures 24 and 25). Figure 24A shows KV7.1/KCNE1 traces obtained after applying 5.5-s depolarizing pulses from a 
holding potential of -80 mV to +60 mV in 10 mV steps, in the absence and in the presence of DHA (20 µM). Figure 
24B shows the I-V relationships under control conditions and in the presence of DHA. As it can be observed, DHA 
increased the KV7.1/ KCNE1 current at all membrane potentials tested positive to +30 mV (n = 8, P < 0.05,). DHA did 
not modified the Vh of the activation curve (+29.9 ± 6.4 vs. +26.4 ± 6.9 mV, in control conditions and after perfusion 
with DHA, P > 0.05, n = 5) or the slope factor of the activation curves (14.2 ± 1.1 mV vs. 16.7 ± 0.7 mV, in control 
condition and after perfusion with DHA, P > 0.05, n = 5) (Figure 24C). We analyzed the voltage-dependence of the 
increasing of the current induced by the compound by plotting the ratio between the current in the presence and in 
the absence of DHA (IDHA/IControl, Figure 24D).Although not significant, the increase in the current induced by DHA 
showed a tendency to decrease after +10 mV (P > 0.05 n = 8). This effect might be due to the slight negative shift 
produced by DHA on the activation curve. Similar qualitative effects to DHA were produced by EPA (225). 
 
 
10 20 30 40 50 60
0
1
2
3
4
5
I 
D
H
A
 /
 I
 C
o
n
tr
o
l
Membrane Potential (mV)
-80 -60 -40 -20 0 20 40 60
0.0
0.2
0.4
0.6
0.8
1.0
Membrane Potential (mV)
N
o
rm
a
liz
e
d
 c
u
rr
e
n
t  CONTROL
 DHA 20 M
-80 -60 -40 -20 0 20 40 60
0
1000
2000
3000
4000
5000
6000
7000
*
*
*
Membrane Potential (mV)
 CONTROL
 DHA 20 M
C
u
rr
e
n
t 
(p
A
)
*
1 s
2
 n
A
2
 n
A
1 s
DHA (20 M)
-40 mV
+60 mV
-80 mV
Control
5.5 s
A B
C D
PART II. n-3 and n-6 PUFAs and their derivatives: KV7.1/KCNE1 channels   Results  
 
55 
 
Figure 25: Voltage-dependent effects produced by AA on KV7.1/KCNE1 current. A: Current traces obtained after applying 
the pulse protocol shown in the top in the absence and in the presence of AA (20 µM). B: I-V relationships obtained under 
control conditions and after perfusion with AA. C: Activation curves of KV7.1/KCNE1 current obtained after representing the 
conductance vs. the previous step potential recorded in the absence (Vh = +39.1 ± 5.0 mV, s = 12.0 ± 2.0 mV) and in the 
presence of AA. D: Ratio between the KV7.1/KCNE1 current in the presence and in the absence of AA. Data are shown as the 
mean ± SEM. *: P < 0.05, n= 8.  
Figure 25 shows the same approach for AA (20 µM). KV7.1/KCNE1 currents were evoked after applying 5.5-s 
depolarizing pulses from a holding potential of -80 mV to +100 mV in 20 mV steps. Figure 25A shows KV7.1/KCNE1 
currents in the absence and in the presence of AA. As it can be observed, AA, similarly to DHA, increased the 
magnitude of the KV7.1/KCNE1 current. Figure 25B shows the I-V relationships in control and after perfusion of the 
cells with AA. This PUFA increased the current at all membrane potentials tested positive to -20 mV (n = 8, P < 0.05, 
Figure 25B). Because the activation curves in the presence of AA did not reach the steady-state level, it was not 
possible to fit the data to a Boltzmann equation (Figure 25C), but it can be observed that AA shifted the threshold 
activation of the current towards more negative membrane potentials. In contrast to DHA and EPA (225), the AA-
induced increase of KV7.1/KCNE1 current was voltage-dependent, decreasing at membrane potentials positive to 
+20 mV (P < 0.05, n= 8, Figure 25D).  
The increase of the current produced by DHA and AA was also measured at shorter depolarization times (1.5 s). The 
increase induced by DHA was not time-dependent, this effect being similar either after long or short depolarizing 
pulses (91.8 ± 19.3 % and 92.7 ± 23.8 %, after 1.5 s and 5.5 s, respectively, n = 13, P > 0.05). Similarly, increase 
produced by AA was not time-dependent, the increase being equal after short or long depolarizations (119.3 ± 45.8% 
and 120.2 ± 37.8%, measured after 1.5 and 5.5 s depolarizing pulses, n = 8, P > 0.05).
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Figure 26: Effects of DHA and AA (20 μM) on KV7.1/KCNE1 activation and deactivation kinetics. A: KV7.1/KCNE1 current 
traces obtained in the absence and in the presence of DHA and AA (left panels). B: Normalized traces of KV7.1/KCNE1 current 
obtained in the absence and in the presence of DHA and AA. C: Normalized tail currents of KV7.1/KCNE1 obtained in the 
absence and in the presence of DHA and AA. Data are mean ± SEM, n= 5-8 per group.  
In order to analyze the activation kinetics, KV7.1/KCNE1 current at +60 mV were fitted to a biexponential equation. In 
control conditions, the activation time constants arose mean values of τs = 3757.8 ± 440.8 ms and τf = 837.5 ± 75.7 
ms (Figure 26, n = 29). Although DHA accelerated the fast time constant of activation (737 ± 53 ms vs. 592 ± 52 ms, 
in control and in the presence of DHA, respectively. P < 0.05, n = 8), the contribution of the slow component of 
activation to the total process increased (0.19 ± 0.04 vs. 0.46 ± 0.07, n = 8, P < 0.0,5 in control and in the presence 
of DHA, respectively), resulting in a slower activation kinetics (Figure 26B). AA also accelerated the fast time 
constant of activation (979 ± 85 ms vs. 455 ± 42 ms, in control and in the presence of AA, n = 13, P < 0.05) and 
increased the contribution of the slow component of activation process (0.10 ± 0.05 vs. 0.77 ± 0.07, n = 8, P < 0.01 
in control and in the presence of AA, respectively). Thus, AA did not modify the activation kinetics of the current 
(Figure 26AB). Therefore, DHA slowed activation kinetics of KV7.1/KCNE1, while AA did not modify the activation 
kinetics. 
Regarding the deactivation kinetics, both DHA and AA accelerated this process, which changed from 
monoexponential to biexponential processes. In the case of DHA, the control deactivation time constant was 502.7 ± 
65.2 ms (n = 18), whereas in the presence of the drug, the τs value was 497.2 ± 45.7 ms (n = 18, P > 0.05 compared 
to the control time constant) and the τf value was 109.5 ± 9.5 ms. The contribution of the fast component of the 
deactivation process reached a mean value of 0.62 ± 0.08, thus accelerating the total process. Similarly, the 
deactivation process became biexponential in the presence of AA (20 µM). Thus, the control time constant was 
341.1 ± 43.5 ms and, in the presence of AA, exhibited a similar slow time constant than the control one (369.1 ± 66.8 
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ms, n = 6, P > 0.05) and a fast time constant of 95.7 ± 13.8 ms (n = 6). The contribution of the fast component to the 
total process was 0.593 ± 0.089 (n = 6), thus accelerating the deactivation. As the slow time constants obtained in 
the presence of DHA or AA resulted to be similar to the time constant obtained under control conditions, DHA and AA 
accelerated the deactivation by adding a fast component to it. 
Effects of DHA in native IKs currents from guinea pig ventricular myocytes 
The effects of DHA were also tested in native IKs currents from guinea pig ventricular myocytes. IKs was recorded at 
36 ºC after applying depolarizing pulses from -40 mV to +20 mV in the presence of nifedipine (10 µM) and E-4031 (5 
µM), to block ICaL and IKr currents, respectively. A total of 14 myocytes were analyzed. In 11 myocytes, DHA (10 μM) 
increased IKs amplitude (37.7 ± 6.0 %, P < 0.05) (Figure 27A) and accelerated its deactivation recorded at -40 mV 
(t1/2 -19.1 ± 8 % vs. control, P < 0.05) (Figure 27B). However, in 5 of 11 myocytes, during long-time recordings, the 
initial increase of IKs was followed by a progressive decrease in the current. Finally, in 3 of them, exposure to 10 μM 
DHA was directly followed by a decline in IKs amplitude (data not shown). 
 
Figure 27: DHA effects on IKs from guinea-pig ventricular myocytes. IKs was elicited a by 5-s voltage step to +20 mV from -
40 mV every 20 s. A: Representative IKs traces, elicited in control and in the presence of DHA (10 µM); statistics of IKs tail 
amplitude on the right. B: Normalized tail currents at -40mV; statistics of IKs deactivation (t½ decay) on the right. n = 11. * P < 
0.05 vs. control. 
4.2.1.2 DHA and AA chronic effect on KV7.1/KCNE1 current 
An increased consumption of PUFAs leads to increased blood and tissue levels of PUFAs (274). However, the 
relative contribution of short- and long-term administration on the electrophysiological effects on ion currents has not 
been determined. We wanted to analyze and correlate the electrophysiological effects produced by DHA with the 
levels of expression of channel protein and also with the channel targeting to lipid rafts. The same conditions were 
used in all these experiments: COS-7 cells were co-transfected with KCNQ1-YFP and KCNE1-CFP and incubated 
for 48 h with DHA and AA (20 μM) in serum-free medium. Controls of these experiments were COS-7 cells co-
transfected with KCNQ1-YFP and KCNE1-CFP incubated for 48 h in serum-free medium without DHA neither AA. 
Three different 
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approaches were performed to elucidate the effects of these compounds on KV7.1/KCNE1 channels related with their 
effects on the plasma membrane. COS-7 cells were transfected with KV7.1/KCNE1 channels and incubated with DHA 
or AA (only for electrophysiological experiments) during 48 h in serum-free medium. Control conditions in serum-free 
medium of KV7.1/KCNE1 currents were studied (Figure S3). In the absence of compound, no differences between 
the currents with or without serum in the medium were observed.  
First, we analyzed the electrophysiological effects after chronic exposure to DHA/AA (Figure28 and 29). Long-term 
conditions of DHA or AA did not modify the magnitude of KV7.1/KCNE1 currents. Long-term conditions for 20 µM 
DHA accelerated the activation process of KV7.1/KCNE1 current recorded in COS-7 cells. The contribution of the fast 
and slow components of the activation kinetics were similar in the absence and in the presence of 20 µM DHA [(Af / 
(As+Af)) = 0.47 ± 0.08 and (Af / (As +Af)) = 0.54 ± 0.08, for control conditions and chronic DHA, P > 0.05, n = 12-18, 
respectively]. However, incubation with DHA during 48 h accelerated the slow activation constant of the activation 
process (5151 ± 788 ms vs. 3100 ± 429 ms for control conditions and chronic DHA, respectively, n = 9-18, P < 0.05) 
without modifying the fast activation time constant (649 ± 42 ms vs. 587 ± 74 ms, P > 0.05, n = 9-18 for control 
conditions and chronic DHA, respectively).  
 
Figure 28: Effects of chronic DHA exposure on KV7.1/KCNE1 currents. A: KV7.1/KCNE1 original traces recorded after 
applying depolarizing 5.5-s pulses from a holding potential of -80 mV to +60 mV in 10 mV steps. B: Original tail current recorded 
at -40 mV after 5.5-s depolarization to +60 mV C:. I-V relationships obtained measuring the current after 5.5s. D: Activation 
curves obtained after representing the maximum tail current amplitude versus the previous step potential. Data are shown as the 
mean ± SEM, n= 12. 
For AA (20 µM), the contribution of each component of activation kinetics was similar in control and after incubation 
with AA [(Af / (As+Af)) = 0.42 ± 0.04 and (Af / (As +Af)) = 0.55 ± 0.09, for control conditions and chronic exposure to 
AA during 48h, P > 0.05, n = 6-18, respectively]. However, the fast time constant of activation was slower after 
chronic exposure to AA than under control conditions (649 ± 42 ms vs. 1233 ± 117 ms, for control and 
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chronic AA, respectively, n = 6-18, P < 0.05) without changes in the slow activation time constant (5298 ± 821 ms vs. 
7348 ± 709 ms, for control and chronic AA, respectively, n = 6-18, P > 0.05, Figure 29). In summary, chronic DHA 
accelerated the activation kinetics whereas chronic AA slowed it. 
 
Figure 29: AA chronic effects on KV7.1/KCNE1 channels. A: Original traces KV7.1/KCNE1 recorded after applying 
depolarizing 5.5 s pulses from a holding potential of -80 mV to +60 mV in 10 mV steps. B: Original tail current recorded at -40 
mV after 5.5 s depolarization to +60 mV. C: I-V relationships obtained after measure the current after 5.5 s. D: Activation curves 
of KV7.1/KCNE1 channels obtained after representing the maximum tail current amplitude vs. the previous step potential 
recorded in cells incubated for 48 h with 20 µM AA. Results are represented as the mean±SEM, n= 6, P > 0.05. 
Figures 28C and 29C show the I-V relationship after chronic treatment of KV7.1/KCNE1 channels with DHA and AA, 
without differences in the mean values. The activation curves under these conditions were also studied (Figures 28D 
and 29D). In control conditions, the Vh = 29.4 ± 2.5 and s = 16.6 ± 1.4 (n = 9) were obtained. DHA induced a 
negative shift of the activation curve (Vh = 13.1 ± 3.7 mV, n = 12, P < 0.05 and s = 14.7 ± 4.0, n = 12, P > 0.05, n = 
12, for DHA). On the contrary, AA did not produce changes in the activation curve (Vh = 29.9 ± 4.2 mV and s = 19.1 
± 1.8 mV, P > 0.05, n = 6, for AA). Thus, DHA, but not AA, after 48 h incubation, shifted to more negative potentials 
the activation curve of the channel. Thus, both DHA and AA exhibited different effects after acute and chronic 
exposure, suggesting that the time of exposure and the differences between n-3 and n-6 PUFAs, promote specific 
effects on KV7.1/KCNE1 channels. 
As it has been shown, DHA and AA modulate KV7.1/KCNE1 channels. Since the effects of DHA were different after 
acute and chronically exposure to this PUFA, our second approach was to examine if the total amount of 
KV7.1/KCNE1 channels, in cells, was susceptible to be regulated by DHA. To that end, western blot analyses were 
performed. Figure 30A shows that DHA reduced the expression of KV7.1 and KV7.1/KCNE1 proteins in a 
concentration-dependent manner (EPA promotes similar results (225)). Indeed, the channels sensitivity to these 
compounds increased in the presence of KCNE1. It has been described for KV1.5 channels, that DHA and EPA are
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able to regulate their degradation via proteasome, and thus, regulate the amount of protein in the cells. In order to 
know if the decrease of KV7.1/KCNE1 channels depends on the increase of degradation via proteasome, 
experiments with MG132 proteasome inhibitor were performed. Figure 30B shows an increase of KV7.1/KCNE1 
channels in the presence of MG132 inhibitor. Moreover, a significant increase in protein levels was observed, in 
increasing concentrations of DHA, in the presence of KCNE1 regulatory subunit. Because of the significant increased 
observed in the presence of KCNE1, experiments with COS-7 cells previously transfected with KCNE1-YFP alone, 
were performed. As we can observe in Figure 30C, the amount of total KCNE1 protein was not altered in the 
presence of DHA (similarly than that observed in the presence of EPA (225)).  
 
Figure 30: DHA decreases the KV7.1 protein abundance in COS-7 cells. A: Left: shown are representative western blots that 
illustrate treatments with DHA. Note that DHA induces dose-dependent reductions of KV7.1 protein. Cellular lysates were 
prepared from COS-7 cells transiently transfected with KV7.1/KCNE1 channels and incubated for 48 h with 30 and 100 µM DHA. 
Samples were subjected to SDS-PAGE, transferred to PVDF membrane and probed with anti-KV7.1. Right: Bar graph 
summarizing densitometry measurements used to compare proteins levels for the treatments of DHA for 48h. β-actin levels were 
used as a loading control (n = 3; *: P < 0.05). B: Representative western blots and graph showing the effects of DHA (0, 30 and 
100 µM) on KV7.1 in cells transfected with KV7.1 or KV7.1/KCNE1 in the presence of MG132 10 μM (proteasome inhibitor). C: 
Representative western blots and graph showing the effects of DHA (0, 30 and 100 µM) on KV7.1 in cells transfected with 
KCNE1, anti-KCNE1 was used. 
These results suggest that n-3 PUFAs reduce the amount of KV7.1 channels via proteasome, without altering the 
concentration KCNE1 regulatory subunit. Previous reports showed that PUFAs may insert within the plasma 
membrane and modify the microdomains (216). It seems that PUFAs are able to modify the lipid composition and, 
therefore, protein location. For this reason, our third aim was to analyze the effects of DHA on KV7.1/KCNE1 
channels and their microenvironment. To that end, lipid rafts extraction assay was performed (analysis of the 
distribution of KV7.1 and KV7.1/KCNE1 channels in a sucrose gradient in chronic administration manner DHA, was 
made). Figure 31 shows that DHA partially disrupts lipids rafts. Indeed, in the presence of DHA the fraction pattern 
observed for caveolin, which indicates these enriched-domains of cholesterol and sphingolipids, were disturbed in 
the presence of this n-3 PUFA (Figure 31). In those lines we analyzed the distribution of KV7.1/KCNE1 channels, in 
the presence of n-3 PUFAs. We observed that the location 
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of KV7.1/KCNE1 channels was different compared with control conditions. These results indicate that these 
compounds modulate the location of these channels in the plasma membrane. All these results suggest that n-3 
PUFAs produced an indirect effect on KV7.1/KCNE1 channels regulating their electrophysiological features, their 
degradation via proteasome and also their location, in lipid-enriched microdomains, in the plasma membrane. 
 
Figure 31: Sucrose density gradient fractions of cells expressing KV7.1 and KCNE1 in the absence (A) and in the 
presence (B) of DHA. While caveolin indicated floating lipids rafts with low density, clathrin labeled non-raft fractions. KV7.1 and 
KCNE1 colocalized with caveolin in low-buoyant density fractions (fraction 2-6) in control experiments whereas DHA triggered a 
wider distribution of proteins (fractions 1-12) and rafts. Pictures are representative images of at least 3 independent lipids rafts 
extractions analyzed by western blot. 
4.2.2 Lipids-derived mediators effects, lipoxins (e-LXA4 and LXA4) and resolvin D1, on KV channels  
As it has been shown, the KV7.1/KCNE1 effects produced by acute and chronic DHA/AA are different. Both are 
metabolized to resolvins and lipoxins, eicosanoids with potent anti-inflammatory effects. Therefore, we studied: 1) the 
effects of 15-epi-lipoxin A4 (e-LXA4) (aspirin-triggered 15-epi-lipoxins), lipoxin A4 (LXA4) and resolvin D1 (RvD1) in 
inflammation-related cells directly modulated by KV channels, bone marrow derived macrophages (BMDM). 2) The 
effects of RvD1 and LXA4 in KV7.1/KCNE1 channels expressed in COS-7 cells. 
4.2.2.1 Lipoxins (e-LXA4 and LXA4) and resolvins D1 effects on bone marrow derived macrophages 
The electrophysiological properties of macrophages depend on their state of functional activation (91, 94). Changes 
in the ion channels along plasma membrane that promote changes in membrane potential are one of the previous 
events to activation process on macrophages (275). In this process, ion channels are widely involved and KV 
channels play a pivotal role in the regulation of macrophage immunomodulatory responses (94, 275). Therefore, our 
purpose was to analyze the electrophysiological effects of e-LXA4, LXA4 and RvD1 on KV currents elicited in BMDM. 
Long-term experiments with e-LXA4 (500 nM) were carried out in resting (control) and with e-LXA4 and LXA4 (500 nM) 
in LPS (100 ng/ml)-activated BMDM. Under control conditions, no significant effects were observed after incubate 
BMDM with e-LXA4 (Figure 32A) at any membrane potential tested. Both e-LXA4 and LXA4 reversed the LPS effects 
while RvD1 (50 nM) did not (Figure 32B). e-LXA4 significantly decreased KV currents at membrane potentials positive 
to +10 mV, the magnitude being similar to that observed in resting BMDM (546 ± 152 vs. 178 ± 48 pA, in LPS-
activated and LPS+e-LXA4 BMDM, respectively, n = 7-9, P < 0.05, Figure 32D). Interestingly, e-LXA4 did not modify 
the inactivation kinetics on resting BMDM, whereas it slowed this process in LPS-activated BMDM (τ = 456 ± 43 ms 
vs. 1123 ± 335 ms, for LPS and LPS+e-LXA4 BMDM, respectively, n = 6-11, P < 0.05 Figure 32D). It has been 
described that LPS-activation up-regulate the expression of KV1.3 channels (91, 94). Also, the KV recorded from 
macrophages is the results of the activation of KV1.3:KV1.5 heteromultimers.  
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Because the level of KV1.5 is not modified in LPS-activated macrophages, the ratio KV1.3:KV1.5 increases under LPS 
activation (91, 276). These results suggest that e-LXA4 prevents the LPS-induced changes in the stoichiometry of KV, 
leading the formation of heterotetramers with a lower KV1.3:KV1.5 ratio (91). Thus, the resulting KV phenotype closely 
resembles that of resting BMDM. LXA4 produced similar effects, but to a lesser extent than those induced by e-LXA4 
(323.6 ± 49.2 pA vs. 177.5 ± 47.9 pA, n=5-7, P < 0.05, in e-LXA4 vs. LXA4).  
 
Figure 32: Effects of long-term treatment with e-LXA4, LXA4 and RvD1 on KV currents in control and LPS-activated 
BMDM. A: Representative currents traces of KV currents recorded from control (resting) BMDM and with e-LXA4 (500 nM) 
treatment for 18 h BMDM, B: Traces obtained in control LPS-activated BMDM (top-middle) and LPS-activated BMDM after 
incubation for 18 h with e-LXA4 (left), LXA4 (middle) and RvD1(right). C: I-V relationships of resting BMDM + e-LXA4 BMDM D: I-V 
relationships of LPS-BMDM + e-LXA4 LPS-BMDM. E: I-V relationships of LPS-BMDM + LXA4 LPS-BMDM and F: I-V 
relationships of LPS-BMDM + RvD1 LPS-BMDM. Data are shown as the means ± SEM. *: P < 0.05, n = 3-10 per group.  
Previous reports showed that RvD1 (50 nM) inhibit the macrophages TNF-α release, which are associated with LPS-
activation of macrophages (236). Long-term RvD1 (50 nM for 18h) experiments did not reverse the LPS-induced 
effect (406 ± 66 pA vs. 367 ± 70 pA, measured at the end of 250 ms pulses applied from -80 to +60 mV, in LPS-
activated and LPS+RvD1-BMDM, respectively, n = 7-18, P > 0.05, Figure 32F). To assess whether the effect 
observed with 500 nM e-LXA4 was due to a direct effect on KV channels or if they act through some cell signaling 
pathway, two different approaches were performed. 
First, KV currents of resting and LPS-activated BMDM were analyzed before and after perfusion with e-LXA4 (1-1000 
nM, only data with 500 nM e-LXA4 are shown). e-LXA4 significantly decreased KV currents, at positive potentials to 0 
mV, elicited by LPS-activated macrophages (20.1 ± 3 % at +60 mV, n = 12, P < 0.05), without producing any effect 
on KV currents elicited by resting macrophages (94.0 ± 18.0 pA vs. 105.2 ± 19.1 pA, n = 12, P > 0.05, Figure 33A). 
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Figure 33: Early effects of e-LXA4 and RvD1 on KV currents. Representative traces of KV currents recorded in control or LPS-
activated BMDM (top panel). Cells were untreated (A, C) or treated with LPS (100 ng/ml) (B, D) for 18h. Current traces were 
recorded in the absence and after perfusion with e-LXA4 (500 nM) and RvD1 (5 nM) (A-D). I-V relationships in the absence and 
in the presence of e-LXA4 (500 nM) and RvD1 (5 nM) in non-stimulated BMDM (E, G), and in LPS-activated BMDM (F, H). Data 
are mean±SEM. *P < 0.05, n = 3-10 per group. 
 Acute RvD1 (5 nM and 50 nM) was tested in resting and LPS-activated BMDM. No significant effects were observed 
at any membrane potential tested in the presence of RvD1 (5 nM) neither resting nor LPS-activated BMDM (Figure 
33GH). Also, no significant effects were observed in the presence of 50 nM RvD1 measured at +60 mV (34.3 ± 3 pA 
vs. 29.0 ± 4 pA, measured at the end of 250 ms pulses applied from -80 to +60 mV, in resting-BMDM and resting + 
RvD1-BMDM, respectively, n = 5-7, P > 0.05 and 207 ± 90 pA vs. 191 ± 89 pA, measured at the end of 250 ms 
pulses applied from -80 to +60 mV, in LPS-activated and LPS+ RvD1-BMDM, respectively, n = 5, P > 0.05, Figure 
S4). 
The second approach performed to elucidate if the effects of lipoxins are due to a direct effect on KV channels was to 
study the effects of e-LXA4 in a heterologous system previously transfected with the KV channels of interest. HEK293 
cells were transfected with KV1.3 and KV1.5 channels, whose activation generates the BMDM KV current. Figure 34 
shows the currents obtained from transfected HEK293 cells after applying a 250-ms depolarizing pulses from -80 mV 
to + 60 mV in 10 mV steps, in the absence and in the presence of 1-1000 nM e-LXA4. The results show that neither 
KV1.3 nor KV1.5 channels were modulated by e-LXA4 (Figure 34). Moreover, the slight effects observed was 
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Figure 34: Effects of e-LXA4 on KV1.5 and KV1.3 currents in transfected HEK293 cells. Currents were elicited after applying 
depolarizing pulses from a holding potential of -80 mV to different depolarizing voltages from -80 to +60 mV in 10 mV steps (250-
ms in duration). Representative traces of KV1.5 (A) and KV1.3 (B) currents in HEK293 cells recorded in the absence (control) and 
in the presence of 100 nM e-LXA4. Concentration-response curve (right panel, A and B) from 1 to 1000 nM e-LXA4 on KV1.5 and 
KV1.3 channels. Plots show the degree of block vs. different e-LXA4 concentrations. Data are shown as the mean ± SEM. P > 
0.05, n = 3-5 per group. 
Taken together, all these results suggest that e-LXA4 and LXA4, but not RvD1, are able to reverse, at least in part, 
the LPS-effect on BMDM. Also, the effects observed with e-LXA4 are not mediated by a direct interaction with KV1.3 
or KV1.5 channels, which are the main KV channels expressed in these cells. 
4.2.2.2 Lipoxin (LXA4) inhibits KV7.1/KCNE1 current 
Figure 35 shows the effects of 500 nM LXA4 on KV7.1/KCNE1 channels. Current recordings were obtained after 
applying the pulse protocol shown in the top of the Figure, both in the absence and in the presence 500 nM of LXA4. 
LXA4 (500 nM) inhibited the KV7.1/KCNE1 current by 33.0 ± 12.1% (n= 5, P < 0.05) measured at the end of 5.5 s 
from -80 to +60 mV. LXA4 decreased the magnitude of the current measured at the end of 5.5-s depolarizing pulses 
at membrane potentials positive to 0 mV (Figure 35B). Figure 35B and 35C show the I-V relationships and the 
activation curves in the absence and in the presence of LXA4. LXA4 did not modify the midpoint of the activation 
curve of KV7.1/KCNE1 current (+43.1 ± 4.6 mV vs. +38 ±.4.5 mV, n = 6, P > 0.05, in control and in the presence of 
LXA4 conditions, respectively) or the slope values (22.1 ± 1.5 mV vs. 21.3 ± 1.2 mV, n = 6, P > 0.05, for control and 
LXA4 conditions, respectively). Block produced by 500 nM LXA4 was not voltage-dependent, being similar at -20 mV 
and at +100 mV (Figure 35D). No changes in the activation kinetics in the presence 500 nM LXA4 were observed (τs 
= 3339.9 ± 851.7 ms and τf = 726.2 ± 160.4 ms vs. τs = 2506.7 ± 369.8 ms and τf = 674.5 ± 194.4 ms, n = 7, P > 
0.05, in control and after perfusion with LXA4 conditions, respectively). However, LXA4 slowed the deactivation 
process (357.9 ± 50.1 ms, vs. 429.6 ± 41.7 ms, n = 7, P < 0.05, in control and after perfusion with LXA4 conditions, 
respectively).
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Figure 35: Voltage-dependent effects of LXA4 on KV7.1/KCNE1 current. A: Current traces were obtained after applying the 
pulse protocol shown in the top, both in the absence and in the presence of LXA4 (500 nM). B: I-V relationships obtained under 
control conditions and after perfusion with LXA4. C: Activation curves of KV7.1/KCNE1 current obtained after plotting the 
maximum tail current amplitude vs. the previous step potential in the absence and in the presence of LXA4. D: Ratio between the 
current in the presence and in the absence of LXA4. Data are shown as the mean ± SEM. *: P < 0.05, n= 5. 
After recording the KV7.1/KCNE1 currents in the presence of LXA4 (500 nM), cells were perfused with drug-free 
external solution. Under these conditions, the LXA4 effects were almost completely washed-out (81.3 ± 7.6%, n = 6, 
P > 0.05 vs. control conditions, Figure S5).  
4.2.2.3 Resolvins D1 (RvD1) inhibits KV7.1/KCNE1 current 
Figure 36 shows current traces of KV7.1/KCNE1 channels generated after applying the pulse protocol shown in the 
Figure, both in the absence and in the presence of 5 and 50 nM of RvD1. RvD1 (5 nM and 50 nM) inhibited the 
KV7.1/KCNE1 current by 48.6 ± 5.7 % (n= 5, P < 0.01) and 86 ± 5 % (n = 6, P < 0.01) measured at the end of 5.5 s 
from -80 to +60 mV. Figure 36B shows the I-V relationships obtained, in the absence and in the presence of RvD1 (5 
nM and 50 nM), after plotting the current measured after 5.5 s depolarizing pulses from -80 to +100 mV versus 
membrane potential. RvD1 (5 nM and 50 nM) inhibits KV7.1/KCNE1 current at membrane potentials positive to 0 mV. 
The activation curve and the slope factor were not modified in the presence of 5 nM of RvD1 (Vh = +31.5 ± 6.5 mV, s 
= 17.1 ± 2.3 mV and Vh = +35.6 ± 11.1 mV, s = 17.9 ± 1.6 mV, n = 4, P > 0.05, for control and 5 nM RvD1 
conditions, respectively). Block produced by RvD1 was not voltage-dependent, being similar at all membrane 
potential tested (Figure 36D). RvD1 did not modify the activation (τs = 3608.3 ± 981.4 ms and τf = 908.5 ± 197.1 ms 
vs. τs = 3577.5 ± 784.1 ms and τf = 920.2 ± 181.4, n = 6, P > 0.05, for control and 5 nM RvD1 conditions, 
respectively) or deactivation kinetics (τ = 426.1 ± 95.3 ms, and τ = 464.6 ± 90.6 n = 5, P > 0.05 for control and 5 nM 
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RvD1 conditions, respectively)
 
Figure 36: Voltage-dependent effects of RvD1 on KV7.1/KCNE1 channels. A: Current traces obtained after applying the 
pulse protocol shown in the top, in the absence and in the presence of 5 and 50 nM RvD1. B: I-V relationships obtained after 
plotting the current at the end of 5.5-s vs. membrane potential, in the absence and in the presence of RvD1 (5 and 50 nM). C: 
Activation curves of KV7.1/KCNE1 current obtained after representing the maximum tail current amplitude vs. the previous step 
potential, recorded in the absence and in the presence of 5 nM RvD1. D: Ratio between the current in the presence of 5 nM 
RvD1 and under control conditions. Data are shown as the mean ± SEM. *P < 0.05, n = 5-8. 
As it was observed with LXA4, the effects produced by RvD1 were washed-out after perfusion of the cells with drug-
free external solution (73.5 ± 17.8 %, n = 4 vs. control conditions, P > 0.05, Figure S5). Therefore, the effects 
produced by RvD1 on the KV7.1/KCNE1 current were much more potent than those observed with LXA4. 
Moreover, we studied the RvD1 (5 and 50 nM) effects on KV7.1 channels alone (Figure S6). At 5 nM, RvD1-induced 
block was lower than that observed for KV7.1/KCNE1 channels (28.9 ± 5.8 % n = 5, P < 0.05, vs. 48.6 ± 5.7% ,n= 5, 
P < 0.01, measured at the end of 5.5-ms pulses applied from -80 to +60 mV, in KV7.1 and KV7.1/KCNE1 channels, 
respectively), However, RvD1 (5 nM) right-shifted the midpoint of the activation curve of KV7.1 channels (-16.5 ± 2.3 
vs. -11.6 ± 1.8 mV, n= 4, P < 0.05, in the absence and in the presence of RvD1, respectively) without modifying the 
slope factor (7.1 ± 0.8 vs. 8.9 ± 0.7 mV, n= 4, P > 0.05). RvD1 did not modify the activation (τs = 18.9 ± 4.3 ms vs. τs 
= 30.3 ± 7.8 ms and τf = 920.2 ± 181.4, n = 6, P > 0.05, for control and 5 nM RvD1 conditions, respectively) or 
deactivation kinetics (τ = 816 ± 275 ms vs. τ = 827 ± 288 n = 5, P > 0.05 for control and 5 nM RvD1 conditions, 
respectively).  
These results suggest that the presence of KCNE1 tunes the sensitivity of KV7.1 channels to RvD1 of KV7.1 
channels, being RvD1 much more potent in the presence of the KCNE1 regulatory subunit. 
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All these results suggest that both LXA4 and RvD1 block KV7.1/KCNE1 channels, without modifying the voltage 
dependence or the activation kinetics of the channels. Moreover, and in contrast to that observed in the presence of 
and DHA, the KV7.1/KCNE1 current magnitude was almost recovered when LXA4 or RvD1 were removed for the 
external solution (Figure S5). 
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In the present Doctoral Thesis, we have studied: 1) the presence of KV7.1/KV7.5 functional channels in vascular 
smooth muscle, and in their role in the control of the vascular tone. 2) The regulation of KV7.1/KCNE1 channels by n-
3 and n-6 PUFAs and their metabolites (lipoxins and resolvins). Also, we have studied 3) the effects of lipoxins and 
resolvins on KV currents from bone marrow derived macrophages. 
5.1 KV7.1/KV7.5 HETEROTETRAMERIC CHANNELS 
In this study, we have demonstrated that KV7.1 and KV7.5 form functional heteromeric channels that seem to be 
involved in the maintaining of the vascular smooth muscle tone. These heterotetramers exhibit intermediate 
electrophysiological and pharmacological properties between KV7.1 and KV7.5 channels. KV7.1/KV7.5 channels 
differently target lipid rafts than KV7.1 channels alone. Indeed, on assembly with KV7.5, KV7.1 subunits are excluded 
from lipid rafts. In addition, the interaction with KV7.1 results in intracellular retention of the KV7.1/KV7.5 
heterotetramer (250). Assembly of KV7.1/KV7.5 channels triggers emerging properties on vascular muscle 
physiology. These results led us to propose that the formation of KV7.1/KV7.5 heteromeric channels provides efficient 
spatial and temporal regulation of smooth muscle cell function. Our results shed light on to new possible interactions 
and also to a highly specialized regulation of different processes in which KV7 are involved.  
Among others KV channels, KV7 channels are crucial in cardiovascular muscle contraction. KV7.1, KV7.5 and KV7.4 
channels are mostly expressed in vascular smooth muscle. Yeung and colleagues challenged the dogma that states 
that KV7.2-7.5 channels are only expressed in neurons and in a few other tissues. These authors described that 
murine arteries like the aorta, carotid, femoral and mesenteric and portal vein express equal or higher levels of KV7.5 
and KV7.4 than KV7.1 channels, and that KV7 channels play a pivotal role on vascular reactivity (111). Furthermore, 
other studies suggest that renal, coronary, aorta and cerebral arteries also express KV7 channels (184). We have 
demonstrated that KV7.1 and KV7.5 channels are expressed in the coronary and aorta arteries, and also in cava vein 
(250). In addition, with immunoprecipitation assays performed in rat aorta arteries, we observed not only that both 
channels are present in the same tissue, but that they also form part of the same protein complex. Previous reports 
have also shown that KV7.4 and KV7.5 channels can form functional heterotetramers (277). KV7.1, KV7.5 and KV7.4 
channels are expressed in cerebral arteries, however, KV7.1 channels do not seem to have relevance in the 
regulation of the vascular tone within this vessel (151, 277). Although KV7.5 and KV7.4 form homotetrameric 
channels, Chadha and colleagues suggest that the main control of the vascular reactivity is due to heterotetrameric 
KV7.4/KV7.5 channels (277). 
Our immunoprecipitation assays revealed that KV7.1 and KV7.5 channels are present in the same protein complex in 
aorta artery isolated myocytes. These results are in contrast with other reports suggesting that KV7.1 channels are 
unable to form heteromeric channels with other KV7 members (Schwake and colleagues). This hypothesis is based in 
the fact that morphological elements of the A-domain from KV7.1 are different to those from other KV7 members. 
However, the reasons why these channels cannot form heterotetramers are still not clear. These authors state that 
KV7.2 and KV7.1 α-subunits cannot interact, whereas KV7.2 and KV7.3 can. This research group made chimeric 
channels between KV7.1 and KV7.3 α-subunits. They performed experiments in which “sid” or “si-domain” (which 
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encompasses A-domain) of KV7.3 was inserted in KV7.1 channels and vice versa. These experiments demonstrated 
that when the “KV7.1 sid” was present, they were unable to detect any interaction with other KV7 channel. However, 
these authors did not perform the experiments needed to show interactions between KV7.1-KV7.4 or KV7.1-KV7.5 
channels (244, 278, 279). The presence of functional KV7.5/KV7.4 channels was demonstrated in middle cerebral 
arteries by Chadha and colleagues (277). In this study, pharmacological and proximity ligation assay (PLA) analysis 
were performed; without analyzing the possible existence of KV7.5/KV7.1 channels. Indeed, they studied the 
interactions between KV7.5/KV7.5, KV7.4/KV7.1 channels but not of KV7.5/KV7.1 channels. In summary, in all these 
reports the possible KV7.1/KV7.5 channel was not explored; and thus, the possibility that KV7.1 and KV7.5 channels 
form heterotetramers cannot be ruled out (244, 277, 279). 
Our results confirmed that KV7.1 and KV7.5 channels interact both in HEK293 cells and also in and aorta arteries. 
Moreover, cells transfected with KCNE1 and both KV7 subunits, demonstrated that all protein tested 
immunoprecipitated, indicating that they form part of the same protein complex. Traffic and FRET experiments 
confirmed physical interactions between both α-subunits (250). 
Lipid rafts are lipid-enriched (cholesterol and sphingolipids) plasma membrane regions. These regions act as 
organizing centers along the membrane, concentrating molecular signaling and/or modulating molecular traffic or 
membrane fluidity. Our results demonstrate that KV7.1 channels target lipids-rafts; however, KV7.5 channels do not. 
Interestingly, when KV7.1 channels and KV7.5 channels were co-expressed together in HEK293 cells, the 
heterotetrameric channels do not target lipid-enriched domains. More importantly, the lipid raft targeting was studied 
in the heart, which only expresses KV7.1 channels, and in aorta artery and cava vein, which express both KV7 
isoforms. Our experiments demonstrated that when both channels are present in the same tissue, KV7.1 channels do 
not target lipid rafts. All these results suggest that there is a physiological relevant change in the targeting in plasma 
membranes when both channels are expressed together. The fact that KV7.1/KV7.5 channels target differentially than 
KV7.1 channels alone may be crucial for its cellular modulation and, thus, for its contribution to the vascular tone. 
The current elicited by KV7.1/KV7.5 channels expressed in COS-7 cells exhibited an intermediate phenotype between 
those observed for KV7.1 and KV7.5 channels. The KV7.1/KV7.5 current activation was slow, similar to other KV7 
members, but faster than those of KV7.5 channels. Also, they exhibited a cummulative current at membrane 
potentials positive to +20 mV, indicative of fast inactivation typical of KV7 channels (145, 146, 152, 153). The 
electrophysiological characteristics observed in KV7.1, KV7.5 and KV7.1/KV7.5 channels suggest that all of them 
exhibit fast inactivation process. However, additional voltage pulse protocols are needed to ensure it in KV7.1/KV7.5 
heteromeric channels (145, 155). The voltage dependency of the activation of KV7.1/KV7.5 channels was very close 
to that exhibited by KV7.5 channels, although the slope factor was closer to that observed in KV7.1 channels. It was 
reported that the current magnitude of KV7.2/KV7.3 and KV7.3/KV7.4 heteromeric channels was greater than those 
elicited by the corresponding homotetramer channels (178). Similar results were reported for KV7.5/KV7.3 channels; 
suggesting that the increased in the current amplitude is promoted by the assembly with KV7.3 α-subunits (280). In 
contrast to that observed in KV7.5/KV7.3 channels, in our experiments, the magnitude of the current generated by the 
activation of KV7.1/KV7.5 channels was similar to those elicited by KV7.1 and KV7.5 homomeric channels.  
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These results suggest that KV7.1 and KV7.5 α-subunits can interact to form functional channels with their own 
electrophysiological properties.  
In addition to the ability to form heteromeric KV7 channels, and because these channels are highly regulated by 
KCNE regulatory subunits that are also present in vascular smooth muscle (183, 184), the interactions between α- 
and β-subunits will lead to a larger and diverse group of KV7 currents.  
KCNEs subunits modify both KV7.1 and KV7.5 channels. All KCNE proteins have been detected in vascular smooth 
muscle (111, 137, 184), but their role in this tissue is not well understood. KCNE1 and KCNE3 modulation of KV7.1 
channels has been widely studied. KV7.1/KCNE1 current is involved in the repolarization of the cardiac action 
potential, whereas KV7.1/KCNE3 channels are constitutively active channels that are essential, at least, in colonic 
crypt cells. In this tissue, KV7.1/KCNE3 channels, though releasing of K+, generate the driving force needed for 
chloride secretion (146, 152, 153, 281). It is considered that the modulation of KV7.5 channels by KCNE3 can be 
important in muscle and brain, where KCNE3 also regulates other KV channels, such as KV2.1, KV3.1 and KV3.4 
channels (270). KCNE3 shifts to more positive membrane potentials the voltage dependence of the activation the 
KV7.5 current. Also, KCNE3 significantly decrease KV7.5 current (137). In addition, KCNE1 modulates KV7.5 
channels, in this case, increasing KV7.5 currents at +60 mV by 2-fold, slowing the activation kinetics process and 
suppressing the inward rectification of the KV7.5 current. The effects produced by KCNE1 on KV7.1/KV7.5 channels 
remind us the regulation by KCNE1 on both, KV7.1 and KV7.5 channels. However, this interaction produced a much 
greater depolarizing shift of the activation curve of KV7.1/KV7.5 channels (~ +80 mV). So, KCNE1 slowed the 
activation kinetics, shifted to positive membrane potentials the voltage-dependent of activation, increased the 
magnitude of the current and slowed the deactivation kinetics. These results suggest that KCNE1 effects are 
potentiated in the heterotetrameric channel. We also analyzed KV7.1/KV7.5/ KCNE3 channels. On the contrary, 
KCNE3 produced opposite effects on the KV7.1/KV7.5 tetrameric channel. KCNE3 did not decrease KV7.1/KV7.5 
current, accelerated the activation kinetics, and shifted to more negative membrane potentials the voltage-
dependence of the activation. Indeed, if we compare KV7.1/KV7.5/KCNE3 channels with KV7.1/KV7.5/KCNE1, we can 
observe that the first ones exhibit a threshold membrane potential of -60 mV (similar to that observed for KV7.1 
channels), whereas for KV7.1/KV7.5/KCNE1 channels is 0 mV. At physiological membrane potentials 
KV7.1/KV7.5/KCNE3 exhibit greater magnitude current than KV7.1/KV7.5/KCNE1 channels. Thus, KCNEs subunits 
modulate KV7.1/KV7.5 channels generating K+ currents with their own electrophysiological properties. 
The fact that the presence of different α- and β-subunits vary in different vascular smooth muscle cells is crucial to 
better understand the functional role and pharmacology of these channels in this tissue. As a result, the 
pharmacological tools have to be adjusted for each scenario expressing distinct KV7 and KCNEs subunits. In fact, we 
demonstrated that chromanol 293B (5 µM) produced a 13% of block of KV7.1/KCNE1 channels, whereas it blocked 
KV7.1/KV7.5/KCNE1 channels by 53%. Therefore, the presence of the heteromeric complex, as well as the presence 
of KCNE subunits, modifies the pharmacology of the channel, as previously shown for other ion channels (136, 254). 
Since the pharmacology of the channels is modified depending on the different subunits, we analyzed the effects of 
the well-known opener of KV7channels, retigabine (282, 283). Retigabine activates all members of the KV7 subfamily 
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with the exception of KV7.1 channels. Our results showed that retigabine increased similarly the current in both 
KV7.1/Kv7.5 and KV7.5 channels and shifted the activation curve towards more negative membrane potentials as it 
was previously described for KV7.3/KV7.5 and KV7.3/KV7.2 channels (109, 280). Retigabine activates KV7.2-5 
channels by interfering with the normal voltage dependent of the channels, i.e. it shifts the voltage-dependence of 
activation to hyperpolarized potentials (284, 285). As a consequence, KV7-mediated currents activate at more 
negative membrane potentials, effectively hyperpolarizing the resting membrane potentials (109, 280). In addition, 
retigabine accelerates the activation and slows the deactivation kinetics of KV7.2, KV7.3, KV7.2/KV7.3 and KV7.4 and 
KV7.5/KV7.3 channels (109, 174). However, retigabine slows the activation kinetics in both KV7.5 and KV7.1/KV7.5 
channels, without modify the deactivation kinetics. 
We observed that KV7.1/KV7.5 channels form functional heteromeric channels, with their own electrophysiological 
and pharmacological properties. Since different α- and β-subunits are expressed widely and their different assembly 
lead different currents, further investigation is necessary to elucidate the role of these channels in different tissues. In 
order to know if KV7.1/KV7.5 channels can regulate vascular tone, a series of experiments were performed. It was 
analyzed the KV current elicited, after depolarization, by coronary myocytes. Using different pharmacological tools 
(chromanol 293B, linopirdine and retigabine), we show that these currents were, in part, elicited by KV7 channels. 
Chromanol 293B inhibits KV currents in these native cells by ~40% and linopirdine produced the same extent of 
inhibition. Interestingly, the simultaneous addition of linopirdine plus chromanol 293B did not trigger any further 
blockade, thus suggesting that KV7 channels are involved in the KV currents elicited by coronary myocytes. Because 
chromanol 293B had significant effects blocking these currents, it is possible suggest that KV7.1 channels are 
involved in these currents. Moreover, these results suggest that these currents are not generated by the activation of 
KV7.2-5 homotetrameric channels. Yeung and colleagues, suggested that in aorta, carotid and mesenteric arteries, 
where KV7.1 channels are present, they do not have any relevance in control vascular reactivity. Chromanol 293B 
blocked KV currents recorded from portal vein cardiomyocytes but not in aorta artery (286). In fact, KV7.1 mRNA was 
detected in aorta, although the pharmacological tools used, failed to detect KV7.1 channels. They suggested that 
KV7.1 channels are not involved in the maintaining of the vascular tone. Therefore, further investigation in the role of 
KV7.1 channels in vascular smooth muscle, is needed (111). Moreover, because KCNE expression is widely 
distributed in different vessels, this may change the pharmacological properties and thus, the study of the regulation 
of the vascular tone becomes more complex. 
Other studies reported that R-L3, a specific KV7.1 channel activator, did not produce any relaxant effect on cerebral 
arteries. Based on these results, they ruled out the possibility of KV7.1 channels were involved in control of cerebral 
arteries vascular tone, even when KV7.1 was detected by other techniques. However, the role of KV7.4/KV7.5 
heterotetramer channels as main regulators of vascular tone seems to be greater than the role of KV7.4 and KV7.5 
homotetramer channels (277). These authors pointed out the possibility that KV7.1 and KV7.4 channels may form 
heterotetramers (but they failed proving their presence). However, they did not perform the same approach for KV7.1 
and KV7.5 channels. Khanamiri and colleagues observed that R-L3 relaxed mesenteric and pulmonary arteries 
whereas it did not relax coronary arteries. On the other hand, the mRNA levels of KV7.1 channels, on coronary 
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arteries, were equal or even higher that those observed for KV7.4 and KV7.5 channels (184). According to these data, 
we cannot rule out the possibility that KV7.1 and KV7.5 channels may form heterotetrameric channels in coronary 
arteries. In our experiments, serotonin pre-constricted coronary arteries were incubated with both, chromanol 293B 
and linopirdine and the retigabine relaxation effects were analyzed. After constricted with chromanol 293B, 30 µM of 
retigabine completely relaxed the artery; while in the presence of linopirdine higher concentrations of retigabine were 
needed. These results suggest that KV7.1 homotetrameric channels do not seem to be responsible of the regulation 
of the vascular tone in coronary arteries. All these results suggest that the vasorelaxant effects of retigabine on 
contracted vessels by chromanol 293B are due to the existence of KV7.1/KV7.5 channels. These data are consistent 
with the expression pattern of these KV channels and with the functional pharmacological effects suggesting that 
neither KV7.5 nor KV7.4 are forming homotetramers. In addition, as we have been observed, the pharmacological 
results could differ from homotetramers to heterotetramers and even more if KCNEs subunits are present.  
Retigabine does not affect cardiac KV7.1 channels, and this pharmacological property has been related with its lack 
of toxicity. However, it has a significant impact on KV7.2-7.5 channels. At higher concentrations than those required 
for anticonvulsant activity, it induces muscle relaxation and motor incoordination (283). A previous report showed that 
retigabine has low ability to cross the blood-brain barrier, being the concentration in plasma 5-fold more than in brain 
tissue. These findings suggest a reduction in antiepileptic efficacy and the increased risk in other tissues (287).  
The study of KV7 channels as pharmacological targets can be used in new drug design. This approach will also 
improve the great variety of drugs that are already in use, such as drugs used to treat epilepsy or cardiovascular 
disorders. 
In summary, the results of this part of the present Doctoral Thesis suggest that KV7.1 and KV7.5 channels, expressed 
in vascular coronary myocytes, form functional heterotetrameric channels that seem to play a relevant role in the 
control of the vascular tone. The confirmation of the presence of KV7.1/KV7.5 heteromers paves the way for novel 
interactions that could shed light on pharmacological results in vascular musculature. The complexity is further 
increased by the KCNE expression pattern, with which they interact, and that has not been currently investigated. 
5.2 n-3, n-6 PUFAs AND THEIR DERIVATIVES: LXA4 AND RvD1, 
MODULATE KV7.1/KCNE1 AND KV1 CHANNELS 
5.2.1 n-3 and n-6 PUFAs on KV7.1/KCNE1 channels 
In this part of the present Doctoral Thesis we investigated the effects of the most abundant n-6 and n-3 PUFAs (AA 
and DHA) on KV7.1/KCNE1 channels. We demonstrated that: (i) At physiological concentrations, DHA and AA 
increased the current magnitude in acute, but not after chronic exposition, both in COS-7 cells and in guinea pig 
ventricular myocytes. (ii) DHA chronic application decreased the expression of KV7.1 channels, but not that of 
KCNE1, due to an enhanced degradation via proteasome. Finally, (iii) chronic exposure of DHA modified the KV7.1 
location in membrane microdomains. 
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DHA and AA modulate KV7.1/KCNE1 channels by modifying the magnitude of the current and the gating of the 
channels. Acute perfusion with DHA increased the KV7.1/KCNE1 current magnitude, slowed its activation kinetics 
and accelerated the deactivation kinetics. However, although AA also increased the KV7.1/KCNE1
current magnitude, it did not modify the activation kinetics, but, similarly to DHA, accelerated the deactivation 
kinetics. All these effects were only observed in the presence of KCNE1, suggesting an essential role for KCNE1 in 
the modulation exerted by acute DHA and AA. These results are in agreement with those previously reported by 
Doolan and colleagues, in which DHA increased KV7.1/KCNE1 currents due to the presence of KCNE1 (210). 
However, Liin and colleagues state that KCNE1 impairs the effects produced by DHA on KV7.1 channels, being 
greater the effects produced by DHA in KV7.1 than in KV7.1/ KCNE1 channels (226). They propose that a negative 
charge in the PUFA carboxyl head group is needed to shift the activation curve towards negative membrane 
potentials and, thus, increasing the magnitude of the current. Moreover, they suggest that the lack of effects 
observed in the presence of KCNE1 is due to a change in the environment of the channel induced by this subunit 
that neutralizes the charge of the head group of the DHA molecule (226). Our data and Liin and colleagues results 
are in agreement with those reported by Hoshi et al., who suggest that DHA can bind both the α and to the β-
subunits of KCa1.1 channels. In fact, some β-regulatory subunits, but not all, highly potentiate the effect of DHA on 
KCa1.1 channels (288). 
Dietary administration of PUFAs produces their incorporation on plasma membranes as part of phospholipids. Free 
PUFAs can modulate different processes or can be metabolized to several eicosanoids. It has been described that 
the acute and chronic effects of PUFAs can be different (207). Therefore, we analyzed both, acute and chronic 
effects of DHA and AA, as well of those of their metabolites (lipoxins and resolvins). Acute exposure of COS-7 cells 
transfected with KV7.1/KCNE1 channels to DHA led to an increased current magnitude at positive membrane 
potentials, a slower activation and faster deactivation kinetics. Similar results were obtained when guinea-pig 
ventricular myocytes were exposed to the same DHA concentration. These results suggest that the primary 
mechanism of the increased magnitude of the KV7.1/KCNE1 current may be due to a modification of the channel 
gating. On the other hand, chronic DHA administration did not increase the current magnitude at any potential tested. 
Interestingly, the effects of this PUFA on the activation were different than those observed for acute perfusion, in this 
case being faster than under control conditions. However, the deactivation kinetics was accelerated. Surprisingly, a 
shift towards more negative membrane potentials was observed in KV7.1/KCNE1 channels after cells were incubated 
48 h with DHA.  
AA effects were slightly different. This n-6 PUFA increased the magnitude of the KV7.1/KCNE1 current at membrane 
potentials positive to -25 mV (close to the threshold of activation of the channel). Similar results were previously 
observed with EPA (225). The effects of AA on KV7.1/KCNE1 resemble those produced by KCNE1 on the KV7.1 
current and, thus, we could explain the increase produced by this PUFA by an increase of the channel conductance. 
However, single channel analysis is needed to assess this hypothesis. Another possibility is that AA promotes the 
transition to the open state of the channel and stabilizes the channel in this state. Interestingly, activation curve could 
not be fitted, because it did not achieve steady-state. On the other hand, long-term administration of AA did not 
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increase the magnitude of KV7.1/KCNE1 currents; however, it slowed the activation and accelerated the deactivation 
kinetics. These results suggest that both, the time of exposure and the differences between n-3 and n-6 PUFAs, 
promote specific effects on KV7.1/KCNE1 channels (224, 225). PUFAs can modify the gating of ion channels by 
simultaneously stablishing a direct interaction and also by modifying the properties of the lipid bilayer. It has been 
observed that PUFAs can alter voltage gated channels both, in acute and after long-term conditions. Some results 
can be attributable to direct interactions, whereas others seem to be indirect. There are several evidences that 
PUFAs interact directly with ion channels. It has been described that specific single mutations in NaV1.5 and KCa1.1 
channels modify PUFAs effects after acute administration (289, 290). Moreover, it has been reported that several 
voltage gated channels, such as Shaker K+ channels or other KV channels like KV7.1, directly interact with PUFAs 
through a specific region located between the S3 and S4 of the VSD (226), whereas in other channels, like KCa1.1, 
PUFAs bind to the ion pore (290). 
It has been also reported that PUFAs modify microenvironments of the plasma membrane in which certain ion 
channels are located. These studies suggest that their effects on the ion channels are a consequence of a disorder 
induced in those regions. Also, there is a correlation between the potency to block the cardiac INa and the ability of 
PUFAs to increase membrane fluidity (219). Moreover, PUFAs might indirectly modulate ion channels by changing 
the cellular redox status, the metabolism of phospholipids or the gene expression (195). 
We wanted investigate further the mechanism by which acute and chronic n-3 PUFAs exert their actions on 
KV7.1/KCNE1 channels. To that end, two other procedures were performed: 1) Because it was described that PUFAs 
decreased the expression of KV1.5 channels (213) and since current magnitude was not increased after long-term 
PUFAs exposure, the KV7.1/KCNE1 channels expression levels were analyzed after 48 h of incubation with DHA. 
After long-term conditions, KV7.1, but not KCNE1, expression levels decreased in a concentration-dependent 
manner. It is stablished that Nedd4-2 ubiquitin-ligase regulates KV7.1 internalization and degradation via proteasome. 
The decreased of expression levels of KV7.1 channels was prevented by a proteasome inhibitor (MG-132), 
suggesting that DHA promotes KV7.1 degradation via proteasome. 2) To investigate if DHA modulates the plasma 
membrane location of KV7.1 channels during long-term incubation, targeting lipid-rafts was analyzed in the absence 
and in the presence of DHA. KV7.1 channels partially target lipid rafts in ventricular myocytes (291), whereas KCNE1 
localizes in low-buoyant density fractions only in association with KV7.1 (269). Our results demonstrate that long term 
exposure to DHA delocalized KV7.1 from lipid rafts (similar results were previously observed with EPA (225)). In 
addition, we previously performed electrophysiological experiments with metil-β-ciclodextrin (MβCD), which triggers 
lipid-rafts disruption (via cholesterol depletion) (225). When cells expressing KV7.1/KCNE1 channels were treated 
with MβCD, the current generated increased and the activation curve was shifted towards positive potentials. Under 
these conditions, EPA effects were similar to those observed in non-cholesterol-depleted cells, suggesting a direct 
effect after acute application of EPA on KV7.1/KCNE1 channels. Based on all these EPA results, and in those 
produced by DHA and AA in acute and after chronic exposure, we suggest that these PUFAs both directly and 
indirectly interact with KV7.1/KCNE1 channels, although further investigations are needed to confirm this hypothesis. 
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Our results observed in KV7.1/KCNE1 channels treated with AA are in agreement with the reported ability of the N-
arachidonoyl-taurine to reverse chromanol 293B effects on action potential duration in rat embryonic cardiomyocytes, 
which do not generates IKr. This negatively-charged AA analogue acts as an antiarrhythmic agent decreasing the 
firing frequency produced by chromanol 293B (226). Given the fact that AA inhibits IKr (212) and increases IKs, our 
results may explain, at least in part, the antiarrhythmic effects observed in this study. These authors propose that the 
antiarrhythmic effects of n-3 PUFAs are due to their inhibitory effects on INa and ICaL, because
they do not observe any increase in KV7.1/KCNE1 (226). However, in our expression system and in agreement to 
Doolan and colleagues (210), we observed the opposite, being necessary the presence of KCNE1 to observe an 
increase of KV7.1/KCNE1 current.  
Action potential simulations incorporating the effects of DHA and EPA showed that these PUFAs have a key role 
shortening the action potential as a consequence of their availability to increase IKs, when other repolarizing current 
are compromised, for instance when IKr or IKur are inhibited (213, 292). Likewise, the AA induced increase of IKs may 
lead similar effects. 
5.2.2 Effects of e-LXA4, LXA4 and RvD1 on KV currents from BMDM 
In this part of the present Doctoral Thesis, we investigated the effects of PUFAs metabolites (e-LXA4, LXA4 and 
RvD1) on KV currents recorded in BMDM. We demonstrate that: (i) e-LXA4 and LXA4, but not RvD1, reverse LPS-
induced phenotype in BMDM in long-term conditions and (ii) e-LXA4, but not RvD1, block KV currents from immune 
native macrophages (BMDM) activated with LPS after acute perfusion.  
e-LXA4, LXA4 and RvD1 are lipid-derived mediators which are products of the metabolism of AA and DHA, 
respectively. e-LXA4, LXA4 and RvD1 are able to mount resolution and anti-inflammation (293, 294).  
RvE1, RvD1/AT-RvD1 (aspirin trigger-RvD1), are originated from EPA and DHA as a result of a transcellular 
biosynthetic route during cell-cell interactions. It is necessary to highlight that, under physiological conditions; the 
increase in consumption of fish oil (EPA and DHA) do not automatically implies an augmentation of resolvins levels. 
In non-injured tissues, the expression levels of the biosynthetic enzymes are low and they strongly increase by acute 
inflammation (295). These lipid-derived mediators together with lipoxins, LXA4 and e-LXA4, which are a AA-derived 
modulators, regulate different processes involved in resolution, such as neutrophil recruitment, dendritic cell 
migration, decrease in leukocyte infiltration, activation of phagocytosis in macrophages, reduction in the number T 
helper cells, blocking of TLR-mediated activation of macrophages, modulation of the cytokines production (as 
reduction of TNF-α in microglia) and chemokines, etc (236, 295-299).  
The electrophysiological properties of macrophages depend on their state of functional activation. In fact, LPS 
activation mimics the TNF-α effects and high levels of TNF-α released are indicative of macrophage activation (91). 
Changes in the membrane potential are one of the first events on the activation process of macrophages (92, 94, 
234). During the activation processes, different ion channels are involved. 
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First, we studied how pro-resolution lipid-derived mediators could affect the KV currents (generated by the activation 
of KV1.3/KV1.5) in resting and LPS-activated BMDM. Potassium channels play a pivotal role in the maintenance of 
Ca2+ electrochemical gradient necessary to allow specific Ca2+ entry and macrophages activation (300). Previous 
reports show that RAW264.7 and BMDM activated with LPS macrophages present an increase in functional KV1.3 
channels, whereas non-stimulated RAW264.7 or BMDM macrophages do not (94, 234). It is described that 
KV1.5 and KV1.3 expression depend on the type of activation and that change between activation and 
immunosuppression.  
Incubation of BMDM with e-LXA4 and LXA4, but not with RvD1, partially reverses the LPS-activation on BMDM. 
Incubation with e-LXA4 decreased the amplitude, the use-dependent decay of the current at fast stimulation 
frequencies and the C-type inactivation of the KV current. These results suggest that e-LXA4 and LXA4 are active pro-
resolution mediators. Their effects are partially mediated by the KV1.3 activity, since the function of KV1.3 is required 
for the attenuation of NF-kB activity, because the e-LXA4 effects on IKK activity and NOS-2 expression were partially 
reverted after selectively blocking KV1.3 channels (234).  
In the resolution phase, it is necessary to avoid the production of TNF-α because its effects are pro-immflamatory 
(295). Our hypothesis was that RvD1, as observed with e-LXA4 and LXA4, can reverse the activation induced by 
LPS, being this reversion reflected in a decrease of the KV1.3 current. Duffield and colleagues reported that BMDM 
treated with LPS and simultaneously with RvD1 or PD1, are limited in TNF-α generation, which is the response to 
cell activation. They analyzed the TNF-α release ability of LPS-activated macrophages. LPS-activated BMDM were 
incubated with different concentrations of DHA, RvD1 and PD1. RvD1 and PD1 exhibited a markedly concentration-
dependent decrease of LPS-induced TNF-α release, suggesting that both have pro-resolution activities in 
macrophages. Because LPS acts through TLR4 (and, to a lesser extent, through TLR2) they suggest that these 
compounds block TLR-mediated activation of macrophages (236). However, in our experiments, RvD1 did not 
reverse the KV1.3 current elicited by LPS activation. This result can be due to several factors: i) RvD1 resolve the 
inflammatory process through a signaling cascade that do not involve KV channels, or ii) the concentrations and the 
time of incubation needed exceed those used in the present study. 
In order to elucidate if the effects observed are related to KV channels, we also analyzed the acute effects of e-LXA4 
and also with RvD1. We observed that in acute perfusion, e-LXA4 diminished the currents elicited by LPS-activated 
macrophages, whereas they did not affect resting macrophages. RvD1 did not modify the magnitude of the currents 
after acute exposition on either resting or LPS-activated macrophages. The increase in KV current induced by LPS 
appeared concomitantly with its use-dependent decay and its increase in the C-type inactivation, characteristics of 
KV1.3 (234). Under these conditions, e-LXA4 decreased the magnitude of KV current in LPS-stimulated BMDM but did 
not modify the use-dependent decrease or the C-type inactivation. These results suggest that there is no direct 
interaction between e-LXA and KV1.3 channels. However, to ensure that the effects of e-LXA on KV1.3 and KV1.5 
channels expressed in HEK293 cells were analyzed. No effects on any channel were observed at any concentration 
tested, suggesting that e-LXA4 actions are a consequence of some effects on a signaling pathway present in 
macrophages but not in HEK293 cells. Our laboratory has described that the effects observed by e-LXA4 on KV 
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channels is dependent, at least in part, on ALX receptor (234). Resolvin actions are mediated by specific GPCRs 
(ChemR23 and GPR32, among others). Interestingly, both lipoxins and resolvins share a common receptor (ALX) 
(236, 301). The lack of effects of RvD1 on KV currents can be explained if these compounds act as pro-resolving via 
other mechanisms 
 5.2.3 LXA4 and RvD1 in KV7.1/KCNE1 channels 
In this part of the present Doctoral Thesis we studied the effects produced by LXA4 and RvD1 on KV7.1/KCNE1 
channels expressed in COS-7 cells. We demonstrated that: i) LXA4 decreased KV7.1/KCNE1 current in a 
concentration-dependent manner, and ii) RvD1 inhibits this current, being much more potent than LXA4. 
The LXA4 and RvD1 inhibit KV7.1/KCNE1 current. However, LXA4 and RvD1 effects did not modify the voltage-
dependence of the KV7.1/KCNE1 channels or the activation kinetics. Moreover, the blocking effects were almost 
completely washed-out when cells expressing KV7.1/KCNE1 channels were perfused with eicosanoid-free external 
solution. These results suggest a direct effect between both pro-resolving compounds and KV7.1/KCNE1 channels. In 
addition, as described above, LXA4 and RvD1 activates GPR32 and ALX receptors. There is no evidence described 
before of the expression of these receptors in COS-7 cells. However, there are needed more experimental evidences 
to rule out the possibility of an indirect effect. It has been described that RvD1 produce an analgesic role. Its ability to 
inhibit TRP channels such as TRPA1, TRPV3 and TRPV4, has been related with the potency as analgesic attributed 
to RvD1 (297). Moreover, it has been shown that PUFAs or cholesterol precursors directly activate or potentiate 
TRPV3 channels (302). In addition, arachidonic acid is able to activate TRPV4 channels (303). Interestingly, we 
observed the same effects: PUFAs activate KV7.1/KCNE1 channels and the lipid-derived compounds, LXA4 and 
RvD1, inhibit KV7.1/KCNE1 currents. Moreover, Bang and colleagues found that RvD1 blocks TRPA1, TRPV3 and 
TRPV4 expressed in HEK293 cells, and they suggest that RvD1 inhibits TRP currents without activating 
metabotropic receptor signaling (297). Although TRPs are Na+ and Ca2+ channels and that their physiological 
implications are completely different. However, the molecular mechanism of activation or block performed by PUFAs 
and its derivatives can be similar.  
Several evidences demonstrate that anti-inflammatory and pro-resolution mechanisms differ for control inflammation. 
Many of the anti-inflammatory therapeutics act by inhibiting COX-2, disrupting the endogenous pro-resolution 
mechanism (295). Moreover, because COX-2 is constitutively expressed in the nervous system and in the 
vasculature, many other processes could be indirectly altered by these anti-inflammatory compounds (238, 304). 
Importantly, there is evidence that aspirin, statins and pioglitazone trigger the synthesis of 15-epi-lipoxin (LXA)4 in the 
myocardium (238, 305). An increase in the levels of these eicosanoids in the heart may produce a decrease in the IKs 
that may have clinical relevance. 
AA and DHA are widely related with the role of preventing arrhythmias, during ischemia and reperfusion and by the 
sum of its effects on voltage gated channels on cardiac action potential, respectively (195, 212, 306). Furthermore, 
resolvins are proposed as a new class of analgesic agents, which can block abnormal pain without losing sensitivity 
(295). Also, COX-2 inhibitors were linked with cardiovascular risks (307). 
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The further investigation of PUFAs and PUFAs-derived modulators, as resolvins and lipoxins, and their targets, as 
potassium voltage-gated ion channels, may serve for the design of effective therapeutics not only in cardiovascular 
disease but also in other main prevalent disease as cancer and Alzheimer´s disease. 
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1. KV7.1 and KV7.5 subunits interact forming functional channels. KV7.1/KV7.5 heteromeric channels exhibit their 
own electrophysiological and pharmacological properties. They can be regulated by KCNE1 and KCNE3. Like 
KV7.5, and opposite to KV7.1 channels, KV7.1/KV7.5 heteromeric channels do not target lipid rafts. Because 
the lipid raft localization of ion channels is crucial for cardiovascular physiology, KV7.1/KV7.5 heteromeric 
channels provide efficient spatial and temporal regulation of vascular smooth muscle function. Moreover, 
KV7.1/KV7.5 heteromeric channels increase the diversity of structures that fine-tune blood vessels reactivity.  
2. The effects of n-3 and n-6 PUFAs on the KV7.1/KCNE1 current are dependent on the presence of KCNE1. 
These effects differ depending on the structure of the PUFA and on the time of exposure of the cells to these 
fatty acids. DHA and AA increase KV7.1/KCNE1 current magnitude when acutely applied. However, after long 
term incubation of cells expressing KV7.1/KCNE1, the magnitude of the current was not modified, although the 
kinetics and voltage-dependent characteristics were changed. DHA decreases the expression of KV7.1 by 
increasing its degradation via proteasome. Also, the modulation of KV7.1/KCNE1 channels after chronic 
incubation with DHA seems to be mainly due to a delocalization of KV7.1 channels from lipid rafts. 
3. In macrophages, long-term exposure to e-LXA4, but not to RvD1, reversed the electrophysiological changes 
induced by LPS. The effects induced by e-LXA4 were not due to a direct interaction with KV1.3 or KV1.5 
channels. 
4. LXA4 and RvD1 inhibit KV7.1/KCNE1 current, RvD1 being more potent. KCNE1 potentiates the RvD1 induced 
effects on KV7.1. LXA4 and RvD1 did not modify neither the voltage-dependence nor the activation of the 
channel and these effects were completely reversible after washed out.  
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1. Las subunidades KV7.1 y KV7.5 interaccionan formando canales heteroméricos KV7.1/KV7.5 funcionales, 
con un fenotipo electrofisiológico y farmacológico intermedio. Además, éstos pueden ser regulados por las 
subunidades accesorias KCNE1 y KCNE3. De igual manera que los canales KV7.5 y, a diferencia de los 
KV7.1, los canales KV7.1/KV7.5 se localizan fuera de las balsas lipídicas, cambiando así, la regulación de 
los canales en aquellos tejidos donde ambos se expresan. Los canales KV7.1/KV7.5 están involucrados en 
la regulación de la reactividad del músculo liso vascular, aumentando la diversidad de mecanismos 
implicados en esta función.  
2. Los ácidos grasos poliinsaturados omega-3 y omega-6 producen efectos diferentes sobre los canales 
KV7.1/KCNE1, ambos dependen de la subunidad reguladora KCNE1 para ejercer dichos efectos. El modo 
de aplicación, perfusión aguda o incubación de 48 horas, también determina el efecto observado en los 
canales KV7.1/KCNE1. La incubación con DHA produjo una expresión a la baja de los canales, promovida 
por un aumento en la degradación de los canales KV7.1 vía proteosoma. Además, la incubación con DHA  
promueve la deslocalización de los canales KV7.1/KCNE1 de las balsas lipídicas.  
3. La incubación de macrófagos con e-LXA4, pero no con RvD1, revirtió los cambios electrofisiológicos 
promovidos por la activación de macrófagos con LPS. Los efectos producidos por e-LXA4 no se debieron a 
un efecto directo sobre los canales KV1.3 ó KV1.5. 
4. Tanto LXA4 como RvD1 bloquearon los canales KV7.1/KCNE1. Sin embargo, la potencia de RvD1 para 
bloquear estos canales fue mucho mayor que la de LXA4. La presencia de la subunidad reguladora KCNE1 
aumenta del efecto producido por RvD1 sobre los canales KV7.1. Estos compuestos no modificaron ni la 
activación ni la dependencia de voltaje de los canales KV7.1/KCNE1 y además, los efectos producidos por 
estos compuestos eran revertidos tras la perfusión de las células con solución externa carente de LXA4 ó 
RvD1. 
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Figure S1: Chromanol 293B effects on KV7.1/KCNE1 currents. A: Representative current records from COS-7 cells co-
transfected with KV7.1/KCNE1. Currents were evoked applying the protocol shown on the top of the figure in the absence or in 
the presence of 5 µM chromanol 293B. B: Representative traces obtained after applying 5.5 s pulses of +60 mV from a holding 
potential of -80 mV, in the absence (black trace) and in the presence of 5 µM chromanol 293B (blue trace). The percentage of 
block is shown. Data are shown as the mean ± SEM. *: P < 0.05, n= 3 
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Figure S2: Voltage-dependent effects produced by AA on KV7.1 current. A: Current traces obtained after applying the pulse 
protocol shown in the top in the absence and in the presence of AA (20 µM). B: I-V relationships obtained under control 
conditions and after perfusion with AA. Data are shown as the mean ± SEM. *: P < 0.05, n= 3 
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Figure S3: Control conditions in serum-free medium of KV7.1/KCNE1 currents. A: KV7.1/KCNE1 original traces recorded 
after applying depolarizing 5.5-s pulses from a holding potential of -80 mV to +60 mV in 10 mV steps. B: I-V relationships 
obtained measuring the current after 5.5s C: Activation curves obtained after representing the maximum tail current amplitude 
versus the previous step potential. Data are shown as the mean ± SEM, n= 18. 
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Figure S4: Effects of acute treatment with RvD1 (50nM) on KV currents in control and LPS-activated BMDM. 
Representative currents traces of KV currents recorded from control (resting) and LPS-activated BMDM. Currents were elicited 
by applying the protocol shown on the top A: control (resting) BMDM in the absence and in the presence of RvD1 (50 nM). Inset 
show the currents bigger to better observation. B: LPS-activated BMDM in the absence and in the presence of RvD1 (50 nM). n 
= 5-6 per group 
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Figure S5: Representative traces of LXA4 and RvD1 wash-out on KV7.1/KCNE1 current. Current traces were obtained after 
applying the pulse protocol shown in the top. A: KV7.1/KCNE1 current in control conditions, B: LXA4 (top) and RvD1 (bottom) 
effects on KV7.1/KCNE1 channels C: Wash-out effects for both, Activation curves of LXA4 (top) and RvD1 (bottom) on 
KV7.1/KCNE1 currents.  
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Figure S6: Voltage-dependent effects of RvD1 on KV7.1 channels. A: Current traces obtained after applying the pulse 
protocol shown in the top, in the absence and in the presence of 5 and 50 nM RvD1. B: I-V relationships obtained after plotting 
the current at the end of 5.5-s vs. membrane potential, in the absence and in the presence of RvD1 (5 and 50 nM). C: Activation 
curves of KV7.1 current obtained after representing the maximum tail current amplitude vs. the previous step potential, recorded 
in the absence and in the presence of 5 nM RvD1. Data are shown as the mean ± SEM. *P < 0.05, n = 4-6. 
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9.1 ORIGINAL PAPERS 
Modulation of voltage-dependent and inward rectifier potassium channels by 15-Epi-Lipoxin-A4 in 
activated murine macrophages: implications in innate immunity 
Moreno C*, Prieto P*, Macías A*, Pimentel-Santillana M*, de la Cruz A, Través PG, Boscá L, Valenzuela C 
Potassium channels modulate macrophage physiology. Blockade of voltage-dependent potassium channels (KV) by 
specific antagonists decreases macrophage cytokine production and inhibits proliferation. In the presence of aspirin, 
acetylated cyclooxygenase-2 loses the activity required to synthesize PGs but maintains the oxygenase activity to 
produce 15R-HETE from arachidonate. This intermediate product is transformed via 5-LOX into epimeric lipoxins, 
termed 15-epi-lipoxins (15-epi-lipoxin A4 [e-LXA4]). KV have been proposed as anti-inflammatory targets. Therefore, 
we studied the effects of e-LXA4 on signaling and on KV and inward rectifier potassium channels (Kir) in mice bone 
marrow-derived macrophages (BMDM). Electrophysiological recordings were performed in these cells by the whole-
cell patch-clamp technique. Treatment of BMDM with e-LXA4 inhibited LPS-dependent activation of NF-κB and IκB 
kinase β activity, protected against LPS activation-dependent apoptosis, and enhanced the accumulation of the Nrf-2 
transcription factor. Moreover, treatment of LPS-stimulated BMDM with e-LXA4 resulted in a rapid decrease of KV 
currents, compatible with attenuation of the inflammatory response. Long-term treatment of LPS-stimulated BMDM 
with e-LXA4 significantly reverted LPS effects on KV and Kir currents. Under these conditions, e-LXA4 decreased the 
calcium influx versus that observed in LPS-stimulated BMDM. These effects were partially mediated via the lipoxin 
receptor (ALX), because they were significantly reversed by a selective ALX receptor antagonist. We provide 
evidence for a new mechanism by which e-LXA4 contributes to inflammation resolution, consisting of the reversion of 
LPS effects on KV and Kir currents in macrophages. J Immunol. 2013 Dec 15;191(12):6136-46. (*: MC, PP, MA and 
PM authors contributed equally to this work). Reviewed in Nature Chemical Biology, February 2014. 
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Functional assembly of KV7.1/KV7.5 channels with emerging properties on vascular muscle 
physiology 
Oliveras A, Roura-Ferrer M, Sole L, de la Cruz A, Prieto A, Etxebarria A, Manils J, Morales-Cano D, 
Condom E, Soler C, Cogolludo A, Valenzuela C, Villarroel A, Comes N, Felipe A. 
OBJECTIVE: 
Voltage-dependent K(+) (KV) channels from the KV7 family are expressed in blood vessels and contribute to 
cardiovascular physiology. Although KV7 channel blockers trigger muscle contractions, KV7 activators act as 
vasorelaxants. KV7.1 and KV7.5 are expressed in many vessels. KV7.1 is under intense investigation because KV7.1 
blockers fail to modulate smooth muscle reactivity. In this study, we analyzed whether KV7.1 and KV7.5 may form 
functional heterotetrameric channels increasing the channel diversity in vascular smooth muscles. 
APPROACH AND RESULTS: 
KV7.1 and KV7.5 currents elicited in arterial myocytes, oocyte, and mammalian expression systems suggest the 
formation of heterotetrameric complexes. KV7.1/KV7.5 heteromers, exhibiting different pharmacological 
characteristics, participate in the arterial tone. KV7.1/KV7.5 associations were confirmed by coimmunoprecipitation, 
fluorescence resonance energy transfer, and fluorescence recovery after photobleaching experiments. KV7.1/KV7.5 
heterotetramers were highly retained at the endoplasmic reticulum. Studies in HEK293 cells, heart, brain, and 
smooth and skeletal muscles demonstrated that the predominant presence of KV7.5 stimulates release of 
KV7.1/KV7.5 oligomers out of lipid raft microdomains. Electrophysiological studies supported that KCNE1 and KCNE3 
regulatory subunits further increased the channel diversity. Finally, the analysis of rat isolated myocytes and human 
blood vessels demonstrated that KV7.1 and KV7.5 exhibited a differential expression, which may lead to channel 
diversity. 
CONCLUSIONS: 
KV7.1 and KV7.5 form heterotetrameric channels increasing the diversity of structures which fine-tune blood vessel 
reactivity. Because the lipid raft localization of ion channels is crucial for cardiovascular physiology, KV7.1/KV7.5 
heteromers provide efficient spatial and temporal regulation of smooth muscle function. Our results shed light on the 
debate about the contribution of KV7 channels to vasoconstriction and hypertension. Arterioscler Thromb Vasc 
Biol. 2014 Jul;34(7):1522-30 
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PKC inhibition results in a KV1.5+KVβ1.3 pharmacology closer to KV1.5 channels. 
Macias A, de la Cruz A, Prieto A, Peraza DA, Tamkun MM, González T, Valenzuela C.  
BACKGROUND AND PURPOSE: 
The KVβ1.3 subunit modifies the gating and pharmacology of KV1.5 channels in a PKC-dependent manner, 
decreasing channel sensitivity to bupivacaine- and quinidine-mediated blockade. Cardiac KV1.5 channels associate 
with receptor for activated C kinase 1 (RACK1), the KVβ1.3 subunit and different PKC isoforms, resulting in the 
formation of a functional channelosome. The aim of the present study was to investigate the effects of PKC inhibition 
on bupivacaine and quinidine block of KV1.5 + KVβ1.3 channels. 
EXPERIMENTAL APPROACH: 
HEK293 cells were transfected with KV1.5 + KVβ1.3 channels, and currents were recorded using the whole-cell 
configuration of the patch-clamp technique. PKC inhibition was achieved by incubating the cells with either calphostin 
C or bisindolylmaleimide II and the effects of bupivacaine and quinidine were analysed. 
KEY RESULTS: 
The voltage-dependent inactivation of KV1.5 + KVβ1.3 channels and their pharmacological behaviour after PKC 
inhibition with calphostin C were similar to those displayed by KV1.5 channels alone. Indeed, the IC50 values for 
bupivacaine were similar in cells whose PKC was inhibited with calphostin C or bisindolylmaleimide II. Similar results 
were also observed in the presence of quinidine. 
CONCLUSIONS AND IMPLICATIONS: 
The finding that the voltage-dependence of inactivation and the pharmacology of Kv 1.5 + Kv β1.3 channels after 
PKC inhibition resembled that observed in Kv 1.5 channels suggests that both processes are dependent on PKC-
mediated phosphorylation. These results may have clinical relevance in diseases that are characterized by 
alterations in kinase activity. Br J Pharmacol. 2014 Nov;171(21):4914-26. 
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Marine n-3 PUFAs modulate IKs gating, channel expression, and location in membrane 
microdomains. 
Moreno C*, de la Cruz A*, Oliveras A, Kharche SR, Guizy M, Ronchi C, Comes N, Rocchetti M, Starý T, 
Baró I, Loussouarn G, Zaza A, Severi S, Felipe A, Valenzuela C  
AIMS: 
Polyunsaturated fatty n-3 acids (PUFAs) have been reported to exhibit antiarrhythmic properties.However, the 
mechanisms of action remain unclear.We studied the electrophysiological effects of eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) on IKs, and on the expression and location of Kv7.1 and KCNE1. 
METHODS AND RESULTS: 
Experiments were performed using patch-clamp, western blot, and sucrose gradient techniques in COS7 cells 
transfected with Kv7.1/KCNE1 channels. Acute perfusion with both PUFAs increased Kv7.1/KCNE1 current, this 
effect being greater for DHA than for EPA. Similar results were found in guinea pig cardiomyocytes. Acute perfusion 
of either PUFA slowed the activation kinetics and EPA shifted the activation curve to the left. Conversely, chronic 
EPA did not modify Kv7.1/KCNE1 current magnitude and shifted the activation curve to the right. Chronic PUFAs 
decreased the expression of Kv7.1, but not of KCNE1, and induced spatial redistribution of Kv7.1 over the cell 
membrane. Cholesterol depletion with methyl-b-cyclodextrin increased Kv7.1/KCNE1 current magnitude. Under 
these conditions, acute EPA produced similar effects than those induced in non-cholesterol-depleted cells. A 
ventricular action potential computational model suggested antiarrhythmic efficacy of acute PUFA application under 
IKr block. 
CONCLUSIONS: 
We provide evidence that acute application of PUFAs increasesKv7.1/KCNE1 through a probably direct effect, and 
shows antiarrhythmic efficacy under IKr block. Conversely, chronic EPA application modifies the channel activity 
through a change in the Kv7.1/KCNE1 voltage-dependence, correlated with a redistribution of Kv7.1 over the cell 
membrane. This loss of function may be pro-arrhythmic. This shed light on the controversial effects of PUFAs 
regarding arrhythmias. Cardiovasc Res. 2015 Feb 1;105(2):223-32. (*: Both authors contributed equally to this work) 
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A new KCNQ1 mutation at the S5 segment that impairs its association with KCNE1 is responsible 
for short QT syndrome. 
Moreno C*, Oliveras A*, de la Cruz A, Bartolucci C, Muñoz C, Salar E, Gimeno JR, Severi S, Comes N, 
Felipe A, González T, Lambiase P, Valenzuela C. 
AIMS: 
KCNQ1 and KCNE1 encode KV7.1 and KCNE1, respectively, the pore-forming and the accessory subunits of the 
slow delayed rectifier potassium current, IKs. KCNQ1 mutations are associated with long and short QT syndrome. The 
aim of this study was to characterize the biophysical and cellular phenotype of a KCNQ1 missense mutation, F279I, 
found in a 23-year-old man with a corrected QT interval (QTc) of 356 ms and a family history of sudden cardiac 
death. 
METHODS AND RESULTS: 
Experiments were performed using perforated patch-clamp, western blot, co-immunoprecipitation, biotinylation, and 
immunocytochemistry techniques in HEK293, COS-7 cells and in cardiomyocytes transfected with WT KV7.1/KCNE1 
or F279I KV7.1/KCNE1 channels. In the absence of KCNE1, F279I KV7.1 current exhibited a lesser degree of 
inactivation than WT Kv7.1. Also, functional analysis of F279I KV7.1 in the presence of KCNE1 revealed a negative 
shift in the activation curve and an acceleration of the activation kinetics leading to a gain of function in IKs. The co-
assembly between F279I KV7.1 channels and KCNE1 was markedly decreased compared with WT KV7.1 channels, 
as revealed by co-immunoprecipitation and Föster Resonance Energy Transfer experiments. All these effects 
contribute to the increase of IKs when channels incorporate F279I KV7.1 subunits, as shown by a computer model 
simulation of these data that predicts a shortening of the action potential (AP) consistent with the patient phenotype. 
CONCLUSION: 
The F279I mutation induces a gain of function of IKs due to an impaired gating modulation of KV7.1 induced by 
KCNE1, leading to a shortening of the cardiac AP. Cardiovasc Res. 2015 Sep 1;107(4):613-23. (*: Both authors 
contributed equally to this work) 
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Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease. 
Naranjo JR, Zhang H, Villar D, González P, Dopazo XM, Morón-Oset J, Higueras E, Oliveros J C, Arrabal 
M D, Prieto A, Cercós P, González T, De la Cruz A, Casado-Vela J, Rábano A, Valenzuela C, Gutierrez-
Rodriguez M, Li J-Y, Mellström B. 
Deregulated protein and Ca2+ homeostasis underlie synaptic dysfunction and neurodegeneration in Huntington 
disease (HD); however, the factors that disrupt homeostasis are not fully understood. Here, we determined that 
expression of downstream regulatory element antagonist modulator (DREAM), a multifunctional Ca2+-binding protein, 
is reduced in murine in vivo and in vitro HD models and in HD patients. DREAM downregulation was observed early 
after birth and was associated with endogenous neuroprotection. In the R6/2 mouse HD model, induced DREAM 
haplodeficiency or blockade of DREAM activity by chronic administration of the drug repaglinide delayed onset of 
motor dysfunction, reduced striatal atrophy, and prolonged life span. DREAM-related neuroprotection was linked to 
an interaction between DREAM and the unfolded protein response (UPR) sensor activating transcription factor 6 
(ATF6). Repaglinide blocked this interaction and enhanced ATF6 processing and nuclear accumulation of 
transcriptionally active ATF6, improving prosurvival UPR function in striatal neurons. Together, our results identify a 
role for DREAM silencing in the activation of ATF6 signaling, which promotes early neuroprotection in HD. J Clin 
Invest. 2016 Feb;126(2):627-38. Reviewed in Nature Reviews Drug Discovery (2016; 15: 169). 
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Fludarabine inhibits KV1.3 currents in human B lymphocytes. 
de la Cruz A*, Vera-Zambrano*, Peraza D, Pérez-Chacon G, Zapata J, Valenzuela C and Gonzalez T 
Fludarabine (F-ara-A) is a purine analog commonly used in the treatment of indolent B cell malignancies that 
interferes with different aspects of DNA and RNA synthesis. KV1.3 K+ channels are membrane proteins involved in 
the maintenance of K+ homeostasis and the resting potential of the cell, thus controlling signaling events, 
proliferation and apoptosis in lymphocytes. Here we show that F-ara-A inhibits KV currents in human B lymphocytes. 
Our data indicate that KV1.3 is expressed in both BL2 and Dana B cell lines, although total KV1.3 levels were higher 
in BL2 than in Dana cells. However, KV currents in the plasma membrane were similar in both cell lines and were 
abrogated by the specific KV1.3 channel inhibitor PAP-1, indicating that KV1.3 accounts for most of the KV currents in 
these cell lines. F-ara-A, at a concentration (3.5 μM) similar to that achieved in the plasma of fludarabine phosphate-
treated patients (3 μM), inhibited KV1.3 currents by 61 ± 6.3% and 52.3 ± 6.3% in BL2 and Dana B cells, 
respectively. The inhibitory effect of F-ara-A was concentration-dependent and showed an IC50 value of 0.36 ± 0.04 
μM and a nH value of 1.07 ± 0.15 in BL2 cells and 0.34 ± 0.13 μM (IC50 ) and 0.77 ± 0.11 (nH ) in Dana cells. F-ara-A 
inhibition of plasma membrane KV1.3 was observed irrespective of its cytotoxic effect on the cells, BL2 cells being 
sensitive and Dana cells resistant to F-ara-A cytotoxicity. Interestingly, PAP-1, at concentrations as high as 10 μM, 
did not affect the viability of BL2 and Dana cells, indicating that blockage of KV1.3 in these cells is not toxic. Finally, 
F-ara-A had no effect on ectopically expressed KV1.3 channels, suggesting an indirect mechanism of current 
inhibition. In summary, our results describe the inhibitory effect of F-ara-A on the activity of KV1.3 channel. Although 
KV1.3 inhibition is not sufficient to induce cell death, further research is needed to determine whether it might still 
contribute to F-ara-A cytotoxicity in sensitive cells or be accountable for some of the clinical side effects of the drug. 
Front Pharmacol. 2017 Mar 31;8:177. (*: Both authors contributed equally to this work) 
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9.2 REVIEWS 
Stereoselective interactions between local anesthetics and ion channels 
Valenzuela C, Moreno C, de la Cruz A, Macias A, Prieto A, González T. 
Abstract: Local anesthetics are useful probes of ion channel function and structure. Stereoselective interactions are 
especially interesting because they can reveal three-dimensional relationships between drugs and channels with 
otherwise identical biophysical and physicochemical properties. Furthermore, stereoselectivity suggests direct and 
specific receptor-mediated action, and identification of such stereospecific interactions may have important clinical 
consequences. The fact that drug targets are able to discriminate between the enantiomers present in a racemic 
drug is the consequence of the ordered asymmetric macromolecular units that form living cells. However, almost 
25% of the drugs used in the clinical practice are racemic mixtures, and their individual enantiomers frequently differ 
in both their pharmacodynamic and pharmacokinetic profiles. Moreover, their effects can be similar to or different 
from the pharmacological effect of the drug and may contribute to the undesired effects of the drug. In other cases, 
the pharmacological effects induced by the two enantiomers on the molecular target are opposite. In the present 
manuscript, we will review the stereoselective effects of bupivacaine-like local anesthetics on cardiac sodium and 
potassium channels. Chirality. 2012 Nov;24(11):944-50. 
Effects of n-3 polyunsaturated fatty acids on cardiac ion channels. 
Moreno C, Macías A, de la Cruz A, Prieto A, González T, Valenzuela C. 
Dietary n-3 polyunsaturated fatty acids (PUFAs) have been reported to exhibit antiarrhythmic properties, and these 
effects have been attributed to their capability to modulate ion channels. In the present review, we will focus on the 
effects of PUFAs on a cardiac sodium channel (Na(v)1.5) and two potassium channels involved in cardiac atrial and 
ventricular repolarization (K(v)) (K(v)1.5 and K(v)11.1). n-3 PUFAs of marine (docosahexaenoic, DHA and 
eicosapentaenoic acid, EPA) and plant origin (alpha-linolenic acid, ALA) block K(v)1.5 and K(v)11.1 channels at 
physiological concentrations. Moreover, DHA and EPA decrease the expression levels of K(v)1.5, whereas ALA does 
not. DHA and EPA also decrease the magnitude of the currents elicited by the activation of Na(v)1.5 and calcium 
channels. These effects on sodium and calcium channels should theoretically shorten the cardiac action potential 
duration (APD), whereas the blocking actions of n-3 PUFAs on K(v) channels would be expected to produce a 
lengthening of cardiac action potential. Indeed, the effects of n-3 PUFAs on the cardiac APD and, therefore, on 
cardiac arrhythmias vary depending on the method of application, the animal model, and the underlying cardiac 
pathology. Front Physiol. 2012 Jul 9;3:245. 
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Polyunsaturated fatty acids modify the gating of Kv channels. 
Moreno C, Macías A, Prieto A, de la Cruz A, Valenzuela C 
Polyunsaturated fatty acids (PUFAs) have been reported to exhibit antiarrhythmic properties, which are attributed to 
their capability to modulate ion channels. This PUFAs ability has been reported to be due to their effects on the 
gating properties of ion channels. In the present review, we will focus on the role of PUFAs on the gating of two Kv 
channels, Kv1.5 and Kv11.1. Kv1.5 channels are blocked by n-3 PUFAs of marine [docosahexaenoic acid (DHA) and 
eicosapentaenoic acid] and plant origin (alpha-linolenic acid, ALA) at physiological concentrations. The blockade of 
Kv1.5 channels by PUFAs steeply increased in the range of membrane potentials coinciding with those of Kv1.5 
channel activation, suggesting that PUFAs-channel binding may derive a significant fraction of its voltage sensitivity 
through the coupling to channel gating. A similar shift in the activation voltage was noted for the effects of n-6 
arachidonic acid (AA) and DHA on Kv1.1, Kv1.2, and Kv11.1 channels. PUFAs-Kv1.5 channel interaction is time-
dependent, producing a fast decay of the current upon depolarization. Thus, Kv1.5 channel opening is a prerequisite 
for the PUFA-channel interaction. Similar to the Kv1.5 channels, the blockade of Kv11.1 channels by AA and DHA 
steeply increased in the range of membrane potentials that coincided with the range of Kv11.1 channel activation, 
suggesting that the PUFAs-Kv channel interactions are also coupled to channel gating. Furthermore, AA regulates 
the inactivation process in other Kv channels, introducing a fast voltage-dependent inactivation in non-inactivating Kv 
channels. These results have been explained within the framework that AA closes voltage-dependent potassium 
channels by inducing conformational changes in the selectivity filter, suggesting that Kv channel gating is lipid 
dependent. Front Pharmacol. 2012 Sep 10;3:163. 
 
In-depth study of the interaction, sensitivity and gating modulation by PUFAs on K+ channels; 
interaction and new targets. 
Moreno C, de la Cruz A, Valenzuela C. 
Voltage gated potassium channels (KV) are membrane proteins that allow selective flow of K+ ions in a voltage-
dependent manner. These channels play an important role in several excitable cells as neurons, cardiomyocytes, 
and vascular smooth muscle. Over the last 20 years, it has been shown that omega-3 polyunsaturated fatty acids 
(PUFAs) enhance or decrease the activity of several cardiac KV channels. PUFAs-dependent modulation of 
potassium ion channels has been reported to be cardioprotective. However, the precise cellular mechanism 
underlying the cardiovascular benefits remained unclear in part because new PUFAs targets and signaling pathways 
continue being discovered. In this review, we will focus on recent data available concerning the following aspects of 
the KV channel modulation by PUFAs: (i) the exact residues involved in PUFAs-KV channels interaction; (ii) the 
structural PUFAs determinants important for their effects on KV channels; (iii) the mechanism of the gating 
modulation of KV channels and, finally, (iv) the PUFAs modulation of a few new targets present in smooth muscle 
cells (SMC), KCa1.1, K2P, and KATP channels, involved in vascular relaxation. Front Physiol. 2016 Nov 24;7:578. 
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9.3 PUBLICATIONS IN PROGRESS 
D242N, a KV7.1 LQTS mutation uncovers a key residue for IKs voltage dependence. 
Moreno C*, Oliveras A*, Bartolucci C, Muñoz C, de la Cruz A, Peraza DA, Gimeno JR, Martín-Martínez M, 
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